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   i	  
ABSTRACT 
	  
Murine mesenchymal stem cells (MSCs) isolated by plastic adherence contain 
contaminating cells and have poor growth and differentiation. I report a detailed 
protocol outlining the steps to prospectively isolate a pure and potent MSC population 
from murine bone marrow based on their expression of stem cell antigen-1 (Sca-1) 
and platelet derived growth factor- alpha (PDGFRα) (PαS cells) using flow 
cytometry. PαS MSCs have augmented growth potential and robust tri-lineage 
differentiation compared to plastic adherent cells. They exert potent 
immunosuppressive effects on proliferating naive CD4+ T cells, which is mediated via 
the production of nitric oxide (NO). Nevertheless, prolonged culture results in cellular 
senescence, loss of adipogenic differentiation and reduced immunosuppressive 
properties. Addition of growth factors to standard media (SM) produced significant 
genotypic and phenotypic changes.  Cells cultured in SM supplemented with basic 
fibroblast growth factor (bFGF) and platelet derived growth factor-BB (PDGF-BB) 
were primed towards fat and cartilage, but had reduced immunosuppressive potential. 
In contrast, cells cultured with transforming growth factor-beta (TGF-β) had reduced 
tri-lineage potential but potent immunosuppressive properties that endured despite 
long term culture. I demonstrate using novel tissue engineering techniques that bFGF 
PαS MSCs generate substantial 3-D cartilage pellets. These data have implications for 
MSC therapy in humans. 
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1 Introduction 
 
1.1 Background 
 
1.1.1 Historical perspective 
 
Friedenstein was first to suggest the presence of a population of multipotent stromal 
cells that reside within the bone marrow (BM) (Friedenstein et al., 1974). These cells 
are readily characterised by their adherence to plastic, spindle shaped morphology and 
the ability to generate colonies termed colony-forming unit-fibroblasts (CFU-Fs) 
when plated as single cells in vitro (Friedenstein et al., 1970). He subsequently 
demonstrated these cells could be readily differentiated into bone in vitro. Caplan’s 
early work using chick limb bud mesodermal cells helped support the concept of a 
BM derived stromal progenitor. He observed that plating these cells at different 
concentrations in vitro affected the fate of the cell (down chondrogenic or osteogenic 
pathways) (Osdoby and Caplan, 1979). He hypothesised that these cells were 
multipotent mesenchymal precursors and that their fate was determined by the 
physiological or pathological conditions imposed upon them. Additional experiments 
in which bone and cartilage formed on a biological matrix following subcutaneous 
transplantation in rodents further supported this concept (Sampath and Reddi, 1981, 
Caplan, 1991). These data suggest the presence of circulating multipotent progenitor 
stromal cells that originate from a stem niche within the BM. 
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Caplan later proposed the term mesenchymal stem cell (MSC) to describe these cells 
and hypothesised ‘the mesengenic process’ to explain the stromal hierarchy which is 
highlighted in Figure 1-1 (Caplan, 1994). Additional plasticity of MSCs has been 
suggested with the demonstration of in vitro differentiation to muscle, liver and 
nervous tissues under defined conditions (Petersen et al., 1999, Pittenger et al., 1999). 
These data have led some to propose a widespread role for MSCs in the maintenance 
and repair of a variety of organs during injury and the aging process. There has been 
intense research interest in MSCs as a putative cellular therapy for tissue regeneration 
over the past decade. 
 
 
Figure 1-1 The mesengenic process.  
This schematic was originally proposed by Caplan and it hypothesises that 
multipotent MSCs have the ability to self-renew and differentiate down all the 
mesenchymal lineage pathways depending on the physiological needs of the organism 
(Caplan, 1994). There are however only limited data available to support the 
existence of such a cell. 
	  
 
	   3	  
1.1.2 Minimal criteria that define MSCs? 
 
Traditionally, MSCs appear as spindle shaped cells that form CFU-Fs when whole 
BM is cultured on plastic. The multi-lineage potential of these colonies is examined 
after a period of culture in defined media that induces cell differentiation to fat, bone 
and cartilage. Historically, MSCs have therefore been defined by their properties in 
culture. Although MSCs cultured in vitro are probably a heterogeneous population, 
there is a consensus that they do not express haematopoietic markers. The Tissue 
Stem Cell Committee of the International Society for Cellular Therapy has proposed 
minimum criteria that define the human MSCs (hMSCs) (Dominici et al., 2006). The 
cell must be plastic adherent when cultured under standard conditions and express 
CD73, CD90 and CD105, without expression of CD45, CD34, CD14 or CD11b, 
CD79 or CD19 and HLA-DR surface markers. MSCs must also be capable of 
differentiating into osteoblasts, adipocytes and chondrocytes in vitro (Figure 1-2). 
While this statement clarified somewhat the cellular characteristics of hMSCs, the 
situation remains unclear for murine MSCs (mMSCs). Until recently specific surface 
markers for mMSCs have been lacking. Thus mMSCs are still defined by plastic 
adherence, spindle shaped morphology, and tri-lineage differentiation. 
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Figure 1-2 MSCs are characterised by surface marker expression and tri-lineage 
differentiation 
hMSC are defined by their spindle morphology when cultured on plastic. They 
typically express surface markers including CD73, CD90 and CD105 and do not 
express haematopoietic markers. Additional they must differentiate to fat, bone and 
cartilage in vitro. 
 
1.2 Tri-lineage differentiation under the microscope 
 
1.2.1 Embryological origin of adult MSCs 
 
To understand the genetic regulation and molecular signalling involved in tri-lineage 
differentiation it is necessary to briefly review some of the early stages in 
embryological development. Gastrulation occurs during early embryonic development 
(week 3) and results in the formation of the 3 germ layers known as endoderm, 
mesoderm and ectoderm. Organogenesis occurs within the germ layers facilitating 
foetal growth. The mesoderm gives rise to muscle, cartilage, bone, fat, blood vessels 
and connective tissue. The formation of mesoderm begins with the migration of a 
Adipocytes 
Osteoblasts 
Chondrocytes 
CD73 
CD105 
CD90 
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layer of cells between the primitive ectoderm and endoderm. This layer spreads along 
the anteroposterior and dorsoventral axes of the developing embryo to give rise to the 
axial, intermediate, lateral plate and paraxial mesoderm. The paraxial mesoderm 
segments into somites and generates the axial skeleton and muscles of the trunk 
(discussed in more detail below). The lateral plate mesoderm generates the skeleton 
and muscles of the limbs. The bones of the skull and face are ectodermal (neural 
crest) in origin. Caplan’s unique hypothesis suggests that each mesoderm-derived 
organ possesses adult ‘MSCs’ capable of regenerating and replacing cells during life. 
 
1.2.2 Adult cartilage progenitors 
 
Chondrogenesis describes the differentiation of embryonic mesenchyme to cartilage 
intermediate (Goldring et al., 2006). It is the earliest phase of skeletal development. 
The first phase of the process involves the recruitment of mesenchymal cells from 
neural crest (craniofacial development), paraxial mesoderm or somites (axial 
skeleton) and lateral plate mesoderm (limbs) (Olsen et al., 2000). Following their 
migration, the mesenchymal cells undergo a process of proliferation and condensation 
to form chondroprogenitor cells. This process requires defined interactions with 
overlying ectoderm and is controlled by a variety of differentiation factors and 
transcription factors highlighted in Figure 1-3.  Specific genes involved in early 
patterning include the homeobox transcription factors encoded by HoxA and HoxD. 
These factors are required for expression of fibroblast growth factor-8 (FGF-8) and 
Sonic Hedgehog (Kmita et al., 2005). Hoxd11 and Hoxd13 regulate the proliferation 
and condensation phase of chondrogenesis while expression of sonic hedgehog is 
maintained throughout (Tickle, 2003). Sonic hedgehog signalling occurs via its 
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receptor Patched and the trans-membrane protein Smoothened. The downstream 
targets of this signalling cascade are Gli3 and Plzf, that act in concert to establish 
correct spatial and temporal distribution of chondrocytes progenitors within the 
developing limb (Barna et al., 2005). Bone morphogenetic protein (BMP) receptor, 
type 1B is required to facilitate such signalling. BMP-2, -4, and -7 signalling regulates 
patterning of limb elements. 
 
 
 
Figure 1-3 The sequence of events in chondrogenesis during the development of 
long bones. 
This figure depicts the sequence of events involved in embryonic chondrogenesis. 
External cellular stimuli that influence differentiation (above arrows) and important 
patterning genes (below arrow) are shown. Extra-cellular matrix also exerts a 
marked effect on chondrogenesis at various time points (Goldring et al., 2006). 
 
 
Chondrocyte differentiation from progenitors requires deposition of cartilage matrix 
collagens including collagen II, IX, and XI and aggrecan. Sox-9 expression is 
required to promote genes encoding cartilage-specific matrix proteins including 
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Col2a1, Col11a2 and CD-RAP (Ng et al., 1997). Sox 6 and L-Sox 5 are expressed 
during chondrocytes differentiation and facilitate expression of Col9a1, aggrecan and 
Col2a1 (Lefebvre et al., 2001, Lefebvre et al., 1998). The expression of SOX protein 
depends on BMP signalling via BMPR1A and BMPR1B as described earlier (Yoon et 
al., 2005). BMP receptor signalling is mediated via the canonical SMAD pathway and 
involves Smads 1, 5 and 8 and inhibitory Smads 6 and 7 (Wan and Cao, 2005). 
Activated Smads, complex with Smad 4, translocate to the nucleus and modulate the 
promoter sites of target genes (Derynck and Zhang, 2003). An alternative signalling 
pathway during chondrogenesis occurs via TGF-β-activated kinase 1 which activates 
p38 and JNK cascades. The p38 pathway contributes to condensation and ERK1/2 
activation cross-reacts with BMP-2 induced signalling to promote chondrogenesis 
(Seghatoleslami et al., 2003). Runx2 is also expressed in cartilage sub-types destined 
to form bone. 
 
1.2.3 Fat progenitors 
 
Lineage tracing studies using PPARγ (a transcription factor essential for fat 
development) expression was initially used to identify adipocyte precursors (Tang et 
al., 2008). Isolation by FACS of PPARγ-GFP cells demonstrated high expression of 
the pre-adipocyte markers Pref1, GATA3, Wisp2, Smo and Gli3 (Tontonoz and 
Spiegelman, 2008). As a demonstration of their potency, transplantation of PPARγ-
GFP cells into nude mice resulted in the formation of ectopic GFP+ fat. These studies 
have also provided insight into the anatomical localisation of fat progenitors. Fat 
precursors reside within the vascular wall and express a variety of surface markers 
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including PDGFRβ, SMA and NG2 (Tang et al., 2008). Fat precursors have recently 
been isolated prospectively based on their surface marker expression: Lin-
/CD29+/CD34+/Sca-1+/CD24+. Transplantation of 500,000 Lin-/CD29+/CD34+/Sca-
1+/CD24+ GFP labelled into A-Zip lipodystrophic mice resulted normal GFP+ fat 
deposits (Rodeheffer et al., 2008). Additional pre-adipocyte markers include pre-
adipocyte factor 1 (Pref-1 or DLK-1) (Villena et al., 2002), type VI collagen alpha 2 
chain (COL6A2) (Ibrahimi et al., 1993) and the Wnt antagonists FRP2/SFRP2 (Hu et 
al., 1998). 
 
1.2.3.1 Transcriptional regulation  
 
The transcriptional cascade responsible for pre-adipocyte development and 
differentiation is being unravelled. There are 4 stages described including growth 
arrest, clonal expansion, early differentiation and terminal differentiation. PPARγ is 
considered a master regulator of this process and is particularly important for the 
terminal differentiation of adipocytes (Rosen and MacDougald, 2006). The C/EBP 
family consists of 5 related proteins (C/EBPα, C/EBPβ, C/EBPδ, C/EBPγ and 
CHOP). These factors are expressed sequentially during adipocyte differentiation. 
Additional genes that play a role of patterning and development of visceral adipose 
tissue include HoxA5, HoxA4, HoxC8, Glypican 4(Gpc4) and Nr2f1. Interestingly 
subcutaneous fat expresses higher levels of HoxA10, HoxC9, Twist1, Tbx15, Shox2 
and Sfpr2 (Gesta et al., 2007). These data might suggest a different origin of visceral 
and subcutaneous adipose tissue. 
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Figure 1-4 Signalling cascades involved in MSC differentiation to bone, muscle 
and fat. 
This cartoon illustrates the different signalling pathways that govern differentiation of 
MSCs. This figure was adapted from Gesta et al., 2007.  
 
1.2.3.2 Signalling during adipose tissue development 
 
The embryonic patterning and development of fat are controlled by signalling systems 
involving Nodal, BMP, Wnt and FGFs (Figure 1-4). Specifically, BMP-4 has been 
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shown to stimulate differentiation of MSCs to adipocytes (Tang et al., 2004).  
Conversely, BMP-2 and BMP-7 promote osteogenic and inhibit adipogenic 
differentiation (Wang et al., 1993). FGF 1, 10, 16 and 19 have been implicated in 
adipose development (Gesta et al., 2007). Activation of the Hedgehog pathway by its 
ligands inhibits adipogenic differentiation of MSCs. Blockade of the Hedgehog using 
a smoothened receptor antagonist stimulates adipogenesis (Suh et al., 2006). These 
effects appear to be mediated through intermediate protein signalling GATA-2 and 
GATA-3, which indirectly results in suppression of the PPARγ promoter region 
(Tong et al., 2005). Wnt signalling favours osteogenic and myogenic differentiation 
over adipogenic. Wnt3a pushes MSCs towards osteoblasts whereas blockade of β-
catenin promotes adipogenic differentiation (Kennell and MacDougald, 2005, Arango 
et al., 2005). 
 
1.2.4 Bone progenitors 
 
The Runx family is composed of 3 genes Runx1/Cbfa2/Pebp2αB, 
Runx2/Cbfa1/Pebp2αA, Runx3/Cbfa3/Pebp2αC. Runx2 deletion results in absence of 
intramembranous and endochondral ossification due to an absence of osteoblasts in 
mice (Komori et al., 1997). Osterix knockout mice have a complete lack of 
osteoblasts (Nakashima et al., 2002). Runx2 expression is under the control of Cbfβ 
and Gata1 (Yoshida et al., 2002). C/EBPβ, C/EBPδ, ETS1, Menin, Smad1 and Smad5 
enhance the transcriptional activity of Runx2. Deletions in the Wnt-β-catenin-Lrp5 
signalling axis also result in low bone mass, while gain in function experiments result 
in higher bone mass (Brault et al., 2001, Logan and Nusse, 2004). Indian hedgehog  is 
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crucial for osteoblasts differentiation and double knockout mice lack osteoblasts and 
endochondral ossification. The signalling events governing MSC differentiation to 
bone are illustrated below (Figure 1-5).  
 
 
 
Figure 1-5 Signalling mechanisms involved in MSC differentiation to bone. 
This cartoon illustrates the key signalling events that control MSC differentiation to 
bone. Figure adapted from Komori, 2006. 
 
 
Other transcription factors that regulate osteoblasts differentiation include Msx1 and 
Msx2. Their role is incompletely understood, however Msx1-/- and Msx2-/- mice have 
severely deficient cranial lobe formation (Satokata et al., 2000). It has been 
hypothesised that Msx2 promotes osteoblasts maturation (Ishii et al., 2003). Similarly 
Dlx5-/- and Dlx6-/- mice have abnormal craniofacial bone formation. Interestingly 
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these genes may also play a role in cartilage development (Robledo et al., 2002). 
Additional genes that influence osteoblast maturation include Twist-1, Ap1, Krox-20, 
SP3 and RSK2 (Komori, 2006). 
 
1.3 Traditional Isolation of murine MSCs 
 
Various methodologies have been employed to isolate a pure population of potent 
MSCs.  Traditional isolation technique relies on plastic adherence and prolonged 
culture to exclude contaminating cells.  Despite this MSC cultures are frequently 
contaminated by haematopoietic cells (Pittenger et al., 1999). Prolonged culture on 
plastic also reduces MSC differentiation and proliferative potential (Wagner et al., 
2008). This section describes in more detail MSC isolation methods and attempts to 
overcome these known limitations. 
 
1.3.1 Plastic adherence 
 
Phinney et al. carried out much of the early work isolating MSCs from mice. In an 
early publication they demonstrated wide variation in the abundance of MSCs 
obtained from the bone marrow of five commonly used inbred strains of mice 
(Phinney et al., 1999). Using the traditional CFU-F assay they found that highest and 
lowest yields were from BALB/c mice (3 ± 0.22 colonies per 106 total cells) and 
C57Bl/6 mice (0.3 ± 0.22 colonies per 106 total cells) respectively. Culturing cells for 
72 hours prior to the removal of non-adherent cells in untreated plastic wells yielded 
the most favourable growth kinetics. Addition of the growth factors (GFs) bFGF and 
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Platelet Derived Growth Factor-BB (PDGF-ΒΒ) promoted cell growth and inhibited 
osteogenic differentiation of cells. A major limitation of the isolation was cellular 
contamination, and using flow cytometry they demonstrate up to 80% of the plastic 
adherent cells were positive for lymphopoietic markers (CD11b and CD45). 
 
1.3.2 Frequent media change 
 
Cellular contamination can be reduced by employing frequent media changes after 
cell plating (Nadri et al., 2007). In brief, 3-4 hours after plating the BM, non-adherent 
cells were washed off and fresh media was replaced. This step was repeated every 8 
hours for 72 hours. The cells were then washed with phosphate buffer and fresh media 
was added every 3 - 4 days. When 90% confluent the cells were trypsinised by adding 
0.025% trypsin containing 0.02% EDTA for 2 minutes at room temperature. Only the 
lifted cells at this time were harvested and re-seeded in flasks. This method appeared 
to be superior to the traditional protocol in which media is changed every 3-4 days 
and generated 3-fold more CFU-Fs (70±3.4 versus 20±4.2). The authors also report 
enhanced osteogenic and adipogenic differentiation in cells isolated by frequent 
media change. The isolated MSCs were stained positively for CD44 and Thy1.2 
(CD90) and were negative for haematopoietic markers (Table 1-1). 
 
1.3.3 Varying cell density 
 
Cell density also appears to influence purity and potency of MSCs (Eslaminejad et al., 
2006). A low-density culture system yielded a more homogeneous population of 
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fibroblastic looking cells. Some cells from the high-density culture were positive for 
the haematopoietic and endothelial cell markers CD135, CD34, CD31 and VCAM. 
Furthermore, cells cultured at lower density also displayed more mineralisation in 
osteogenic culture when compared to high-density culture cells. Taken together the 
authors concluded that low-density culture systems yield a purer population of MSC 
like cells. 
 
1.3.4 Magnetic beads 
 
The use of magnetic beads conjugated to CD11b, CD34 and CD45 has been used to 
remove contaminating cells and obtain a pure population of MSCs (Baddoo et al., 
2003). MSCs isolated by this method uniformly expressed CD90, CD29, and CD81 
and variable levels of Sca-1, CD44 and CD106. MSCs did not express haematopoietic 
or endothelial markers. The purified cells also readily differentiated into fat, cartilage 
and bone in vitro. The in vivo osteogenic potential of the isolated cells was then 
assayed by inducing a fracture of the tibia and femur of female mice and infusing 
50,000 gender mismatched BrdU labelled cells into the resulting haematoma. 3 weeks 
post injury the mice were sacrificed and the authors demonstrated new bone 
formation the infused cells. 
 
Table 1-1 demonstrates the heterogeneity in the published isolation methods and the 
phenotype of isolated MSCs. There is significant variation in the methodology used to 
isolate murine MSCs in the listed studies. There is no clear consensus on a panel of 
surface markers that define these cells. Additionally, many of these papers report 
cellular contamination of isolated MSC populations. Furthermore, the differentiation 
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potential and proliferative ability of traditionally isolated MSCs gradually diminishes 
as the cells mature (Digirolamo et al., 1999). Finally, prolonged culture on plastic 
changes the surface marker expression of MSCs, making identification of specific 
makers difficult (Quirici et al., 2002, Boiret et al., 2005). For these reasons, little 
information exists concerning the in vivo identity and biological function of MSCs 
within the BM niche.  
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Table 1-1 Summary of studies describing murine MSC isolation. 
The table highlights the variability in utilised techniques and surface marker 
expression of isolated cells. 
 
 
Paper Strain Markers Technique 
Baddoo et al. 
(Baddoo et al., 
2003) 
FVB/N + 
BALB/c 
CD 9,29,44,81 
Variable Sca-1, CD44,106 
Immunodepletion with 
beads 
FGF2 to augment growth 
Meirelles LS et al. 
(Meirelles Lda and 
Nardi, 2003) 
Bl/6 + 
BALBc 
CD29,44,49e 
Moderate Sca-1 
Plastic adherence 
Multiple passages 
Jiang et al. (Jiang 
et al., 2002) 
Bl/6 CD13, SSEA-1 
Weak Sca-1, Flt-1 
Immunodepletion 
GFs: EGF, PDGF-BB and 
LIF 
Nadri  et al. (Nadri 
et al., 2007) 
BALB/c CD44, 90, Sca-1 
 
Frequent media changes 
Peister et al. 
(Peister et al., 
2004) 
Bl/6, 
BALBc,  
FVB/N, 
DBA1 
CD34/Sca-1 
 
Plastic adherence 
 
 
 
1.4 Controversy in the MSC field 
 
1.4.1 Are MSCs stem cells? 
 
The term MSC has generated controversy. The classic definition of a stem cell 
requires that it possess unlimited self-renewal ability and plasticity. Experimentally, 
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serial transplantation experiments demonstrating that infused stem cells give rise to 
terminally differentiated daughter tissue cells while maintaining their naive phenotype 
provide evidence of stemness. Historically such experiments have not been performed 
with MSCs (Bianco et al., 2008) and many remain sceptical if the title of ‘MSC’ is a 
proper and correct term for the cell it now routinely describes. 
 
1.4.2 Are MSCs fibroblasts? 
 
The similarities between MSCs and fibroblasts are manifold (Haniffa et al., 2009). To 
start with fibroblasts and MSCs share surface marker expression including CD73 and 
CD90. By definition fibroblasts also lack expression of haematopoietic markers 
CD14, CD34 and CD45 (Ishii et al., 2005). Both fibroblasts and MSCs can be 
differentiated into bone, cartilage and fat in vitro. The immunosuppressive effects of 
MSCs are also shared by fibroblasts and many of the underlying mechanisms are 
similar (including production of soluble factors including prostaglandin E2 (PGE2) 
and indolamine 2,3-dioxygenase (IDO)) (Lysy et al., 2007). These overlapping 
features cast doubt on the novelty of much MSC literature and have led some to 
question their existence. 
 
1.4.3 Are cultured MSCs transformed cells? 
 
There are growing concerns that much of the mMSC literature is based on cells that 
have transformed during prolonged in vitro culture. One of the earliest descriptions of 
this occurred unexpectedly during a series of experiments examining the fate of 
transfused MSCs (Tolar et al., 2007). Several weeks (between week 12-18) after MSC 
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(passage 9) infusion the mice started developing tumours. The cancers were donor-
cell derived and identified as sarcomas. Further investigation demonstrated that 
chromosomal atypia readily occurred in cultured mMSCs as early as passage 3 (Zhou 
et al., 2006). Once again transfusion of these cell resulted in the formation of sarcoma 
in nude and SCID mice. The exact factors that cause freshly isolated cells to 
transform in culture are unclear. Several mechanisms including accumulated 
chromosomal abnormalities, gradual elevation in telomerase activity, and increased c-
myc expression have all been hypothesised (Miura et al., 2006). More recently over 
expression of H19 (a downstream target of c-myc) has been implicated in malignant 
transformation of murine MSCs (Shoshani et al., 2012). In any case these data have 
cast a shadow on much of the mMSC field and raised concern about the therapeutic 
use of hMSCs for clinical indications. 
 
1.5 Identification of specific murine MSC markers 
 
1.5.1 Defining the need for selective markers 
 
As described previously there are numerous and significant limitations to isolating 
MSCs by plastic adherence. Exciting progress has recently been made in the 
identification of specific mMSC and hMSC surface markers allowing their 
prospective isolation by flow cytometry. Prospective MSC isolation has several 
advantages compared with the traditional method by plastic adherence  (Figure 1-6). 
Firstly, the isolated population is likely to be more potent as it avoids the prolonged 
culture period routinely required to select MSC like cells from whole BM. Secondly, 
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haematopoietic cells can be excluded by using a gating strategy based on lineage 
markers. Finally, the biology of naive MSCs (unchanged by plastic adherence) can be 
interrogated immediately following isolation.  
 
 
 
Figure 1-6 Comparison of prospective and traditional MSC isolation techniques. 
This figure illustrates the different methods for isolating MSCs from tissue. MSCs 
isolated by plastic adherence frequently contain contaminating cells. The isolated 
population are heterogeneous and lack specific surface marker expression. In 
contrast the prospective isolation of MSCs using defined surface markers over comes 
these issues and yields a purer population (Mabuchi et al., 2013). 
 
1.5.2 PDGFRα and Sca-1 identify murine MSCs  
 
The identification of specific MSC markers began with the observation that 
haematopoietic and mesenchymal lineage cells are derived from individual lineage-
specific stem cells (Koide et al., 2007). Based on the hypothesis that MSCs most 
likely resided in the endosteum a detailed screening of candidate surface marked was 
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performed in BM and collagenase digested bone. The surface markers PDGFRα and 
Sca-1 were significantly enriched in the digested fraction and dual positive cells were 
isolated (Houlihan et al., 2012, Morikawa et al., 2009a). PDGFRα+Sca-1+ (PαS) cells 
fulfil the basic requirements of the definition of MSCs. They are capable of potent 
self-renewal and differentiate into osteoblasts, chondrocytes and adipocytes under 
appropriate conditions in vitro (Morikawa et al., 2009a). PαS cells proliferate rapidly 
when cultured on plastic, yielding more than 107 cells from the original 5000 cells 
seeded with a doubling time of 50.6 hours. The CFU-F frequency of PαS cells is 
120,000-fold higher compared to unfractionated BM mononuclear cells. PαS cells 
reside in the perivascular space adjacent to vascular smooth muscle. They express 
Angiopoietin-1 and CXCL12 suggesting that MSCs may play a physiological role in 
the haematopoietic niche. Transplantation experiments in which 1x104 freshly 
isolated PαS cells were intravenously injected into lethally irradiated recipient mice 
demonstrate the stemness of PαS cells. The infused cells homed to their niche in the 
BM expressing niche factors (Angiopoietin-1 and CXCL12) and also differentiated 
into osteoblasts and adipocytes in vivo. Sixteen weeks following the transplantation 
the mice were sacrificed and the isolated PαS cells were capable of forming CFU-Fs 
and tri-lineage differentiation. The identification of PDGFRα as a selective mMSC 
marker supports evidence presented in a series of developmental studies 
demonstrating that a proportion of adult BM MSCs might have a developmental 
origin in the neural crest (Morikawa et al., 2009b, Takashima et al., 2007). 
 
1.5.3 Nestin identifies murine MSCs 
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More recently the neural marker, Nestin, has successfully been used to identify and 
prospectively isolate murine MSCs (Mendez-Ferrer et al., 2010). Nestin+ cells 
represent a small subset of non-haematopoietic stromal cells in BM. These cells are 
anatomically located in the perivascular space, in close proximity to 
catecholaminergic nerve fibres and haemopoiteic stem cells (HSCs). In keeping with 
PαS MSCs, the Nestin+ cells express haematopoietic niche factors and are capable of 
tri-lineage differentiation in vitro and in vivo. Nestin+ MSCs also play an important 
functional role in maintaining the HSC niche. Following depletion of Nestin+ MSCs 
there is a dramatic reduction in the number and function of HSCs. Additionally, 
homing of transplanted HSCs back to their BM niche was significantly impaired 
following irradiation. These data suggest an important role of MSCs in the 
maintenance of the HSC niche. 
 
These are the first studies to identify specific markers that can be used for prospective 
isolation and in vivo localization of mMSCs. PαS and Nestin+ MSCs have been 
assayed in the traditional stem cell assays (including serial transplantation assays and 
clonogenic assays) and their properties of self-renewal and potency confirmed. We 
have also gained a valuable insight into the importance of these cells in maintaining 
the HSCs niche. It is not entirely clear if Nestin+ cells are the same as PαS cells. We 
know that Nestin+ cells largely overlap the PDGFRα+CD51+ population however, this 
population contains Sca-1 positive and negative cells (Pinho et al., 2013). These data 
suggest that the Nestin+ population is comprised of PαS and PDGFRα+ cells. 
Interestingly, investigations using Nestin-Cherry and Nestin-GFP double transgenic 
mice demonstrates Nestin-Cherry expression around larger vessels but not around 
sinusoids, while Nestin-GFP expression was detected around both (Ding et al., 2012). 
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Thus, different Nestin transgenes seem to be expressed by different subpopulations of 
perivascular stromal cells. Nonetheless, the identification and prospective isolation of 
PαS and Nestin+ cells will provide an invaluable substrate for on going research into 
biological function, hierarchical structure and therapeutic potential of MSCs. 
 
1.6 Identification of specific hMSCs markers 	  
1.6.1 Defining the need for selective markers 
 
Numerous putative hMSCs surface markers including CD49a (Boiret et al., 2005), 
CD73 (Pittenger et al., 1999), CD105 (Aslan et al., 2006), CD106 (Gronthos et al., 
2003), CD271 (Quirici et al., 2002), MSCA-1 (Battula et al., 2009), Stro-1 (Simmons 
and Torok-Storb, 1991) and SSEA4 (Gang et al., 2007) have been identified. These 
markers have been used singly or in combination to enrich for CFU-F in human BM 
and avoid cellular contamination. Unfortunately, many of these markers are widely 
expressed in stromal cells and lack specificity for MSCs, contributing to the 
significant heterogeneity seen among clonogenic colonies from single isolations. The 
lack of specific markers has hindered attempts to uncover the true identity and 
function of MSCs in vivo. Additionally, as in the case of mMSCs the traditional 
isolation of hMSCs by plastic adherence reduces the differentiation potential and 
proliferative ability of the CFU-Fs as the cells senesce reducing their therapeutic 
potential. (Kim et al., 2009). The prospective isolation and culture of such cells (with 
or without manipulation) may facilitate the development of safer and more effective 
clinical therapies in the future. 
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1.6.2 CD146 identifies hMSCs in vivo 
 
CD146 has provided valuable insight into the in vivo localization and function of 
hMSCs (Sacchetti et al., 2007). It marks an adventitial reticular cell that resides in the 
endothelial space in human BM. These cells express typical stromal markers (CD105, 
CD49a, CD63, CD90, CD140b) and are capable of robust tri-lineage differentiation. 
Their physiological function was demonstrated by subcutaneous transplantation of 
CD146+ clonogenic cells on a scaffold into immunodeficient mice. The CD146+ 
MSCs supported formation of bony ossicles, sinusoidal vasculature and finally 
established a functioning haematopoietic microenvironment. Immunohistochemical 
analysis demonstrated a small proportion of the infused cells in the murine HSC 
niche. These cells expressed supporting factors including Ang-1. The transplanted 
CD146+ MSCs were re-isolated, cultured and formed CFU-Fs capable of tri-lineage 
differentiation demonstrating the self-renewal potency of these cells.  Traditionally, 
MSCs were thought to reside only within the BM as the stromal counterpart to HSCs. 
Interestingly, the utility of CD146 as a prospective marker of hMSCs is not limited to 
adult BM. Crisan et al. used immunohistochemistry to examine various different 
tissue types including both adult and foetal human skeletal muscle, pancreas, adipose 
tissue, and placenta and identified CD146, NG2 and PDGFRα as prospective pericyte 
markers (Crisan et al., 2008). A pure population of pericytes was prospectively 
isolated from each tissue type by flow cytometry. These cells were then differentiated 
into muscle, bone, fat and cartilage using the standard assays used for MSCs. 
Furthermore, isolated pericytes expressed typical stromal markers including CD73, 
CD90 and CD105. These data clearly identify CD146 as a specific marker of 
mesenchymal progenitor cells in a wide range of organs. 
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1.6.3 CD271 identifies hMSCs 
 
CD271 is also known as low affinity nerve growth factor receptor (LNGFR). Isolation 
of CD271+ MSCs enriches for CFU-F potential and the growth kinetics of this 
subpopulation greatly exceeds that of plastic adherent cells (Quirici et al., 2002). 
Additionally the growth and differentiation potential CD271+ cells exceeded that of 
isolated populations expressing CD146, CD106 and CD166 respectively (Jones and 
McGonagle, 2008). The therapeutic potency of this cell population has also been 
confirmed. CD271+ MSCs are more efficient at inhibiting the proliferation of 
allogeneic T- lymphocytes in mixed lymphocyte reaction assays compared to cells 
isolated by plastic adherence. Furthermore, in an interesting assay of therapeutic 
function CD271+ MSCs greatly augmented CD133+ haematopoietic engraftment 
following sub-lethal irradiation (Kuci et al., 2010). A recent study demonstrated that 
CFU-Fs were highly enriched in both lin-/CD271+/CD146+ and lin-/CD271+/CD146low 
stem cell fractions. The authors demonstrate that CD146 is up regulated in normoxia 
and down regulated in hypoxia. This information is of physiological significance with 
CD146/CD271+ reticular cells located in the perivascular space whereas CD271+ 
MSCs were located adjacent to bone. Interestingly, in both locations the MSCs were 
flanked by CD34+ haemopoiteic progenitor stem cells (Tormin et al., 2011). 
 
1.7 Physiological role of MSCs 
 
1.7.1 Hypothesised role of MSCs 
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The physiological role proposed for MSCs are manifold.  The best characterised 
includes the provision of a suitable microenvironment for haematopoiesis 
(Friedenstein et al., 1974, Calvi et al., 2003). Following transplantation into NOD-
SCID, hMSCs differentiate into pericytes, myofibroblasts, marrow stromal cells, 
osteocytes, osteoblasts and endothelial cells, all of which are necessary for functional 
haematopoiesis to occur (Muguruma et al., 2006). MSCs also play an important role 
in wound healing and provide a constant source of osteogenic and chondrogenic 
precursors for bone development and growth (Caplan, 1991). There is accumulating 
evidence that MSCs exert a profound regulatory effect on our immune system 
(Uccelli et al., 2008). This property has obvious potential for the treatment of a 
variety of autoimmune and inflammatory diseases. 
 
 
1.7.2 MSCs support haematopoiesis 
 
The HSC niche provides a specialised microenvironment that promotes stem cell 
maintenance and function. Several cell types including osteoblasts, endothelial cells, 
and adventitial reticular cells to the niche function are thought to maintain it (Wilson 
and Trumpp, 2006). A contribution of MSCs to niche function has been proposed, 
however until recently this has remained unproven. The observation by Morikawa et 
al. that PαS cells reside in the HSC niche (perivascular space adjacent to HSCs), and 
express niche factors (Angiopoietin-1 and CXCL12) supports this hypothesis 
(Morikawa et al., 2009a). Indeed, Nestin+ MSCs appear to play a critical role not only 
the maintenance of HSCs within the niche, but also the homing of transplanted HSCs 
back to the BM. Interestingly, a significant proportion of perivascular PDGFRα+ cells 
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express Nestin and the exact contribution of each subpopulation to the niche is not 
entirely clear. Recent data suggest that non-myelinating Schwann cells play an 
important role in maintaining the HSC niche via modulation of TGF-β (Yamazaki et 
al., 2011). Interestingly these cells are Nestin+ generating some controversy in the 
field. Recently, Morrison et al. confirmed the importance of perivascular cells in 
maintaining the HSC niche through production of stem cell factor (Ding et al., 2012). 
In summary, HSC frequency and function were not affected when stem cell factor 
was conditionally deleted from hematopoietic cells, osteoblasts, Nestin+ cells. 
However, HSCs were depleted from BM when stem cell factor was deleted from 
endothelial cells or leptin receptor expressing perivascular stromal cells (also positive 
for PDGFRα, PDGFRβ, CXCL12 and alkaline phosphatase expression). Clearly 
much remains unknown in this complex microenvironment, however the data suggest 
that one or more MSCs subtypes contribute to HSC niche homeostasis. 
 
1.8 Therapeutic potential of MSCs 
 
1.8.1 MSCs hold significant therapeutic promise 
 
MSCs are defined as non-haematopoietic, plastic adherent self-renewing cells that are 
capable of in vitro tri-lineage differentiation to fat, bone and cartilage (Pittenger et al., 
1999).  Additional plasticity of MSCs has been suggested by experiments 
demonstrating their in vitro differentiation to myocytes, neuron-like cells and 
hepatocytes (Drost et al., 2009, Galvin and Jones, 2002, Tao et al., 2009). These 
multipotent cells are found in various foetal and adult human tissues, including BM, 
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umbilical cord blood, liver and term placenta (Battula et al., 2007, Erices et al., 2000, 
Yen et al., 2005, Zvaifler et al., 2000). MSCs are multipotent and have low 
immunogenicity, and therefore, are considered as potential candidates for a variety of 
clinical applications (Jung et al., 2012c, Stappenbeck and Miyoshi, 2009). There are 
currently 276 studies registered on ‘ClinicalTrials.gov’ investigating MSCs in a 
variety of different diseases. Examples of such trials include cartilage reconstitution 
and the treatment of rheumatoid arthritis, acute osteochondral fractures, spinal disk 
injuries, and inherited diseases such as osteogenesis imperfecta (OI) (Guillot et al., 
2008).  
 
1.8.2 Regenerative therapy 
 
1.8.2.1 Cartilage 
 
An amazing demonstration of the regenerative potential of hMSCs was published as a 
case report in the Lancet in 2008 (Macchiarini et al., 2008). Claudia (30 years of age) 
suffered from pulmonary TB and following it’s eradication developed stricturing 
tracheitis. Over time the stricturing of her left main bronchus progressed such that she 
developed significant hypoxia from under ventilation of her left lung. Repeated 
interventions including surgical resection and stenting made little difference. In 2008, 
a decision to carry out a cadaveric tracheal transplant was made. In brief, the trachea 
from a matched donor was decellularised. Epithelial cells and MSCs were then 
isolated from the patient’s endobronchial and BM biopsies respectively. The 
expanded epithelial cells were then painted onto the inner surface of the decellularised 
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graft, while chondrocytes derived from BM MSCs were coated on the outer surface. 
Transplantation of the graft produced dramatic improvements in Claudia’s respiratory 
function. 3 months following the procedure the graft had developed it’s own blood 
supple from vascular co-laterals. Over the past 5 years Claudia has had set backs with 
recurrent graft stenosis. This has been treated successfully with stents and she 
continues to live a normal life following her transplant. 
 
1.8.2.2 Bone Regeneration 
 
OI is a rare inherited condition of bone metabolism (Sillence et al., 1979). Affected 
patients develop profound osteopenia, short stature and have recurrent non-traumatic 
fractures. Bone biopsy reveals a marked paucity of osteoblasts accompanied by a lack 
of collagen type 1 and structural protein. There is no proven effective treatment for 
this condition (Glorieux et al., 1998). In 1999, a pioneering study was carried out in 
which 3 children with OI received matched BM transplants as treatment for their 
condition. Serial biopsies over the first year following therapy demonstrated greatly 
increased numbers of donor osteoblasts (4 fold increase compared to the pre-treatment 
biopsy). In addition the bone was of superior quality with increased mineralisation 
(range 45 - 77% increase).  2 of the treated children had an 80 – 90% reduction in 
their fracture rates and this was accompanied by increased growth (Figure1-7). 
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Figure 1-7 Growth and bone mineral content in each patient before and after 
therapy is shown. 
This figure illustrates the growth rates and bone mineral content of 3 patients with OI 
before and after BM transplantation. Growth was measured over a 6-month period 
before and after treatment. Bone mineral content was estimated 100 days following 
BM transplant. The figure illustrates the striking gains in bone quality and growth 
resulting from the treatment (Horwitz et al., 2001). 
 
These data provide compelling evidence that MSCs within the donor transplant 
migrate back to their niche in the BM and differentiate to functional osteoblasts 
reversing the genetic phenotype of OI. Prolonged follow up (> 2 years) demonstrated 
that although growth of the children slowed, bone mineralisation continued to 
increase (Horwitz et al., 2001).  
 
1.9 Strategies to optimise the regenerative potential of MSCs 
 
Despite the large number of trials on going worldwide there are several unanswered 
questions surrounding the use of MSCs in humans including: 
1. What is the best MSC isolation method?  
A B
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2. Do culture conditions including the addition of GFs influence regenerative or 
immunosuppressive potential?  
3. Does the culture flask material impact on MSC therapeutic potential?  
This section of the thesis sets about reviewing the literature to address as far as 
possible these pressing questions. 
  
1.9.1 What is the best MSC isolation method? 
 
I have discussed previously recent advances in both mMSC and hMSC isolation 
methods. A large number of selective markers for the isolation of hMSCs have been 
proposed. Of these CD146, CD271, Stro-1, VCAM-1, MSCA-1 used alone or in 
combination appear to be the most selective for hMSC isolation.  For example Stro-
1+VCAM-1+ cells are 5000 fold enriched for CFU-F compared to whole BM 
(Gronthos et al., 2003). Using serial dilution 1 in every 3 Stro-1+VCAM-1+ cells yield 
viable colonies.    Differing combinations of MSCA-1, CD271, and CD56 have also 
been used to isolate a pure potent MSC population (Battula et al., 2009). MSCA-1 
largely overlaps CD271 bright cells and the CD271+/CD56+ fraction produces 
approximately 38 colonies per 500 seeded cells.  CD271 has also been used in 
combination with CD146 and CD271+/CD146+ cells produce approximately 4 
colonies per 100 seeded cells (Tormin et al., 2011). In addition, MSCs selected using 
these marker combinations have enhanced tri-lineage differentiation compared to 
conventional MSCs. 
 
A recent publication reports an improved prospective clonal isolation technique. The 
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combination of three cell surface markers, LNGFR, Thy-1 and VCAM-1, selects 
highly enriched clonogenic MSCs (one out of three isolated cells) (Mabuchi et al., 
2013; In Press). CD271+/CD90+ MSCs have higher CFU- F potential compared to 
CD271+/CD140+ and CD271+/CD146+ populations. Transplanted CD271+/CD90+ 
MSCs engraft the BM of recipient mice and are capable of tri-lineage differentiation 
in vitro following re-isolation 3 months after infusion. The clonal characterization of 
LNGFR+/Thy-1+ cells demonstrated significant cellular heterogeneity between the 
clones.  Colonies were designated slowly-, moderately- or rapidly- expanding clones 
(SECs, MECs and RECs respectively) based of their growth following single cell 
sorting. RECs exhibited robust multi-lineage differentiation and self-renewal potency, 
while the others tended to acquire cellular senescence via p16INK4a and exhibited 
frequent genomic errors.  Furthermore, RECs exhibited unique expression of VCAM-
1 and higher cellular motility compared to other clones.  Collectively, the marker 
combination LNGFR+/Thy-1+/Vcam-1high+ (LTVhi) identifies RECs and can be used 
prospectively to isolate the most potent and genetically stable MSCs described to 
date. 
 
There is no clear consensus on which MSCs should be used for clinical therapy. 
Intuitively, a potent population of MSCs that can be easily expanded in vitro would 
suit best for regenerative therapy. For inflammatory disease, the choice is less clear. 
While bone and cartilage are considered to be immune-privileged sites, fat is a pro-
inflammatory tissue. As MSCs have the potential to differentiate down all 3 lineages 
to seems plausible that osteogenic or chondrogenic primed MSCs may be more 
immunosuppressive than fat primed or naive MSCs. To my knowledge this 
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hypothesis has not been tested. Nonetheless, if this is the case, defining conditions 
that lineage restrict or prime the most potent population of MSCs down required 
lineages is appropriate. 
 
1.9.2 Ex-vivo MSC expansion 
 
1.9.2.1 Growth factors  
 
Despite the large number of trials on going worldwide there is little or no consensus 
on how clinical grade MSCs should be isolated or cultured. Ex-vivo expansion (prior 
to infusion) induces cellular senescence and reduced MSC plasticity (Wagner et al., 
2008). Supplementing culture media with GFs is now common to avoid these 
complications. There are currently 3 commercially available media for the expansion 
of MSCs including Mesencult-XF (STEMCELL Technologies), StemPro MSC SFM 
Zeno-Free (Invitrogen) and MSCGM-CD (Lonza). Many of these formulations are 
supplemented with GFs (FGF, PDGF-BB and TGF-β) and are optimised for the 
expansion of MSCs and multi-lineage differentiation potential. For example one 
media, PPRF-msc6, is supplemented with all 3 GFs (Jung et al., 2012a, Jung et al., 
2010). There are however little data examining the impact of GF supplemented media 
on the regenerative and immunosuppressive potential of MSCs. Analysis of the 
pathways involved in tri-lineage differentiation of MSCs reveals an important role for 
PDGF, FGF and TGF-β signalling pathways (Ng et al., 2008). Specifically, PDGF 
signalling was active during adipogenesis and chondrogenesis, TGF-β signalling was 
active during chondrogenesis, and FGF signalling was active during osteogenesis, 
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adipogenesis and chondrogenesis. Inhibition of any of the three pathways resulted in 
an altered differentiation potential and increased population doubling times. These 
data suggest that many of the commercial MSC media most likely lineage prime or 
restrict immature MSCs potentially altering their therapeutic potential. Further data 
are necessary to clarify these complex issues. 
 
1.9.2.2 Matrix stiffness 
 
The direct effects of matrix stiffness on MSC differentiation is interesting. In an 
elegant investigation, Engler et al. utilised a gel system, where controlled cross-
linking reactions, predicted the elastic modulus (or stiffness) of the gel (Engler et al., 
2006). hMSCs plated on gels of increasing stiffness (1, 11, 34 kPa respectively) were 
morphologically different and expressed gene patterns in keeping with neuronal, 
myogenic and osteogenic differentiation respectively. Additionally, following 1 week 
of culture on soft, moderate and stiff matrix, MSCs expressed key tissue proteins 
involved in neuronal (P-NFH), muscle (Myo-D) and bone (CBFα1) (Figure 1-8). 
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Figure 1-8 Elasticity-directed protein expression in MSCs cultured on variable 
stiffness substrates. 
hMSCs were cultured on substrates with variable stiffness. Cells cultured on the stiff, 
intermediate and soft matrix expressed osteogenic (CBFα1), myogenic (MyoD) and 
neurogenic (P-NFH) differentiation markers respectively.  The values are normalised 
using expression of the relevant markers in primary myoblast, osteoblast and 
neuronal cell lines (Engler et al., 2006). 
 
Matrix stiffness influences MSC fate by signalling through surface 
mechanotransducers that translate environmental stimuli into cytoskeletal responses. 
The non-muscle myosin type II proteins function as mechanotransducers on a wide 
variety of cells (Kim et al., 2005). A potent inhibitor of this protein family, 
Blebistatin, effectively inhibited the effects of matrix stiffness on MSCs. 
 
Recent data confirms the profound influence of matrix stiffness on MSCs cultured in 
3D matrix (Pek et al., 2010). In brief, MSCs cultured in thixotropic gel of variable 
rigidity have different lineage specifications. Specifically, increased expression of 
neurogenic (ENO2), myogenic (MYOG) and Osteogenic (Runx2, OC) transcription 
factors were seen in MSCs when cultures in gels with tau(y) of 7, 25 and 75Pa 
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respectively. The RGD active tri-peptide site is a key binding site in ligands that bind 
integrins (including all 5 αV integrins) (Humphries et al., 2006). MSCs embedded in 
RGD enriched gels have enhanced proliferation and differentiation suggesting a role 
of integrins in mechanotransduction. These observations have been confirmed more 
recently with the demonstration that α5 and αV integrins cluster in response matrix 
stiffness to bind complementary RGD motifs (Huebsch et al., 2010).     
 
1.9.2.3 Culture in hypoxia 
 
Hypoxic preconditioning of MSCs has been investigated in detail (Das et al., 2010). 
MSC cultured at low oxygen tension have accelerated cell division and augmented 
cell differentiation to both bone and fat (Ren et al., 2006, Hung et al., 2012). In 
addition, enhanced MSC migration and survival is seen (Liu et al., 2010, Annabi et 
al., 2003). HIF-1α and AKT dependant up regulation of CXCR4 and CXCR7 may 
underlie these effects. Therapeutically, MSCs cultured in hypoxic conditions produce 
increased amounts of pro-angiogenic and pro-survival factors and in a model of 
cardiac infarction produce superior angiogenesis and functional benefit compared 
with control MSC infusions (Hu et al., 2008).  
 
1.9.3 Enhancing tissue specific MSC migration 
 
Targeted cells therapy requires that the infused cells migrate specifically to diseased 
tissue to enhance therapeutic efficacy and minimise off target side-effects. Plastic 
adherent MSCs have poor homing capability (Rombouts and Ploemacher, 2003). It is 
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therefore of therapeutic interest to modify MSCs to enhance organ specific homing. 
For example promoting MSC migration to bone is therefore an attractive option for 
treating diseases such as OI. MSCs do not however express ligands to E-selectin, 
which is constitutively expressed on the microvasculature of BM capillaries, and is 
important for haematopoietic cell homing. Sackstein and colleagues report ex-vivo 
glycosyltransferase-programmed stereo-substitution of CD44 on hMSCs converting it 
to haematopoietic binding E-selectin/L-selectin ligand (HCELL). Intra-vital 
microscopy demonstrates that the HCELL modification augments MSC migration to 
bone by 100 fold. The initial interaction between HCELL and complimentary 
selectins, triggers VLA-4/VCAM-1 binding between endothelium and hMSCs, that 
ultimately leads to arrest and transmigration (Thankamony and Sackstein, 2011). 
Integrins play an important role in hMSC binding to hepatic sinusoidal endothelial 
cells (HSEC). In an elegant study carried out by Aldridge et al show that rolling of 
hMSCs on HSEC is regulated by CD29/VCAM-1. CD29/CD44 interactions with 
VCAM-1, fibronectin, and hyaluronan on HSECs determine firm adhesion in vitro 
(Aldridge et al., 2012). In the CCL4 induced model of liver injury, hMSC migration 
was reduced following antibody blockade of CD29 and CD44 demonstrating the 
functional relevance of these findings. 
 
1.10 The Immunosuppressive potential of MSCs 
 
1.10.1 MSC suppress inflammation 
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The immunosuppressive potential of MSCs was highlighted by Bartholomew et al. 
who showed that MSC infusion prolonged skin-graft survival in primates 
(Bartholomew et al., 2002). Subsequently, MSCs have been shown to have a 
beneficial immunosuppressive effect in a variety of inflammatory and immune 
mediated disease models including encephalitis, stroke, diabetes mellitus, renal 
disease, rheumatoid arthritis, lung fibrosis, cardiac injury in rodents (Augello et al., 
2007, Lee et al., 2006, Li et al., 2002, Orlic et al., 2001, Ortiz et al., 2007, Zappia et 
al., 2005). These positive results have led to the use of MSCs in human clinical trials 
in a variety of different settings. Before describing the myriad of mechanisms by 
which MSCs exert immunosuppressive effects it is necessary to describe individual 
components of the immune system. 
 
1.10.2 Function and structure of the immune system 
 
The human immune system protects the host from infectious diseases including 
bacteria, viruses, fungi and parasites. It is highly evolved to identify and kill 
pathogens without causing self-harm. The immune system may be divided into two 
distinct arms (Chaplin, 2006). The innate immune system is comprised of neutrophils, 
macrophages, monocytes, cytokines and acute phase proteins. These cells recognise 
molecular patterns specific to microbes and provide immediate host defence against 
pathogen. In contrast the adaptive immune system is mediated by T- and B- cells and 
is highly specific due to the presence of highly conserved antigen receptors on their 
surface. For effective immunity however there has be close interaction between cells 
of the innate and adaptive immune systems. This frequently involves antigen 
presentation by innate immune cells to complimentary T- and B- cells. Lymph nodes 
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are specially adapted immune organs that facilitate and promote such interactions and 
may be considered functional organ of immunity. The next section describes how 
these immune cell interactions occur and how stromal subsets (including 
mesenchymal cells) within lymph nodes are key orchestrators of this process. 
 
1.10.3 Antigen presentation and recognition by T-cells 
 
Naïve T cells (following exit from the thymus and BM) move in a continuous fashion 
between lymph nodes and other secondary lymphoid structures in search of their 
respective antigen. These cells recognise antigen only when presented with self-
structures termed antigenic-peptide binding MHC molecules. Antigen can be loaded 
onto MHC in two ways (Parkin and Cohen, 2001). Firstly the antigen may be 
processed within a tissue cell (as occurs during viral infection) and then presented on 
the surface of the cell in association with MHC class I. Alternatively, exogenous 
antigen is endocytosed by antigen presenting cells (APCs), which may then be 
processed and presented in association with MHC class II molecules. CD4 
lymphocytes respond to antigen presented with MHC class II, while CD8 cells 
respond to co-stimulation with MHC class I. CD8 responses are therefore generally 
targeted towards infected or transformed host cells while CD4 activation occurs in 
response to microbial infection. 
 
1.10.4 T-cell receptor signalling 
 
Antigen binding to the T-cell receptor embedded in the CD3 complex results in 
phosphorylation of tyrosine residues and activation of a second messenger cascade 
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resulting in gene transcription and cell proliferation (Brownlie and Zamoyska, 2013). 
Lymphocyte activation requires the activation of co-receptors including CD80, CD86 
and CD40 that bind CD28, CTLA-4 and CD40 ligand respectively. T cell receptor 
activation in the absence of co-stimulation results in cell anergy or apoptosis.  Once 
activated single lymphocytes can undergo up to 10 population doublings. The 
lymphocyte clone acquires the necessary receptors to exit the lymph node and traffic 
to the disease where they will mount a cytotoxic attack or initiate an inflammatory 
response. Some T cells will remain in the node as memory cells and will mount an 
accelerated response following re-exposure to the same antigen. 
 
1.10.5 Effector T cells (CD4+ T helper and cytotoxic T cells) 
 
CD4+ T helper (Th) cells effectively organise and activate other cells of the immune 
system in response to antigen. Precursor Th0 cells (following appropriate stimulation) 
differentiate into Th1 or Th2 cells. Th1 responses essentially control intracellular 
pathogen infection. They are characterised by interlukin-2 and Interferon-γ production 
which serves to increase the proliferation and activation of lymphocytes and 
macrophages (Sallusto et al., 1999). Interferon-γ also stimulates Th0 precursor cells to 
differentiate into Th1 cells and inhibits Th2 differentiation. Activated macrophages 
produce IL-12 which also promotes a Th1 response. Th2 response is characterised by 
IL-4, IL-5, IL-6 and IL-10 production, which favour antibody mediated responses and 
have been implicated in allergic disease. IL-4 favours IgE production by B cells and 
also feeds back to support Th2 and inhibit Th1 responses. IL-5 promotes the growth 
of eosinophils. 
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1.10.6 Cytotoxic T (CD8+) cells  
 
Following activation, cytotoxic T cells kill host cells that express specific antigen 
(Barry and Bleackley, 2002). Mechanistically the cytotoxic T cell binds to the host 
cell, inserts perforins into its cell membrane through which granzymes are infused 
into the cytoplasm of the cell inducing DNA fragmentation and apoptosis. Cytotoxic 
T cell binding also trigger apoptosis by activating target cell surface Fas molecules by 
their Fas ligand. These mechanisms play a critical role in controlling virally infected 
cells that cannot be targeted by the innate immune surveillance. 
 
1.10.7 B lymphocytes 
 
B cells produce antibodies including IgM, IgG and IgA (Mauri and Bosma, 2012). 
The function of antibody is manifold and includes neutralising toxin, preventing 
organism adherence to the mucosal surface, complement activation, opsonisation and 
sensitising infected cells and tumour cells for antibody dependant cytotoxic attack by 
killer cells. All B cells produce IgM initially following antigenic stimulation. 
Antibody class switching, is mediated by the binding of CD40 on B cells to CD40 
ligand on T cells and occurs later if the immune response is augmented. Naive B cells 
can process antigen (via the B cell receptor) and function as an APC for T cell 
activation. In this way B cells can facilitate elements of the innate and adaptive 
immune systems. B cells reside and traffic between mucosal associated lymphoid 
tissues in the gut, lung and genitourinary tract where they provide first line protection 
from environmental pathogens. The marginal zone of the spleen also contains a large 
compliment of B cells that have a particular role in protection from encapsulated 
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pathogens (including haemophilus, pneumococcus and meningococcus). B cells can 
be activated when bound to free antigen in the lymph nodes. Alternatively in cases of 
re-infection follicular dendritic cells (DCs), which bear Fc and complement receptors 
can activate the B-cell response in an accelerated fashion. 
 
1.10.8 Autoimmune responses 
 
The development of T and B cells is tightly regulated to prevent the generation of 
auto-reactive cells (Rioux and Abbas, 2005). Specifically, activation of immature 
cells in the BM or thymus triggers cell death by apoptosis and clonal death. This 
process occurs when antigen is detected in the absence of co-stimulation or 
supporting cytokines. Indeed the vast majority of thymocytes die in the thymus 
following negative and positive screening process (frequently involving exposure to 
auto-antigen). Additional mechanisms to prevent autoimmunity include receptor 
editing of auto-reactive antibody on B cells and the production of neutralising 
antibody that recognises auto-antigen. 
 
1.10.9 The lymphatic and lymphoid systems 
 
The circulatory system is specially adapted to allow nutrient rich plasma escape from 
capillary beds facilitating the delivery of essential metabolites to tissue and the 
removal of cellular waste. The majority of this plasma is reabsorbed back into venules 
and returns to the systemic circulation. The remainder is collected by a network of 
conduits called lymphatic vessels (Schmid-Schonbein, 1990). These vessels collect 
into larger lymphatics that eventually flow back into the systemic blood circulation. 
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Lymph nodes are secondary lymphoid structures, through which lymph passes on it’s 
way back to the blood stream. The nodes act as they act as site-specific filters and are 
ideally positioned to receive foreign antigen (unbound or APC- bound) and facilitate 
interactions required for effective acquired immunity. Naive lymphocytes enter the 
nodes via high endothelial venules. Lymphocytes that do not encounter cognate 
antigen re-enter the systemic circulation within a few days. In contrast activated 
lymphocytes under go clonal expansion and acquire effector function (as described 
above) facilitating elimination of the pathogen or foreign antigen (Malhotra et al., 
2013).  
 
1.10.9.1 Structure 
 
The lymph node is comprised 2 sections – the cortex and the medulla. The cortex is 
subdivided into the T-cell (paracortex) and B-cell areas (Katakai et al., 2004). The 
medulla is comprised of a network of lymph draining sinuses and contains large 
numbers of immune cells including plasma cells, macrophages, and memory T cells. 
The microstructure of lymph nodes is specially adapted for immune cell interaction 
(von Andrian and Mempel, 2003). The paracortex is arranged into paracortical cords 
that originate between B cell follicles and extend into the medulla. These cords are 
bordered by lymph filled sinuses and are permeated by reticular fibres. Interstitial 
fluid and migratory dendritic cells percolate through these channels facilitating 
antigen detection be innate immune cells. At the centre of each paracortical cord is a 
high endothelial venule that is surrounded by layers of pericytes known as fibroblastic 
reticular cells (FRCs). The space between the FRCs and endothelium is termed the 
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‘perivenular channel’ and this receives lymph from the FRC conduit (Figure 1-9b).  
Functionally naive lymphocytes gain access to the node through the high endothelial 
venule. The FRCs directly communicate with trafficking lymphocytes and provide a 
reticular structure upon which lymphocytes can interface with antigen loaded 
dendritic cells. 
 
 
This schematic diagram shows the major structural components of a lymph node. 
Lymph (carrying free antigen and APC bound antigen) enters through the afferent 
lymph vessel and percolates through the subcapsular sinus, the trabecular sinuses 
and along FRC conduits towards the medulla (Figure 1-9a). Figure 1-9b shows a 
paracortical cord. This structure allows lymph to flow through a fine network of 
channels comprised of reticular fibres and FRCs and facilitates close interaction 
between APCs and lymphocytes in the perivenular channel (von Andrian and 
Mempel, 2003). 
 
Figure 1-9 Lymph-node architecture 
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1.10.9.2 Function 
 
Lymph nodes provide a scaffold to facilitate effective adaptive immune responses. 
Given the low frequency of antigen specific T cells, one critical function of the node 
is to attract antigen (either bound or unbound) into it. There are several mechanisms 
that help achieve this. Firstly, tissue –resident dendritic cells can migrate to draining 
lymph nodes via lymphatics. The lymphatic vessels also express numerous adhesion 
molecules that facilitate the migration of DCs into the node (Johnson et al., 2006). 
Secondly, the lymph node is specially designed to detect and sample antigen as it 
passes through it. For example, the FRC lymph channels are enclosed in mannose 
receptor-expressing endothelial cells, macrophages and CD11b+ DCs, which sample 
the lymph and remove microorganisms and debris within it. These cells function as 
APCs and can under appropriate circumstances activate T-cells and B-cells. Thirdly, 
afferent lymphatics facilitate the flow of antigen and immune cells into the node while 
efferent vessels regulate their release (Cyster and Schwab, 2012). During active 
inflammation leukocyte recruitment to the lymph node is increased dramatically while 
their exit is blocked. These changes occur as a result of alteration in levels of 
chemokines, cytokines and adhesion molecules and ultimately increase the chances of 
antigen – T-cell interaction.   Activated T-cells can leave lymph nodes via cortical 
sinuses and efferent lymphatics. This process is tightly regulated by lymphatic 
endothelial cells that produce sphingosine 1-phosphate allowing egress of the 
activated cells.    
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1.10.9.3 Stroma and Lymph nodes 
 
FRCs (CD38+/CD31-/CD140a+/VCAM-1+) are one of the main stromal populations 
identified in lymph nodes (Fletcher et al., 2010). FRCs provide the reticular scaffold 
for lymph nodes. In addition, FRCs regulate immune cell trafficking within the lymph 
node. The FRC conduits regulate immune cell migration by ensuring that low 
molecular weight lymph borne signals, particularly chemokines, are transported from 
subcapsular sinuses to the high endothelial venules (Malhotra et al., 2013). In this 
way FRCs facilitate direct communication between lymph and blood and directly 
determine leukocyte migration from systemic circulation to the node. FRCs also play 
an important role in T cell homeostasis. They promote the survival of naïve T cells by 
production of IL-7 and CCL19 (Link et al., 2007). On the other hand the presentation 
of peripheral tissue antigen on these stromal cells represents a key mechanism for 
tolerising autoreactive CD8+ T cells (Lee et al., 2007). Interestingly FRCs showed 
reduced stimulation of T cells after Toll-like receptor 3 ligation (Fletcher et al., 2010). 
In addition it has been proposed that the inhibitory effects of FRCs on the immune 
system extends beyond the induction of peripheral tolerance. In an elegant experiment 
FRCs exerted potent anti-proliferative effects on stimulated T cells. This effect was 
IFN-γ dependant and was mediated via increased NOS2 expression and NO 
production (Lukacs-Kornek et al., 2011). These studies illustrate the complex role of 
FRCs in promoting and modulating adaptive immune responses. These data provide 
mechanistic and physiological insights into the interactions between mesenchymal 
cells and the immune system that are described in the next section. 
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1.11 MSCs suppress cells of the immune system in vitro 
 
1.11.1 MSCs and the innate immune system 
 
An overview of the immunosuppressive effects of MSCs on the immune system is 
shown in Figure 1-10. DCs have a critical role in antigen presentation to naive T cells. 
Maturation of DCs is accompanied by expression of co-stimulatory molecules (CD80 
and CD86) and up-regulation of MHC class I and class II molecules. Secretion of IL-
6 and PGE2 by activated hMSCs inhibits the maturation and function of monocyte-
derived DCs, impairing their ability to function as APCs (Nauta et al., 2006). MSCs 
can potently inhibit cytokine production by mature DCs in vitro in particular reducing 
IL-12 secretion (Jiang et al., 2005, Nauta et al., 2006). In addition, co-culture of DCs 
and plasmacytoid DCs with MSCs reduces TNFα and IFNγ production and increases 
production of the regulatory cytokine IL-10 (Aggarwal and Pittenger, 2005).  MSCs 
also inhibit cytotoxic effects of NK cells by down regulation of NKp30 and NKG2D. 
Activation and INFγ production by activated NK cells is completely abrogated by co-
culture with MSCs (Moretta et al., 2001, Spaggiari et al., 2006).  The effects of MSCs 
on neutrophils are complex. MCSs can inhibit the respiratory burst of neutrophils. 
They also appear to prolong neutrophil life span (via IL-6 production) by inhibiting 
cellular apoptosis (Raffaghello et al., 2008). 
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Figure 1-10 MSCs suppress innate and adaptive immune cells via a variety of 
different mechanisms.  
This figure illustrates the effects MSCs exert on cells of the innate and adaptive 
immune system. MSCs have potent immunosuppressive effects mediated by both direct 
contact and the production of soluble factors. These effects are described in detail in 
the text. Figure adapted from Uccelli et al., 2008. 
 
1.11.2 MSCs and the adaptive immune system 
 
T cell proliferation in vitro may be induced by a variety of different mechanisms 
including addition of polyclonal mitogen, allogeneic cells or addition of specific 
antigen. There are countless published manuscripts demonstrating inhibition of T cell 
proliferation by MSC co-culture (Uccelli et al., 2008). Although the mechanisms of 
suppression vary, induction of cell cycle arrest in the G0/G1 phase appears to be a 
common final pathway (Sato et al., 2007, Benvenuto et al., 2007).  In addition MSCs 
alter the cytokine profile, changing a pro-inflammatory IFN-γ rich milieu into an anti-
inflammatory IL-4 producing state (Zappia et al., 2005). Co-culture experiments also 
demonstrate that MSCs can prevent the formation of cytotoxic T cells (Rasmusson et 
al., 2003). In addition to dampening or inhibiting components of the adaptive 
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immune, MSCs can also induce a regulatory phenotype. As described above MSC can 
induce plasmacytoid DC to produce IL-10 that triggers the generation of regulatory T 
cells (T-regs) (Beyth et al., 2005, Aggarwal and Pittenger, 2005). MSCs can also 
specifically stimulate T-regs to proliferate in response to HLA-G5 (Selmani et al., 
2008).  There are significant data to support a suppressive effect of MSCs on B cells 
(Corcione et al., 2006). As outlined above B cell proliferation and activation occurs as 
a consequence of T cell activation. As the latter is largely suppressed by MSCs it is 
logical to assume that B cell activation will also. 
 
1.11.3 Mechanisms of immune suppression 
 
There are numerous mechanisms documented by which MSCs exert their 
immunosuppressive effects. Broadly speaking immunosuppressive mechanisms can 
be divided into contact dependant and independent. Some studies clearly demonstrate 
that inhibition of T-cell proliferation requires close contact with MSCs facilitating 
Programmed Death 1–ligand interaction leading to T cell exhaustion (Augello et al., 
2005). Direct cell-cell contact also induces IL-10 production (Selmani et al., 2008). 
IL-10 is an anti-inflammatory cytokine that that regulates inflammation and induces T 
reg formation. IL-10 has also been linked with HLA-G5 production by MSCs, which 
suppresses T-cell proliferation as well as NK cell and T-cell cytotoxicity. On the other 
hand MSCs can produce soluble factors that inhibit immune activation. NO and IDO 
are produced by stimulated MSCs act to induce cell cycle arrest in proliferating 
lymphocytes directly (via NO) or indirectly by depleting tryptophan (via IDO) 
(Krampera et al., 2006, Ryan et al., 2007). Additional mechanisms include the 
production of TGF-β1 and hepatocyte growth factor that suppress T cell proliferation 
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in MLRs using allogeneic DCs or peripheral blood lymphocytes for antigen 
presentation (Di Nicola et al., 2002). Other soluble immunosuppressive factors that 
are produced by MSCs include IL-6, IL-10 and PGE2. Production of PGE2 by 
transplanted MSCs conferred a significant survival advantage over untreated mice in 
the ‘caecal ligation and perforation’ sepsis model (Nemeth et al., 2009). Interestingly, 
in this model stimulated MSCs (TNFα and/or lipopolysaccharide) produce PGE2, 
which acts on local macrophages to induce a regulatory phenotype secreting the anti-
inflammatory cytokine IL-10. The effects of IL-6 are diverse and include inhibition of 
the respiratory burst by neutrophils and monocyte maturation (Djouad et al., 2007, 
Raffaghello et al., 2008). An additional mechanism of interest is matrix 
metalloproteinase production (MMP) by MSCs that cleaves CD25 (Il-2 receptor) on 
responding T cells. In fact MSC infusion significantly reduced delayed-type 
hypersensitivity responses to allogeneic antigen and markedly prolonged survival of 
fully allogeneic islet grafts in transplant recipients by MMP-2 and MMP-9 production 
(Ding et al., 2009). 
 
1.12 MSC therapy in GVHD 
 
1.12.1 Overview 
 
Graft-versus-host-disease (GVHD) occurs in patients following an allogeneic tissue 
transplant and commonly occurs in patients receiving a BM transplant. Essentially 
donor immune cells (T cells) in the graft recognise recipient antigen as foreign. T cell 
activation is accompanied by release of inflammatory cytokines including TNFα and 
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Interferon-γ, both of which prompt a severe immune attack in the recipient. The most 
commonly affected organs are skin, gastrointestinal tract and liver. The mucous 
membranes are also commonly affected causing severe discomfort to patients. There 
are 2 different forms of GVHD. Acute GVHD occurs within 100 days of 
transplantation and a major cause of morbidity and mortality following BM 
transplantation (Goker et al., 2001). Chronic GVHD (>100 days following 
transplantation) carries a more benign prognosis however, can result in pre-mature 
death (Lee et al., 2003). Experimentally, GVDH can be induced in rodents by 
carrying out strain mis-matched BM transplants (Schroeder and DiPersio, 2011). This 
allows for the investigation of potential therapeutic compounds. 
 
1.12.2 Rodent data 
 
Ren et al have published elegant data demonstrating the efficacy of MSCs for the 
therapy of GVHD (Ren et al., 2008). In summary (C57BL/6 x C3H) F1 mice 
(genetically uniform and heterozygous for all the genes for which the two parental 
strains differ) were lethally irradiated  (13Gy) and after 24 hours were reconstituted 
with nucleated bone marrow cells (5 x 106) and splenocytes (5 x 106) isolated from 
C57BL/6 mice. These positive control mice develop extensive GVHD 2 – 3 weeks 
following the infusion resulting universally in death of the recipients, while negative 
controls receiving syngeneic BM transplant and were unaffected. The authors 
demonstrated that MSC treated rodents had a survival advantage if treated with MSCs 
(0.5 x 105 cells via tail vein infusion). The therapeutic effect could be significantly 
diminished by blockade of NO and/or interferon γ signalling (Figure 1-11).  
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Figure 1-11 Survival curves for MSC treated mice with GVHD. 
This figure shows the survival curves of mice with GVHD with and without MSCs 
MSc treatment. MSC therapy clearly improved survival overall survival. In order to 
identify important signalling mechanisms involved in this effect, additional 
experiments were performed blocking antibodies (including anti-Interferon-γ or a 
combination of anti-TNFα, IL-1α, and IL-1β) and MSCs isolated from iNOS and 
Interferon-γ knockout mice. Notably, blockade of NO signalling (L-NNMA) and 
interferon-γ dramatically reduced the benefit of MSC infusion. 
 
 
Interestingly, the authors also demonstrate that the immunosuppressive effect is 
dependant on MSC chemokine production. Activated MSCs produce a variety of 
leukocyte chemo-attractants that draw activated immune cells into close proximity for 
NO-mediated immunosuppression to function effectively. 
 
1.12.3 MSC efficacy in humans with GVHD 
 
Le Blanc and colleagues published the first demonstration of the efficacy of MSCs for 
the treatment of acute GVHD. In a particularly striking case report, peripheral venous 
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MSC infusions were used to treat refractory GVHD in a 9-year-old boy with acute 
lyphoblastic leukaemia (Le Blanc et al., 2004). This boy received 2 infusions of 
MSCs at 60 days and 180 days following his stem cell transplant and enjoyed a full 
clinical response to this therapy 1 year following the transplant (Figure 1-12).  
 
 
Figure 1-12 Response of refractory GVHD to autologous MSC therapy. 
This figure illustrates the clinic course of a 9-year-old boy with refractory GVHD 
treated with MSC infusions. The bilirubin and number of stools per day reflect the 
severity of liver and bowel involvement. The figure highlights the dramatic response 
to repeated MSCs infusions as evidenced by a return to baseline of liver and bowel 
function (Le Blanc et al., 2004). 
 
1.12.4 MSCs are licensed for GVHD 
 
The excitement surrounding the therapeutic potential of MSCs has in part been 
justified this year when Prochymal (MSCs derived from unrelated volunteer donors) 
was the first stem cell therapy to be approved for use in humans. Prochymal has been 
approved for the treatment of acute GVHD in children in Canada. The landmark 
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phase 3 trial responsible for this randomised patients (2:1 ratio) with steroid resistant 
GVHD to receive 8 infusions of 2 x 106 MSC/kg over 4 weeks (an equivalent volume 
of placebo) with an additional 4 infusions administered weekly after day 28 to those 
patients that had a partial response. The primary end point was attainment of a durable 
complete response. 244 patients were enrolled in the study. Although there was no 
significant difference between the groups regarding the primary endpoint (35 versus 
30% in MSC and placebo groups respectively in the ITT population), there were 
important differences between the groups in the secondary endpoints. Notably 
patients with more severe GVHD (liver, skin and gastrointestinal involvement) had a 
63% response compared to no response in the placebo arm. Additionally patients 
treated with MSCs had less progression of GVHD at weeks 2 and 4 respectively (32% 
versus 59% (P=0.05) and 37 versus 67% (P=0.05) respectively (Martin et al., 2010). 
These data formed the basis of a successful campaign to license MSC therapy for the 
treatment of severe GVHD by an internationally recognised regulatory authority. 
Prochymal is now approved in Canada, New Zealand and is currently available in 
several other countries including the USA under the expanded access program. 
 
1.13 Enhancing the immunosuppressive potential MSC 
 
1.13.1 Non-adherent culture 
 
Culture of cells as 3D spheroids affects the immunosuppressive potential of MSCs 
(Bartosh et al., 2010). Spheroid-derived MSCs are capable of tri-lineage 
differentiation and express typical MSC markers including CD73, CD90 and CD105. 
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They have higher expression of the anti-inflammatory molecule, TNFα stimulates 
gene/protein 6 (TSG6). hMSC spheroids also exerted enhanced anti-inflammatory 
effects on LPS-stimulated macrophages compared to monoculture MSCs. When 
infused into the rodent model of zymogen induced model of peritonitis, spheroid 
derived cells were more anti-inflammatory than monoculture derived cells as 
evidenced by lower levels of TNFα, IL-1β, PGE2 and myeloperoxidase in the lavage 
fluid. 
 
1.13.2 Modulating Toll-like receptor expression 
 
The anti-inflammatory phenotype of MSCs is well described and is a key factor for 
their use in on-going clinical trials (Le Blanc and Mougiakakos, 2012). We now know 
that the in vivo immune-regulatory phenotype of MSCs, once thought of as 
constitutively active, is carefully regulated and affected by factors such as infusion 
time and dose (Auletta et al., 2012, Shi et al., 2012). This complexity is reflected in a 
few studies that show although MSCs could suppress T cell proliferation in vitro, they 
failed to elicit clinical improvements in vivo (Inoue et al., 2006, Sajic et al., 2012, 
Sudres et al., 2006). An emerging field in MSC biology involves studying the effect 
of Toll-like receptor (TLR) stimulation and its effect on the immunosuppressive 
capacity of MSCs (Keating, 2012). TLRs consist of a family of proteins expressed on 
innate immune cells that recognise danger signals. Activation of these receptors 
initiates a variety of defence mechanisms geared towards eliminating pathogenic 
microorganisms and restoring homeostasis (Takeda et al., 2003).  
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Of the 10 known TLR family members, TLR 1-6 expression has been detected in both 
mMSCs and hMSCs (DelaRosa and Lombardo, 2010). Early work by Liotta and 
colleagues showed that activation of TLR3 and TLR4 on hMSCs inhibited their 
ability to supress T cell proliferation in vitro (Liotta et al., 2008). This effect was 
mediated by TLR-mediated down regulation of Jagged-1 on MSCs, resulting in 
impaired signalling to Notch receptors on T cells. Tomchuck et al. report that TLR4-
activated MSCs secrete pro-inflammatory cytokines such as TNFα, IL6 and IL1β. 
Conversely, TLR3 activation results in the secretion of anti-inflammatory cytokines 
such as IL10 and IL12 (Tomchuck et al., 2008). More recently, Waterman et al. report 
that short-term priming with TLR3 or TLR4 agonists can polarise MSCs towards an 
immunosuppressive (TLR3-primed) or pro-inflammatory (TLR4-primed) phenotype 
(Waterman et al., 2010). Addition of TLR3-primed MSCs to stimulated lymphocyte 
cultures prevented T cell activation and proliferation by up to 90%.  However, 
addition of TLR4-primed MSCs had the opposite effect, and promoted lymphocyte 
proliferation compared to control samples.  
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Figure 1-13 TLR-primed polarisation of MSCs towards a pro-inflammatory or 
anti-inflammatory phenotype. 
Lipopolysaccharide, a ligand for TLR-4, primes MSCs towards a pro-inflammatory 
phenotype in which they lose their ability to suppress immune cells. Conversely, TLR-
3 activation primes MSCs towards a more suppressive phenotype (Keating, 2012). 	  
 
The physiological relevance of TLR priming of MSCs is only beginning to be 
unravelled (Auletta et al., 2012). The current hypothesis suggests that MSCs can both 
promote (TLR4-primed) the immune response during the early stages of tissue injury 
as well as suppress (TLR3-primed) the response during resolution (Figure 1-13). 
Although these early findings raise interesting questions about the role of MSCs in 
injury and repair, future work should concentrate on studying the role of TLR-priming 
in vivo. In addition there may be ways to enhance MSC immunosuppressive potential 
by modulating TLR3 signalling. 
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1.14 Avoiding complications of therapy 
 
1.14.1 Can MSCs contribute to scar formation? 
 
There has been considerable interest in the use of BM-derived stem cells for the 
therapy of liver cirrhosis and numerous clinical trials have been performed (Houlihan 
and Newsome, 2008).  Reports suggest that BM-derived cells, can differentiate into 
hepatic stellate cells, myofibroblasts and fibrocytes and can directly contribute to liver 
scar tissue formation (Forbes et al., 2004, Russo et al., 2006). Using sex mismatched 
BM transplants, Russo et al. demonstrated a contribution of donor BM cells to scar 
tissue (stellate and myofibroblasts cells) during CCL4 injury. In order to determine 
which BM cell was giving rise to hepatic myofibroblasts, BM transplants were 
enriched with either MSCs or HSCs prior to infusion. In female mice that received 
BM enriched for male MSCs, 53% of hepatic myofibroblasts contained the Y 
chromosome unlike female recipients that received BM enriched for male HSCs, in 
which only 8.2% of hepatic myofibroblasts contained the Y chromosome. These data 
suggest that BM-derived MSCs may contribute to scar formation. Li et al. 
demonstrate that MSCs migrate to the chronically injured liver along a concentration 
gradient of sphingosine 1-phosphate and make a contribution to scar tissue formation 
(Li et al., 2009). In their study infused MSCs marked with GFP comprised over 80% 
of total liver myofibroblasts (Li et al., 2009). These studies are also in agreement with 
a number of other studies that demonstrate a contribution of BM derived cells to scar 
tissue producing cells in a variety of other tissues (Hashimoto et al., 2004, Li et al., 
2007). These data have generated a nervous air in the setting of on going clinical trials 
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investigation the effects MSCs cells in patients with advanced liver injury and other 
chromic scarring diseases. 
 
1.14.2 MSCs and cancer 
 
There is a growing body of evidence to show that embryonic and induced pluripotent 
stem cells acquire chromosomal abnormality in culture (Mayshar et al., 2010). This 
has led to suggestions that cellular therapy of either type may be accompanied by risk 
of tumourigenesis (Ben-David and Benvenisty, 2011). The first clinical case of brain 
tumour associated with cell therapy occurred in a boy (13years od) with cerebellar 
ataxia. He had been treated with multiple infusions of foetal neural stem cells 4 years 
earlier and presented with headache from multifocal brain tumours derived from 
infused cells from at least 2 donors (Amariglio et al., 2009). Until recently, hMSCs 
(unlike murine MSCs) were considered genetically stable during in vitro expansion, 
however some evidence to contrary has recently emerged (Rosland et al., 2009). 
These preliminary data prompted a large scale analysis of 144 MSC samples (mostly 
BM derived) for chromosomal abnormality (Ben-David et al., 2011). The analysis 
detected chromosomal abnormality in approximately 4% of samples studied. 
Specifically, two monosomies of chromosome 13, four monosomies of chromosome 
6q as well as gains of chromosomes 7q and 17q and trisomy 19 were identified. The 
clinical relevance of these mutations is not known, however in an independent 
analysis of stromal tumours (lipomas, as well as chondrosarcomas and osteosarcomas) 
demonstrated monosomy 13 as a common occurrence. These data are of concern with 
the high number of clinical trials proceeding worldwide. In addition to these data, 
studies have suggested that co-infusion of MSCs with cancer cell lines accelerate 
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metastatic tumour spread. It is thought that tumour associated MSCs allow the cancer 
to evade immunesurviellance which would otherwise kill the cancerous cells 
(Karnoub et al., 2007). Finally, the first randomised study addressing the benefits of 
MSC infusion in the context of HSC infusion was published in 2008 (Ning et al., 
2008). In total 30 patients (most with acute myeloid leukaemia) received a standard 
therapy (HSC infusion) alone or in combination with culture expanded MSCs at a 
dose of 0.3 – 15.3 x 105 cells per Kg. They found that only 1 out of 10 patients in the 
MSC treatment group developed grade II GVHD compared with 8 out of 15 patients 
in the non-MSC group. Notably, there was a dramatic increase relapse of the primary 
disease in the MSC arm (60% versus 20%) raising the possibility that MSCs also 
suppress the beneficial effects of graft versus leukaemia. 
 
1.15 Aims  
 
The therapeutic potential of MSCs holds great promise for a variety of diseases. 
Traditionally, rodent-based experiments have provided a critical step in bridging the 
gap between the scientific bench and the clinician’s surgery. Limitations of isolation 
methods, malignant transformation of cultured MSCs and variability in published data 
have significantly weakened the translational relevance of MSC data from animal 
studies. Therefore the first objective of this thesis is to isolate and characterise a pure 
population of mMSCs. Secondly, I will vary culture conditions in an attempt to 
lineage prime or restrict MSCs at both a genotypic and phenotypic level. Finally, I 
will assess the different MSCs groups in well-described cartilage assays in an attempt 
to improve regenerative potential of these cells. 
	  
 
	   60	  
2 Methods 
 
2.1 Prospective Isolation of Murine MSCs 
 
2.1.1 Cell isolation from compact bone 
 
C57BL/6 mice at 8-10 weeks old (3 or more) were sacrificed by cervical dislocation.  
The carcass was sprayed liberally with 70% ethanol.  A wide pelvic incision on the 
torso of the mouse was made and a forceps was inserted through the exposed knee 
joint. The skin and hair covering the leg was retracted towards the ankle joint.  The 
ankle joint was cut using a scissors, freeing the limb from overlying skin and hair.  
The tibia was then dissected free from adherent muscle by blunt dissection.  The 
muscle was then cut away from the limb and the knee joint severed.  The tibia was 
then carefully cleaned using tissue paper and all non-adherent tissue removed.  The 
bone was stored in ice-cold PBS. The femur was dissected free from adherent muscle 
in a similar fashion.  Gentle pressure dislocated the femur from the hip joint and the 
bone was then cut free from the torso.  It was cleaned and stored as previously 
described.  
 
The bones were then washed 3 times by vigorously shaking them in fresh PBS. The 
washed bones were then crushed gently using a sterile pestle and mortar achieving 1 
fracture per bone. The bone fragments were then cut with sterile scissors into tiny 
fragments for approximately 5 minutes. Bones and fragments were collected into 
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50ml container and incubated in 20mls of pre-heated DMEM (Invitrogen, cat. no. 
11960085) + 0.2% (40mg) collagenase (Wako, cat. no. 034-10533).  This was done in 
a temperature-regulated (pre-heated) shaker at 110 rpm and 37°C for 1 hour.  
The cell suspension was then placed on ice (to quench collagenase activity) and 
filtered through a 70µm sterile filter (BD Falcon, cat. no. 352350).  The remaining 
bony fragments including those in the filter were collected and placed in the mortar.  
The bony fragments were then suspended in 2.5mls HBSS+ (Hanks-balanced salt 
solution (Invitrogen, cat. no. 14170112) supplemented with 2% FBS (Invitrogen, cat. 
no. 10500064), 10mM Hepes (Sigma, cat. no. H3375), and 1% 
penicillin/streptomycin (Sigma, cat. no. G6784)) and crushed by gently tapping with 
the pestle 50 times.  A further 5 mls of HBSS+ was then added and using the pipette, 
the liberated cells were washed out of the bone into solution.  The liquid suspension 
was then aspirated, filtered and added to the filtrate from step 8 and kept on ice. This 
step was repeated up to 6 times, such that, the total volume of cell suspension became 
50 mls.  
 
The cell suspension was then spun in a pre-cooled centrifuged at 280g for 7 minutes 
at 4°C. The supernatant was discarded and the pellet resuspended by taping the 
container vigorously until the cell suspension is homogenous and the pellet fully 
dispersed.  The red blood cells in the suspension were lysed by adding ice cold sterile 
H2O (1ml) for 5 seconds.  This was quickly followed by adding double strength PBS 
+ 4% FBS to quench the reaction.  I them made the total volume up to 15 mls with 
HBSS+ immediately after. The cell suspension was then filtered as before and the 
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cells are collected by centrifugation at 280g at 4°C for 5 minutes. The resulting pellet 
was resuspended in 1ml HBSS+ and is ready for staining.  
 
2.1.2 Cell staining 
  
I set up additional tubes for compensation during flow cytometry including: negative 
control, positive control-PE, positive control-FITC, positive control-APC.  To each of 
these cuvettes I added 100µl of HBSS+. 3-5 µl of the cell suspension is then added to 
each tube.  The main sample can be stained in the 50ml container on ice. 1µl (1:100 
dilution) CD45-PE (eBioscience, cat no.12-0451-81), Sca-1-FITC (eBioscience, cat 
no. 11-5981-81) and PDGFRα-APC (eBioscience, cat no. 17-1401-81) was added to 
the appropriate labelled tube and incubate on ice in the dark for 30 minutes.  I aimed 
to stain approximately 100,000 -500,000 cells in 100µl of HBSS+. For the main 
sample, 1µl per mouse of each of the above antibodies and Ter-119-PE (eBioscience, 
cat no. 12-5921-81) was added and the cells stained in a total volume of 1ml.  Once 
completed, all samples were vortexed and incubate on ice in the dark for 30 minutes. 
The compensation samples are then washed by adding 1 ml HBSS+ to each of the 
compensation tubes and 10mls HBSS+ to the main sample.  The main sample is was 
collected by centrifugation at 280g at 4°C for 5 minutes. Each pellet was then re-
suspended in 2µg/ml PI staining solution (Sigma, cat. no. P4170) and filtered through 
a sterile 35µm filter into sterile cuvettes and stored on ice in the dark.  
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2.1.3 Cell sorting 
 
The cell sorter should be set up in accordance with the manufacturing specifications.  
488nm and 647nm lasers are required for antibody detection.  The negative control 
was run to ensure that the voltages were set appropriately and the cell population is 
clearly discernible in all channels. Each single colour (PE, FITC and APC) was run 
and compensated against the other channels. After creating a live gate (PI negative), I 
selected lineage negative cells (PE-negative) and examined for expression of 
PDGFRα and Sca-1.  I placed a gate around the brightest PαS cell population and 
these cells were sorted into α-MEM media supplemented with 10% FCS.    
 
2.2 Cell culture and differentiation 
 
2.2.1 Standard cell culture 
 
The sorted cells were cultured in α-MEM media with GlutaMAX (Invitrogen, cat. no. 
325710280), supplemented with 10% FBS and penicillin/streptomycin.  I used a 
minimum density of 5,000 cells per cm2.  The media was changed every 3 days and 
the cells were split when they became confluent.  In brief, cells were washed with 
PBS to remove all serum and Tryplee (trypsin + EDTA) was then added to the culture 
dish and incubated at 37°C for 3 minutes.  Gentle tapping of the culture dish freed any 
remaining adherent cells.  The trypsin was neutralized by adding an equal volume α-
MEM media supplemented with 10% FCS.  The cells were collected by centrifugation 
and re-seeded in a bigger well.  
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2.2.2 Clonogenic assays and growth curves 
 
To perform CFU-F assays 2000 cells were seeded in a 10cm plastic dish.  The cells 
were incubated in 10 mls α-MEM media supplemented with 10% FCS for 14 days.  I 
removed half (5 mls) the culture media and replaced it with  fresh after 1 week.  
Adherent cell clusters of greater than 50 cells were counted as a single colony on day 
14.  
 
2.2.3 Adipocyte differentiation 
 
Once confluent, I commenced culture in adipogenic induction media (Lonza, hMSC 
Adipogenic BulletKit; PT3004) for 4 days. The media was replaced with adipogenic 
maintenance media for 4 days. One cycle of this was sufficient to induce robust fat 
differentiation. I stained for fat using Oil red O as follows: Adipogenic cells were 
fixed by adding 4% PFA. 60% 2-propanol was then added for 1 minute after which  
pre-filtered Oil red O solution (Oil red O: Water = 3:2) was added to the cells for 30 
minutes.  Following removal of the staining solution, I added 60% 2-propanol for 1 
minute. The wells were washed three times with water and then counter stained by 
adding Mayer's haematoxylin for 30 seconds. Finally, the wells were washed by 
adding an excess of water 3 times. 
 
2.2.4 Osteogenic differentiation  
 
Sub-confluent (approximately 60-70%) cells were cultured with osteogenic media 
(Lonza, hMSC Osteogenic BulletKit; PT-3924) for a period of 2 weeks. The media 
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was changed every 3 days. I confirm osteoblast differentiation by performing alkaline 
phosphatase staining and demonstrate calcium deposition using alizarin red staining 
solution. The alkaline phosphatase staining was performed using Histofine assay kit 
(NICHIREI BIOSCOENCE INC.). In brief the osteogenic cells were fixed using 4% 
PFA. The cells were washed three times (10 minutes each) with PBS. Alkaline 
phosphatase staining solution was then added and the cells were incubated at room 
temperature (25°C) for 30 minutes. Excess solution was then removed and the cells 
were washed three times (5 minutes each) with water. The well was counter stained 
by adding Mayer's haematoxylin for 30 seconds and then washed with water 3 times. 
The alizarin red staining and quantification was performed using an Osteogenic assay 
kit (Millipore). In brief the osteogenic cells were fixed using 10% formaldehyde. The 
cells must be washed three times (10 minutes each) with distilled water. The alizarin 
red staining solution was then added and the cells incubated at room temperature 
(25°C) for 20 minutes. Following this the excess dye was removed and the cells were 
washed four times (5 minutes each) with deionized water. At this point I imaged the 
well. For alizarin red quantification, 10% acetic acid was added to the stained well for 
30 minutes. The suspension along with any adherent cells was transferred to a 1.5ml 
microcentrifuge tube. The tube was vigorously vortexed and then heated to 85°C for 
10 minutes. The resulting slurry was centrifuged at 20,000g for 15 minutes. I 
neutralise the pH with 10% Ammonium hydroxide. Finally the samples and standards 
were added to a 96-well plate and read the sample at OD405.  The alizarin red 
concentration of the sample was measured against the standard curve. 
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2.2.5 Chondrogenic differentiation 
 
I harvested cultured cells by trypinisation as described above. 2.5 x 105 cells were 
transferred to a 15ml conical tube and washed in αMEM + glutaMAX. The tube was 
centrifuged at 150g for 5 minutes at 25°C. The supernatant was discarded and the 
pellet was resuspended in 1ml Differentiation Basal Medium Chondrogenic, with 
supplements from the Chondrogenic SingleQuots kit and TGF-β3 (10ng/ml, Lonza) 
and BMP-6 (500ng/ml; R&D Systems). The cells were centrifuged again at 150g for 
5 minutes at 25°C. After discarding the supernatant and the cell pellet was 
resuspended in supplemented Differentiation Basal Medium Chondrogenic.  The 
pellet was then cultured in the incubator at 37°C for 21 days. I replaced the 
supplemented media every 3 days. Following completion of the differentiation 
protocol the pellet was cryoembeded and sectioned. To prepare the slides the sections 
were deparaffinised and hydrated in distilled water. The sections were stained in 
toluidine blue working solution for 30 minutes. The stained sections were then 
dehydrated quickly once through 95% and twice through of 100% alcohol and cleared 
in xylene, 3 changes, 10 minutes each. Finally I placed a coverslip with Entellan 
(resinous mounting medium) (1.07961.0500: MERCK) over the section. 
 
2.3 Immunophenotyping of MSCs 
 
In order to identify surface marker expression of PαS MSCs, cultured cells were 
washed with PBS. The cells were then incubated for 3-5 minutes in cell dissociation 
buffer. Non-adherent cells were collected by centrifugation and resuspended in 1ml 
	  
 
	   67	  
HBSS+ for counting. 5 x 104 cells were resuspended in 100µl HBSS+ and stained 
with each of the antibodies listed in Table1. As previously described unstained cells 
are initially run to ensure visualised on the histogram and a live dead cell gate is 
constructed. Isotype controls are then run and a gate that identifies positive antibody 
expression is created. Each sample is then run and an overlay histogram of negative 
control, matched isotype and related antibody was constructed.  
 
Table 2-1 List of antibodies used 
Protein and 
Fluorochrome 
eBiosciences 
No. 
Concentration Clone Isotype 
CD45-PE 12-0451 0.2mg/ml 30-F11 Rat IgG2b kappa 
Ter 119-PE 12-5921 0.2mg/ml Ter-119 Rat IgG2b kappa 
Sca-1-FITC 11-5981 0.5mg/ml D7 Rat IgG2a kappa 
PDGFRα-APC 17-1401 0.2mg/ml APA5 Rat IgG2a kappa 
CD44-FITC 11-0441 0.2mg/ml IM7 Rat IgG2b kappa 
CD34-FITC 11-0341 0.5mg/ml RAM34 Rat IgG2a kappa 
CD105-PE 12-1051 0.2mg/ml MJ7/18 Rat IgG2a kappa 
CD49e-PE 12-0493 0.2mg/ml HMa5-1 Armenian Hamster IgG 
CD29-PE 12-0291 0.2mg/ml HMb1-1 Armenian Hamster IgG 
CD 90-PE 12-0902 0.2mg/ml 53-2.1 Rat IgG2a kappa 
Control-FITC 11-4321 0.5mg/ml - Rat IgG2a kappa 
Control-FITC 11-4031 0.5mg/ml - Rat IgG2b kappa 
Control-PE 12-4321 0.2mg/ml - Rat IgG2a kappa 
Control-PE 12-4031 0.2mg/ml - Rat IgG2b kappa 
Control-PE 12-4888 0.2mg/ml - Armenian Hamster IgG 
Control-APC 17-4321 0.2mg/ml - Rat IgG2a kappa 
 
 
 
 
	  
 
	   68	  
2.4 Lymphocyte Proliferation Assay 
 
2.4.1 Isolation of CD19+ B cells 
 
Mice were killed by cervical dislocation. The spleen was dissected free from adherent 
tissue and stored in cold P2 (PBS + 2%FCS) buffer on ice. A single cell suspension 
was then made by pushing the spleen through a sterile fine mesh for 2-3 minutes, 
using the rubber end of a 2ml syringe plunger. 3ml of P2 was then added and the 
suspension was re-suspended with a pipette to collect any loose cells. The cell 
suspension was transferred into a 15ml falcon tube and spun at 1400rpm for 7 minutes 
at 4˚C. The resulting pellet was resuspended in 1ml lysis buffer for 60 seconds. 8ml 
P2 was added to stop the reaction and the sample was centrifuged at 1400rpm, 7mins, 
at 4˚C. The pellet was resuspended in 3ml P2 buffer and the cells were counted. An 
aliquot containing about 40 x106 cells was removed for the bead purification stage 
and centrifuged again at above speeds. The pellet was resuspended in 90µl cold 
MACS buffer per 107 cells and 10µl CD19 microbeads per 107 cells was added. The 
suspension was mixed (brief vortex) and incubated in the dark at 4˚C for 15 minutes. 
After incubation, the cells were washed with cold MACS buffer (total volume 8mls). 
The sample was centrifuged at 1400rpm, 7mins, at 4˚C. Meanwhile, the MACS 
separator and columns were prepared. I used the LS column for positive selection of 
up to 108 cells. In brief, a 70µm sterile filter (BD Falcon, cat. no. 352350) was placed 
over the column to ensure debris did not flow through. 3ml of warm MACS buffer 
was put through the column to prepare it and collected in a waste universal tube. The 
pellet was resuspended in 500µl warm MACS buffer and added to the column. The 
follow through was collected in the waste pot. 3x rinse steps using 3ml warm MACS 
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buffer each were then performed to ensure all cells passed through the column. After 
finishing the washes, the collected cells are flushed from the column using 4 mls of 
warm MACS buffer. The sample is centrifuged at the usual speed (1400rpm, 7mins, 
at 4˚C), and the purified CD19+ B cell population is resuspended in 2ml of complete 
C10 (RPMI + 10%FCS + 2-mercaptoethanol) medium. This is stored on ice until 
required. I counted the cells as described previously. 
 
2.4.2 Isolation of CD4+CD25- T cells 
 
Mice were killed by cervical dislocation. Lymph nodes were removed and placed in 
cold P2 buffer on ice (Figure 2-1). A single cell suspension was prepared by pressing 
the nodes through a sterile fine mesh using the rubber end of a 2ml syringe plunger 
for 2-3 minutes. 3ml of P2 was added and washed up and down to collect any loose 
cells. The cells were transferred into a 15ml falcon tube and spun at 1400rpm for 7 
minutes at 4˚C. The resulting pellet was resuspended in 3ml P2 buffer and counted. 
The pellet was resuspended at 107 cells in 40µl MACS buffer and 15µl of biotin 
antibody cocktail per 107 cells (contains antibodies to CD8a, CD11b, CD45R, and 
Ter-119) was added. The suspension was mixed (brief vortex) and incubated in the 
dark at 4˚C for 15 minutes. Following incubation, 30µl MACs buffer, 20µl of anti-
biotin microbeads and 10µl of CD-PE antibody was added per 107 cells. After mixing 
well (brief vortex) the sample was incubated in the dark at 4˚C for 15 minutes. The 
reaction was quenched by adding 10mls cold MACS buffer and centrifuged at the 
usual settings. The MACS separator and columns were then prepared. The LD was 
used to remove CD4- negative cells. In brief the column was placed on the magnet 
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(with a 70µm strainer on top) and 2 x 1ml warm MACS buffer was added to prepare 
it. The pellet was resuspended in 500µl MACS buffer and allowed to run through the 
wet column. The unlabelled CD4-positive cells were collected in a fresh sterile 
container. The column was washed with 2 x 1ml MACS buffer and the collected cells 
were counted.  Following centrifugation, the pellet was resuspended at the following 
concentration 90µl MACS buffer per 107 cells. 10µl anti-PE microbeads per 107 cells 
was added. The sample was mixed well (brief vortex) and incubated in the dark at 4˚C 
for 15 minutes. The reaction was quenched by adding 10mls cold MACS buffer and 
centrifuged at the usual speed for the same time. The MS column was then used to 
remove CD25 positive cells. In brief, the column was placed on the magnet (with a 
70µm strainer on top) and 500µl warm MACS buffer was added to it. The stained 
pellet was resuspended in 500µl warm MACS buffer and added to the wet column. 
The column was washed with 3 x 500µl of warm MACS buffer and the CD4+CD25- 
T cells were collected. The CD4+ CD25- T cells were resuspended in C10 culture 
media and placed on ice until required 
.  
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Figure 2-1 Distribution of mouse lymph nodes. 
This figure shows the anatomical distribution of mouse lymph nodes. Careful 
dissection allows the removal of all the named nodes. 
 
2.4.3 Proliferation assay 
 
T cells were cultured in RPMI 1640 supplemented with 10% FCS, 1x P/S/G solution 
and 50mM 2-mercaptoethanol (β-Me) at a density of 25,000 cells/well in round-
bottomed 96-well plates with or without graded numbers of MSCs. 50,000 CD19+ B 
cells (2:1 ratio) were added for co-stimulation to each well (via CD86-CD28 
interaction) and cultures were supplemented with 0.8µg/ml of anti-mouse CD3e (BD 
Biosciences) to ligate the T cell receptor and stimulate T cell proliferation. Cultures 
were maintained for 72 hours before staining with anti-CD4 (1/100 dilution; BD 
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Biosciences) to determine total CD4+ cell number. A pictorial representation of this 
procedure can be seen in Figure 2-2.  
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Figure 2-2 Cartoon demonstrating the steps involved in performing a CD4+ 
CD25- proliferation assay. 
Following lymph node dissection CD19+ B cells and CD4+CD25- T cells are isolated 
using magnetic bead separation as described. The proliferation assay is then 
performed by titrating the appropriate cell populations into the culture well in the 
presence or absence of varying MSC concentrations. 
 
2.4.4 Mechanism of MSC mediated immunosuppression  
 
A variety of different mechanisms have been reported to explain the 
immunosuppressive effects of MSCs. Of these the most commonly reported include: 
1. Production of NO 2. Production of PGE2 3. Production of MMP 2 and 9 and 4. 
Production of IDO. We sequentially added blockers of each of these pathways at 
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known physiological concentrations to the assay and calculated their impact on 
lymphocyte proliferation. The table below shows at blocking compounds and the final 
tissue bath concentrations used. 
 
Table 2-2 A list of inhibitors used to determine the mechanism of MSC mediated 
immunosuppression. 
Reagent Supplier Solvent used Final bath 
concentration 
 
Indomethacin Sigma DMSO 5µM 
SB-3CT Sigma DMSO 6µM 
1-Methyltryptophan Sigma Media 1mM 
L-NMMA Sigma Water 1mM 
 
 
2.4.5 Griess Assay 
 
NO release from PαS cells was indirectly quantified using the Griess Assay 
(Promega). As NO is a volatile agent with a short half-life, the Griess reagent 
measures the total amount of nitrite (NO2-), a stable breakdown product of NO. 
Passage 3 MSCs were seeded at a density of 15,000 cells/well in 96 well plates and 
cultured overnight in RPMI 1640 supplemented with 10% FCS, 1x P/S/G solution, 
50mM β-Me, 20ng/ml IFN-γ and 20ng/ml TNF-α (Peprotech) to re-create a pro-
inflammatory environment. Following overnight incubation, supernatants were 
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removed and processed according to manufacturer’s instructions. The absorbance was 
read at 520nm and nitrite values determined by comparison against a standard curve.  
 
2.5 Growth factor priming experiments  
 
2.5.1 Effects of GFs on MSC traits 
 
To investigate the concept of lineage priming in PαS, freshly isolated cells were 
cultured in SM alone or supplemented with bFGF, PDGF-BB or transforming growth 
factor-beta (TGF-β) at a concentration of 10ng/ml respectively.  The standard assays 
including growth potential, tri-lineage differentiation and immunosuppression were 
performed and compared for each group of cells. In order to identify the signaling 
pathways responsible for phenotypic changes observed in each group we performed 
additional experiments in the presence of the following compounds: PDGF-AA, 
Dasatinib (Src inhibitor), SU5402 (Akt inhibitor) and SB-431542 (TGF-β1 activin 
receptor like kinase inhibitor).  
 
2.6 RNA isolation  
 
2.6.1 Preparation 
 
The work area was cleaned with RNAase ZAP and all pipettes, tips, collection tubes 
and buffers are UV-irradiated prior to use. Samples were kept on ice while 
processing. DNase I solution (Qiagen 79254) was prepared prior to starting. 10µl of 
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stock DNase I solution was added to 70µl RDD buffer and mixed gently by inverting 
(do not vortex) and centrifuged to pool liquid at the bottom.  This was enough for one 
RNA collection column. RLT buffer was prepared by adding 10µl ß-ME (inhibits 
endogenous RNases) to 1ml of stock in a fume cupboard.  
 
2.6.2 Cell lysis 
 
For lysis, we first washed the cells with ice cold PBS multiple times to remove all 
residual medium. 350µl RLT+ß-ME buffer (<6cm diameter well; 600µl if 6-10cm 
well) was then added to the culture dish and a pipette tip to lyse cells. The lysate was 
then collected into an eppendorf tube and mixed using the vortex. I passed the lysate 
through a 20-gauge needle (0.9mm diameter) at least 5 times to homogenise the 
sample. An equal volume of 70% ethanol was then added to the sample (i.e. 350µl or 
600µl ethanol depending on size of dish or number of cells) and mixed by pipetting.  
 
2.6.3 Spin column and DNase digestion 
 
700µl of the sample was transferred into RNeasy spin columns placed over a 
collection tube. The samples were spun at >8000xg or >10,000rpm for 15 seconds. 
The flow-through was discarded and the collection tube re-used. 350µl of RW1 buffer 
is now added to the RNeasy spin column and centrifuged for 15 seconds at max speed 
to wash the membrane. The flow through was discarded. 80µl of the DNase I 
incubation mixture (i.e. 10µl DNase I stock to 70µl RDD buffer) was added directly 
	  
 
	   76	  
onto the membrane and incubated at room temperature for 15 minutes. The column 
was washed with 350µl of RW1 buffer by centrifuging at max speed for 15 seconds 
and the flow through was discarded.   
 
2.6.4 RPE wash step  
 
The RNeasy spin column was placed in a new collection tube. 500µl of RPE buffer 
(should have ethanol added to it) was added to the spin column and centrifuged at 
max speed for 15 seconds. The flow through was discarded. 500µl RPE buffer was 
once again added and the sample was centrifuged at max speed for 2 minutes to 
completely dry the silica capture membrane ensuring no ethanol is carried over. The 
RNeasy spin column was then transferred into a new collection tube and centrifuge at 
max speed for 1 minute, eliminating carryover of RPE buffer. Finally, the spin 
column was transferred into a sterile 1.5ml eppendorf for RNA collection. 30-50µl of 
RNase-free water was pipetted directly onto the membrane and the sample was 
centrifuge at max speed for 1 minute to elute the RNA. The RNA was then stored on 
ice prior to the quantification step using a Nanodrop.  
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2.7 Microarray 
 
2.7.1 Sample preparation 
 
PαS cells were isolated and cultured in SM alone or supplemented with one of the 
following: bFGF, PDGF-BB or TGF-β.  Upon reaching confluence the cells were split 
as described earlier in a 1 to 2 to ratio. Passage 1 cells were cultured until confluent 
and then lysed in situ for RNA extraction as described above. RNA quality was 
monitored using a Bioanalyzer 2100 (Agilent, Stockport UK) then prepared for 
transcriptional profiling on GeneChip Mouse Exon 1.0 ST Arrays (Affymetrix, High 
Wycombe UK) according to the manufacturer's recommendations. Briefly, 100 ng of 
RNA was used to transcribe single stranded cDNA using oligo dT primers. A second 
strand was then synthesised and the double stranded cDNA purified. This double 
stranded cDNA was used as a template to generate fluorescently labelled cRNA by in 
vitro transcription, which was purified and fragmented before being hybridised to the 
microarray chip. 
 
2.7.2 Bioinformatic analysis 
 
The gene expression data were generated using quantile normalization and RMA 
(robust multi-array analysis). Probe level quantile normalization. and robust multi-
array analysis on the raw CEL files was performed using the affy package of the 
Bioconductor (http://www.biocondutor.org) project and custom cdf 
MOGENE10ST_Mm_ENTREZG (version 17). To generate the heatmaps, gene 
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expression data from microarray was quantile normalized and then scaled. Gene 
annotation was based on NCBI gene database downloaded on May 28, 2013. 
 
2.8 Karyotyping 
 
2.8.1 Cell preparation 
 
The MSC groups were cultured in SM alone or supplemented with either bFGF, 
PDGF-BB or TGF-β in a 25cm tissue culture flask as described earlier. When the 
cells were approximately 70% confluent we added B-ONC to the media (final tissue 
flask concentration) approximately 16 hours before cell harvest. On the day of harvest 
0.05ml colcemid was added to the tissue flask and re-incubated for 1 hour. The cells 
were trypsinised (as described earlier) and pipetted to give a single cell suspension. 8 
mls of aqueous 0.025M KCl supplemented with colcemid was added to the cell 
suspension and the sample was incubated at 37C for 20 minutes. If a previous harvest 
had shown total failure to rupture the cell membrane then add 8ml plain distilled 
water to the 2ml of trypsinised cell suspension (and 0.1 ml of 10% Colcemid 
containing BrdU) as a hypotonic. Again incubate for at least 20 minutes, possibly 
longer. The cells were collected by centrifugation at 1000 rpm for 5 min.  The 
supernatant was removed and cells resuspended by gently flicking the tube. The cells 
were then ‘slow fixed’ in 1 mL of fresh Carnoy’s fixative at room temperature and the 
suspension was topped up to 7 mls with fixative. 
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2.8.2 Chromosome spreads 
 
The slides were prepared by cleaning them in a mixture of absolute ethanol and 
concentrated HCl (1:1). To make chromosome spreads on these slides, three drops of 
the cell suspension was added from a prepared Pasteur pipette (~0.2-mL capacity, 
drawn to deliver 10-µL drops), and allowed to spread to their maximum size. Once 
dry, the slides were inspected under low-power phase-contrast microscopy (final 
magnification 160X). Before G banding, the slides were “aged” for between 3 and 21 
d by leaving them in a closed box at room temperature. 
 
2.8.3 G banding 
 
The next step is G banding. The prepared slides were placed in 2X SSC in a Coplin 
staining jar with a lid in a water bath at 60°C-65°C for 1.5 h. The slides were cooled 
by running tap water over the closed jar and then transferred to 0.85% (w/v) NaCl at 
room temperature for 5 min. The slides were drained by touching them onto filter 
paper and then placed on a flat surface. The chamber was flooded with 0.025% 
trypsin in 0.85% NaCl for 15-20 seconds. The reaction was quenched by placing the 
slides back into 0.85% NaCl and then the slides were rinsed in phosphate buffer (pH 
6.8) and stained in fresh Giemsa stain in 5 mM phosphate buffer (pH 6.8). After 10 
minutes in the stain, the wet slides were inspected under low-power, bright-field 
microscopy (160X) for staining intensity. If necessary, staining was repeated.  Slides 
were examined with a 100X oil-immersion lens and cover sips were applied for 
storage. The banded slides were than scanned on the ‘Metafer system’ (which scans 
the slides and captures metaphases) and then analysed on the ‘IKAROS’ system. 
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2.9 Additional Cartilage experiments 
 
2.9.1 Micromass pellet chondrogenic differentiation (Bristol Method) 
 
ITS basal medium consisting of DMEM (4.5g/liter glucose, Sigma) supplemented 
with 1mM sodium pyruvate (Sigma), 1% insulin-transferrin-selenium (Invitrogen), 
Glutamax (1×; Invitrogen) and 1% (v/v) penicillin (100 units/ml)-streptomycin (100 
µg/ml) (Invitrogen) was prepared. Culture expanded PαS MSCs were harvested by 
trypsinisation. 5 × 105 cells were placed in a 15ml conical tube, washed once in cell 
expansion medium, and then resuspend in chondrogenic differentiation medium (ITS 
basal medium freshly supplemented with 50 µg/ml ascorbic acid-2-phosphate 
(Sigma), 100nM Dexamethasone (Sigma), and 10ng/ml TGF-β3 (R&D System)). The 
cells were centrifuged at 1,500 rpm for 5 minutes at room temperature to make the 
cell pellet. The cell pellets were cultured in 1.0 ml chondrogenic differentiation 
medium per tube. Chondrogenic differentiation medium was changed every 2-3 days. 
After the first week, the medium was further supplemented with 50 µg/ml insulin 
(Sigma). The chondrogenic pellets were harvested for further analysis after 21 days. 
 
2.9.2 Cartilage tissue engineering 
 
Polyglycolic (PGA) scaffolds were placed in a Petri dish and covered with absolute 
ethanol for 5 minutes to sterilize it. The ethanol was then removed and the scaffolds 
were washed three times in sterile PBS. The scaffolds were then inserted into one well 
of a 12 well plate and covered with 1ml of 100µg/ml fibronectin (aliquots stored at -
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20ºC) for 30 minutes. The scaffolds were removed and placed alone in each well and 
left to dry in the hood overnight (with the lid on). A 1% (w/v) solution of agarose in 
distilled water was prepared and sterilized in the autoclave. The agarose was 
microwaved until molten and then used to coat the bottoms of the wells in 24-well 
tissue culture plates (500µl agarose per well). Only use the central two rows of the 
plate. The plates were left in the hood with the lids off until the agarose solidified. 
One fibronectin-coated scaffold is then added to each well in the agarose coated plate. 
The scaffolds were then fully immersed in stem cell medium and left for 
approximately 30 minutes to re-hydrate. The PαS cells were then harvested and 
counted as previously described. A cell suspension equivalent to 600,000 cells was 
then placed in a separate tube for each scaffold to be seeded. The samples were 
centrifuged at 1500rpm for 5 minutes and the resulting pellets were resuspended in 
30µl culture medium. The medium from the wells containing the scaffolds was then 
removed. A pipette should be used to suck the medium out of the scaffolds until they 
turn from pink to white.  The white scaffold is then placed in the middle of the well 
and the 30µl cell suspension is slowly added to it.  The empty wells in the 24-well 
plate are filled with sterile water to minimise evaporation and the seeded scaffolds are 
placed in the incubator over night. 
 
On the next day, the scaffolds are turned over and left in the incubator for another 2 
hours. ITS Basal Medium was prepared as previously described. 1ml Differentiation 
Medium (ITS basal medium freshly supplemented with 50 µg/ml ascorbic acid-2-
phosphate (Sigma), 100nM Dexamethasone (Sigma), 10ng/ml TGF-β3 (R&D 
System) and 100ng/ml BMP-2(R&D System) was then added to each scaffold and the 
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culture dish was placed on a rotating platform (50rpm) within the incubator. Medium 
on the scaffolds was changed after day 6 and 8 using fresh Differentiation Medium. 
After day 10, the chondrogenic differentiation medium was further supplemented with 
50 µg/ml insulin (Sigma). The medium was then changed every 2 or 3 days for a total 
of 35 days (5 weeks). 
 
2.9.3 Sample fixation and sectioning 
 
Chondrogenic micromass pellets or tissue engineered cartilage samples were frozen in 
O.C.T. embedding matrix (BDH). Full-depth sections (thickness, 12µm) were cut 
with a cryostat (Leica), fixed in 4% (w/v) paraformaldehyde (sigma) in PBS, pH 7.6 
for 30 min and washed three times (5 min each time) in PBS.  
 
2.9.4 Haematoxylin and Eosin staining 
 
A circle was drawn around pre-fixed section using a PAP pen (Sigma) and let dry. 
Sections were re-hydrated in distilled water for about 5 minutes. Hematoxylin QS 
(Vector Laboratories, H-3404) was then added to the section for 2 minutes. Excess 
haematoxylin was removed by dipping briefly in distilled water followed by addition 
of 1% (v/v; 0.15g / 15ml water) eosin for 2 minutes. The slide was then dipped briefly 
(for 30 seconds) in 70% ethanol and then 100% ethanol respectively. Finally, the slide 
was cleared in xylene (Sigma) for 2 minutes and mounted in DPX mounting medium 
(Fisher scientific) and a cover-slip was added. 
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2.9.5 Safranin O staining 
 
A circle was drawn around pre-fixed sections using a PAP pen and let dry. The pre-
fixed slides were hydrated in distilled water for approximately 5 minutes. 0.02% 
(0.1g/500ml distilled water) FastGreen FCF (Sigma) was added to the sections for 4 
minutes and then quickly rinsed off with 1% acetic acid solution for no more than 10 
–15 seconds. The slides were stained in 0.1% (0.5g/500ml) Safranin O solution 
(Sigma) for 5 minutes. Then they were dehydrated and cleared using 95% Ethanol (10 
dips), 100% Ethanol (20 dips), 100% Ethanol (2minutes) and Xylene (2 minutes). 
 
2.9.6 Immunolocalisation of Types I and II Collagen 
 
A circle was drawn around the pre-fixed section using a PAP pen and let dry. The 
fixed sections (12µ in thickness) were digested with hyaluronidase (Sigma H-3506) in 
PBS (0.01 g/ml), at 37ºC for 30 min in a humidified chamber (cover the bottom of a 
tray with wet paper towels). The solution was tipped off into the tray and sections 
were washed in PBS for 5 minutes on a shaker. The section was treated with pronase 
(Boehringer Mannheim 165921) in PBS (0.002 g/ml) at 37ºC for 30 min. It was then 
washed in PBS, for 5 min, on a shaker. Endogenous peroxidase activity was quenched 
using a solution of 3% hydrogen peroxidase (Sigma) in water, for 5 minutes (1ml 
30% H2O2 + 9ml distilled water). It was washed again in PBS, for 5 min, on the 
shaker. Next the section was blocked with 3% BSA (Sigma A-7638; crystalline grade) 
in TBS/Tween (0.15M (13.15g) NaCl; 0.05M (9.08g) Trizma Base (Sigma T-1503); 
Tween 20  (0.75ml) made up to 1.5 litres with ultra-pure distilled water and adjust pH 
to 7.5-7.6), to avoid non-specific background staining, at room temperature for 1 hour 
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(0.3g BSA in 10ml TBS-Tween). This was washed off 3 times with TBS/Tween for 
10 minutes each. The respective antibodies were then made up as follows: goat-anti-
type I collagen (Southern Biotech; 0.4mg/ml; 1310-01) and goat-anti-type II collagen 
(Southern Biotech; 0.4mg/ml; 1320-01) as 1:100 and 1:20 dilution in 1% BSA in 
TBS/Tween respectively. A negative control was also prepared by diluting normal 
goat Iggy (Santa Cruz; 0.4mg/ml; SC-2028) 1:20 in 1% BSA in TBS/Tween. The 
section was incubated with 70µl primary antibody (diluted in glass or screw-top 
Eppendorf tubes) for 1 hour at room temperature in a humidified chamber. This 
antibody was washed off for 15 minutes in a high salt wash (HSW: TBS/Tween 
containing 2.5% NaCl) and twice for 15 min in TBS/Tween. It was then incubated 
with rabbit anti-goat IgG secondary antibody (Vectastain Elite ABC kit; Vector 
Laboratories PK6105) for 1 hour at room temperature in a humidified chamber (5µl 
Ab + 15µl normal rabbit serum (NRS) + 1ml Ab diluent). ABC reagent from 
Vectastain Elite ABC kit was then prepared and allowed to stand for 30 minutes 
before use (2.5ml TBS/Tween + 1 drop Reagent A + 1 drop Reagent B. Mix 
immediately). The antibody was rinsed for 1 x 15 min in the high salt water and then 
2 x 15 min in TBS/Teen. The section was incubated with ABC reagent for 30 min at 
room temperature after which it was washed for 3 x 10 min with TBS/Tween. DAB 
substrate was prepared just before use (1 drop ImmPACT DAB chromogen 
concentrate in 1ml ImmPACT diluent) (ImmPACT DAB peroxidase substrate; SK-
4105)).  The substrate was added to the slides for 5 min until suitable staining 
developed. It was then quickly washed in distilled water and then washed for a further 
5 minutes in distilled water. A few drops of Hematoxylin QS nuclear counterstain 
(Vector H3404) were added to each slide for approximately 60 seconds following 
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which it was dipped briefly in excess water and again for 10 seconds in fresh distilled 
water. The slide was checked under the microscope and more stain added if required. 
The sections were then dehydrated in 70, 90 and 100% ethanol for 2 minutes each. 
The slide was cleared in xylene and using DPX was fixed  onto a cover slip. 
 
2.9.7 Digesting Samples with Trypsin for Biochemical Assays 
 
The chondrogenic micromass pellet samples or tissue engineered cartilage samples 
were freeze-dried and then digested. The dry weight of micromass pellet samples or 
tissue engineering samples was determined after freeze-drying. The following 
solutions were prepared for sample digestion for measurement of Type 1 and 2 
collagen content: 1. 200mM Iodoacatamide (37mg / ml dH2O) 2. 200mM EDTA (76 
mg/ ml dH20) 3. 2mg/ml Pepstatin A (2mg / ml 95% ethanol) and 4. 50mM Tris/HCl 
(0.303g / 50ml dH2O, pH 7.6) (all from Sigma). Additionally trypsin solution at 
concentration of 2 mg/ml in Tris, containing 3 inhibitors diluted 1/200 from above 
stock solutions (10mg TPCK-treated trypsin (Sigma T-1426) + 4.925ml Tris + 25µl 
each inhibitor) was prepared. Half of the final volume of trypsin (125µl) was added to 
the cartilage sample and incubated overnight at 37ºC. The following morning the 
remaining volume of freshly prepared trypsin (125 µl) was added and the sample was 
incubated for 2 - 3 hours at 65ºC, mixing every 10 minutes initially. The sample was 
then boiled for 15 minutes to denature the trypsin. The supernatant was then collected 
by centrifugation at maximum speed for 2mins. After removal of the supernatant into 
freshly labelled tube (stored supernatant at 4ºC until assay) 500µl water was added to 
remaining undigested pellet. This was then, vortexed briefly and centrifuged at 
maximum speed for 2 minutes. After discarding the supernatant, freeze dry and weigh 
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the pellet. The weight of solubilized sample was calculated by subtracting the dry 
weight of the sample and the dry weight of remaining undigested sample. 
 
2.9.8 Glycosaminoglycans (GAGs) Assay 
 
The cationic dye dimethyl-methylene blue (DMB) can be used for the measurement 
of GAGs. Reaction between the dye and GAG, at acid pH, produces a dye-GAG 
complex. Absorbance for the complex is optimally measured at 525nm. DBD solution 
was made by adding 16mg DMB (Sigma 341088), 3.04g glycine and 2.37g NaCl to 
900ml water for 2 hours. The mixture was shielded from light. The pH was adjusted 
to 3.0 with HCl and the volume to 1L. The solution was stored at room temperature in 
the dark. 
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Table 2-3 Chondroitin sulphate standards 
Chondroitin sulphate (stock at 50µg/ml; Sigma C9819) standards are prepared as 
follows: 
Standard Number Standard Conc 
(µg/ml) 
Amount of stock 
CS (µ l) 
Amount of water 
(µ l) 
1 0 0 300 
2 5 30 270 
3 10 60 240 
4 15 90 210 
5 20 120 180 
6 25 150 150 
7 30 180 120 
8 35 210 90 
9 40 240 60 
10 45 270 30 
11 50 300 0 
 
Firstly, samples were diluted as indicated in water. In a 96-well round-bottomed 
plates (Costar), 20µl water was added to the first column as blanks (wells A1-H1). 
The standards were added, in duplicate, using 20µl / well (wells A2-F4). Samples 
(20µl / well) were then added in duplicate (wells G4-H12). 250µl DMB was added to 
all wells and OD was read immediately at 525nm. The concentrations of GAGs in 
each sample were read from the standard curve. 
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2.9.9 Preparing Standards for Type I Collagen Assay 
 
0.5mg AH23 peptide (SFLPQPPQ) was dissolved in 2ml 0.8% SDS/Tris and 24µl of 
this solution was added to 5.976ml 0.8% SDS/Tris to give a concentration of 
1000ng/ml. This was the top standard. This was diluted serially with an equal volume 
(3ml) of 0.8% SDS/Tris to give the remaining 8 standards (500, 250, 125, 62.5, 31.3, 
15.6, 7.8 and 3.9 ng/ml). The samples were stored at 4ºC. 
 
2.9.10 Coating plates with AH23 
 
Carbonate buffer was made up by adding Na2CO3 solution (0.212g Na2CO3 / 20ml 
H2O) into NaHCO3 solution (0.84g NaHCO3 / 100ml H2O) and adjusted to achieve 
pH 9.2. AH23 peptide was dissolved in carbonate buffer to a final concentration of 
40µg/ml. 50µl of AH23 solution was added to all wells of 96-well Immulon-2 high-
binding flat-bottomed plates (Thermo). The plates were tapped to ensure even 
distribution over bottom of wells, wrapped in cling-film and stored at 4ºC for 3 days. 
The plates were then washed 3x with PBS-Tween and 60µl PBS-1% BSA was added 
to each well. The plates were incubated at room temperature for 30 minutes. Plates 
were then washed 1x with PBS-Tween and dried in the oven for 15 minutes at 50ºC. 
The plates were stored at 4ºC until use. 
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2.9.11 Type I Collagen Assay 
 
Digested samples were diluted in 0.8% (w/v) SDS in Tris (0.8g SDS in 100 ml Tris). 
Using 96 well round bottomed plates (Costar), all wells were blocked (except outer 
wells, to minimise evaporation) with 110µl of 1% BSA-PBS for 30 min at room 
temperature. The primary antibody (AH23-1319 from Rabbit) was prepared by 
diluting 1 / 1000 in Tris buffer containing 4% (v/v) Triton-X100. 5 mls was prepared 
per plate consisting of 4.8 ml Tris buffer, 5µl primary antibody (AH23-1319) and 
200µl of Triton-X100. Wash plate once with PBS-Tween washing buffer and dry 
thoroughly. 
 
Samples were diluted in Tris buffer (50mM Tris/HCl; 0.303g Trizma base in 50ml 
dH2O, pH 7.6; Sigma) as required. A 96 well plate was set up and included: 1. Blanks 
(100 µl SDS-Tris buffer); 2. Maximum binding (50 µl of SDS-Tris); 3. Prepared 
standards at each concentration; 4. Diluted samples (in triplicate). 50µl of primary 
antibody was added to all wells except the blanks. The plate was sealed with Parafilm 
and incubated at 37°C overnight. The following day using a multi-channel pipette, 50 
µl was transferred from each well to the equivalent well of an AH23-coated flat-
bottom plate. This was incubated at room temperature for exactly 30 min. The 
secondary antibody (AP conjugated goat anti-rabbit; Southern Biotech 4010-04) was 
prepared by diluting 1/1000 in 1% BSA/PBS containing Tween-20 also diluted 
1/1000. After exactly 30 minutes, the plate was washed three times with PBS-Tween 
and 50µl of secondary antibody was added to all the wells.  The plate was wrapped in 
parafilm and incubated at 37°C for 2 hours. After this the plate was washed 3x with 
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PBS-Tween and 1x with distilled water to eliminate bubbles. The substrate was 
prepared by adding 1 alkaline phosphatase substrate tablet (Sigma) to 10ml 
diethanolamine buffer (0.25mM MgCl2, 8.9mM diethanolamine (sigma), pH9.8). 50µl 
of substrate solution was added to each well and the plate was allowed to develop 
(approximately 20 – 30 minutes). The plate was read at 405 nm with the O.D. of the 
maximum binding wells approximately 0.5. The amount of detected peptide was 
converted to the amount of type I collagen in the sample by a factor of 146 according 
to the molecular weight. 
 
2.9.12 Preparing Standards for Type II Collagen Assay 
 
The peptide CB11B (CGKVGPSGAP[OH]GEDGRP[OH]GPP[OH]GPQY) was 
dissolved in PBS to make 7 standards (0.5, 1, 2, 3, 4, 5, 6 ug/ml).  
 
2.9.13 Coating plates with heat denatured collagen type II (HDC) 
 
Carbonate buffer was made up as previously described. 2-5 mg bovine tracheal type II 
collagen (Sigma) was dissolved with 1ml carbonate buffer in a screw top Eppendorf 
tube. The collagen was heated for 20mins at 80°C. It was mixed continuously while 
heating. The denatured collagen type II was diluted in carbonate buffer to a 
concentration of 40µg/ml. 40µl of denatured collagen type II solution was added to 
the wells (B2-O13) of 384 well high-binding flat bottomed ELISA plates (Corning). 
The plates were tapped gently to ensure even distribution over bottom of wells. The 
plates were wrapped in cling-film and stored at 4ºC for 3 days. Prior to use the plates 
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were washed 3x with PBS-Tween after which 50µl PBS-1% BSA was added to each 
well. After a 30 minute incubation at room temperature the plates were washed 1x 
with PBS-Tween and dried in oven for 15min at 50ºC. The plates were stored at 4ºC 
until needed. 
 
2.9.14 Type II Collagen Assay  
 
The samples were diluted in Tris buffer (50mM Tris/HCl; 0.303g Trizma base in 
50ml dH2O, pH 7.6; Sigma) as required. A 384 well plate was set up and included: 1. 
Blanks (20 µl Tris buffer); 2. Maximum binding (10 µl Tris buffer); 3. Prepared 
standards at each concentration; 4. Diluted samples (in triplicate). 10µl sample was 
added in triplicate to relevant wells. The primary antibody was prepared by 1 in 600 
dilution (5µl COL2-3/4m antibody in 3ml Tris per plate) and 10µl was added  to all 
wells except the blanks (reverse pipetting). The plate was sealed with a plate-seal and 
incubated overnight at 37°C. 10µl was transferred the following day from each well to 
the equivalent well heat denatured collagen-coated plate (40µl of 40µg/ml). The plate 
was incubated at room temperature for exactly 30 minutes and then washed 3 times 
with PBS-Tween. 10µl of anti-mouse secondary antibody, diluted 1/1000 in PBS-
1%BSA-0.1% Tween (3µl antibody + 3µl Tween in 3ml PBS-BSA per plate) was 
then added to all wells (reverse pipetting). The plate was then sealed and incubated at 
37°C for 2 hours. After this the plate was washed 3 times with PBS-Tween and once 
with distilled water to remove bubbles. 10µl of the substrate was then added to all 
wells (1 tablet in 10ml diethanolamine buffer) using reverse pipetting and the reaction 
was allow to develop at room temperature. The plate was read at 405nm. The amount 
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of detected peptide was converted to the amount of type II collagen in the sample by a 
factor of 44 according to the molecular weight.  
 
2.10 Detection of mRNA using Q-PCR 
 
2.10.1 RNA isolation and reverse transcription  
 
RNA was extracted from cell cultures using Norgen Total RNA Purification kit 
(Norgen Biotek), according to the manufacturer’s instructions. Reverse transcription 
(RT) was carried out using the PrimeScript RT reagent Kit (TAKARA BIO). 1 µg 
total RNA sample was diluted in 13 µl RNase free distilled water then reverse 
transcribed with 5× PrimeScript Buffer (4 µl), PrimeScript RT Enzyme Mix I (1 µl), 
Oligo dT primer (1 µl), and random 6 mers (1 µl) from the kit to make a total 20 µl, at 
37°C for 15 minutes, and then subsequently 85°C for 5 seconds.  
 
2.10.2 Primer design 
 
Published primers for the housekeeping gene β-actin were used as a reference for 
normalization in all Q-PCR (Raff et al., 1997). Published primers for mouse collagen 
type II, collagen type I and Aggrecan were used for Q-PCR (Salvat et al., 2005). A 
BLAST search against all known sequences confirmed specificity.  
 
β-actin  
Forward 5'-GACAGGATGCAGAAGGAGATTACT-3'  
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Reverse 5'-TGATCCACATCTGCTGGAAGGT-3' 
 
Collagen type II 
Forward 5'-CAG GTG AAC CTG GAC GAG AG-3' 
Reverse 5'-ACC ACG ATC TCC CTT GAC TC-3' 
 
Collagen type I 
Forward 5'-AAC GAG ATC GAG CTC AGA GG-3' 
Reverse 5'-GAC TGT CTT GCC CCA AGT TC-3' 
 
Aggrecan 
Forward 5'-GTT GGT TAC TTC GCC TCC AG-3' 
Reverse 5'-GTC CTC CAA GCT CTG TGA CC-3' 
 
2.10.3 Quantitative real-time RT-PCR 
 
Quantitative RT-PCR was performed in a 12.5 µl reaction volume containing of the 
Rotor-Gene SYBR Green PCR Master Mix 6.25 µl (Qiagen), 4 µl of DEPC water, 
1.25 µl of primers (10mM) diluted in DEPC water and 1 µl cDNA sample from the 
reverse transcription, using Rotor-Gene-6000 (Qiagen) machine. The amplification 
program consisted of initial denaturation at 95°C for 5 minutes followed by 40 cycles 
of 95°C for 5 seconds and annealing at 60°C for 10 seconds. After amplification and 
90 seconds waiting pre-melting, melt analysis was performed by heating the reaction 
mixture from 60°C to 95°C at a rate of 1°C/5 seconds. The threshold cycle (Ct) value 
for each gene of interest was measured for each RT sample. The Ct value for β-actin 
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was used as housekeeping gene for normalization. Real-time RT-PCR assays were 
done in triplicate. 
 
 
2.11 Statistical analysis 
 
Continuous laboratory variables are reported as means and standard error as all 
variables had parametric distribution on D’Agostino and Pearson Omnibus Normality 
testing. Categorical variables are reported as number and percentages. For comparison 
of single variables, unpaired Student t-tests were used. Where repeated samples were 
taken (i.e. MSC concentrations in proliferation assay), repeated-measures of analysis 
of variance (ANOVA) was used, incorporating the appropriate post hoc analysis (i.e. 
Dunnett’s test) for multiple comparisons. The significance level was set at p < 0.05 
(*p<0.05, **p<0.01, ***p<0.001; unless specified). All analysis was performed using 
the GraphPad Prism version 5.0 software package. 
 
3 The prospective isolation and characterisation of mMSCs 
 
3.1 Introduction 
 
3.1.1 Limitations of traditional methods 
 
Despite extensive investigation the identification, physiological function and 
biological properties of MSCs have remained elusive until recently.  There are many 
reasons for this, including the low frequency of these cells in tissue, lack of specific 
surface markers to identify the cells and inherent limitations of isolating MSCs by 
plastic adherence as discussed (da Silva Meirelles et al., 2008).  MSCs isolated by 
plastic adherence are heterogeneous cell populations, which are frequently 
contaminated with hematopoietic cells (Phinney et al., 1999, Peister et al., 2004). 
Prolonged culture on plastic (necessary to remove contaminants) also reduces their 
differentiation potential and proliferative ability, as the cells mature and begin to 
senescence (Wagner et al., 2008).  In a recent publication however Morikawa et al. 
isolated murine MSCs prospectively based on their positive expression of PDGFRα 
and Sca-1 (Morikawa et al., 2009a).  The prospective isolation of PαS cells allow the 
isolation of a purer and more potent population of MSCs directly from their boney 
niche. Therefore, PαS cells have the potential to provide valuable insights into the in 
vivo localisation and properties of bone-derived MSCs (Nombela-Arrieta et al., 2011). 
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3.1.2 Modifications to MSC isolation methods 
 
Numerous attempts at improved murine MSC isolation have been published however 
each has its own limitations. The use of beads (anti-CD11b, CD34 and CD45) 
(Baddoo et al., 2003), cytotoxic agents (Falla et al., 1993), and frequent media 
changes (Soleimani and Nadri, 2009) have been used to try to eliminate cellular 
contamination. These methods however failed to avoid the irreversible changes to 
native MSC biology that occurred following prolonged growth on plastic.  The 
prospective identification of murine MSCs based on expression of CD34 appeared to 
enrich for murine MSCs (Nadri and Soleimani, 2007).  CD34 is, however, expressed 
by diverse cell types including haematopoietic cells and endothelial cells, and cellular 
contamination was therefore still inevitable.  While, MSC isolation based on 
expression of wheat germ agglutinin helped avoids contamination, the isolated cells 
had reduced clonogenic potential and colony forming potential (Van Vlasselaer et al., 
1994).  In contrast to these methods, the prospective isolation of MSCs based on 
expression of PDGFRα and Sca-1 yielded a pure and potent cell population isolated 
directly from their boney niche.  
 
3.1.3 Technical advances    
 
The isolation of PαS cells incorporated many additional steps compared to traditional 
methods. Collagenase digestion is required similar to that used previously to enrich 
for MSCs (Zhu et al., 2010).  The rationale for this step is based on the observation 
that PαS cells reside in the endosteum of the bone (Muguruma et al., 2006).  The 
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protocol used lineage specific antibodies (including CD45 and Ter119) that identify 
haematopoietic cells and hence prevented contamination of the isolated MSCs.  
Following sample labelling with the appropriate antibodies, the cells were 
resuspended with Propidium iodide staining solution.  The exclusion of dead cells is 
an important part of the protocol, as cellular debris can interfere with subsequent 
culture and growth of MSCs.  PαS cell isolation also required high-speed cell sorting, 
making it more challenging than traditional methods that use plastic adherence only.   
 
3.1.4 Aims 
 
Nonetheless, successful isolation of PαS cells will allow investigators to interrogate 
the biology and physiological functions of MSCs, which until recently has proven 
difficult. To my knowledge the isolation of PαS MSCs has not been successfully 
achieved outside of Professor Matsuzaki’s laboratory. I therefore aimed to develop a 
detailed protocol that would facilitate the isolation of PαS cells in our laboratory in 
the University of Birmingham. I wanted to perform detailed characterization of 
growth potential, tri-lineage differentiation and immunosuppressive properties of PαS 
MSCs.  
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3.2 Results 
 
3.2.1 Representative flow cytometric profiles 
 
Mice aged between 8 – 10 weeks gave the best cellular yield and in total 
approximately 10,000 PαS cells may be isolated per mouse using the method 
described here.  The total duration of the procedure takes approximately 7 hours, 
however this depends on the number of mice used in the experiment.   
 
 
 
After crushing and washing, the boney fragments were collagenase digested to 
release the MSCs from their niche. Cells were labelled with CD45, Ter-119, PDGFRα 
and Sca-1. The cells were then sorted using a sequential gating strategy that allowed 
for the exclusion of dead cells (propidium iodide positive) on a Beckman Coulter 
MoFlo XDP high speed cell sorter (Figure 3-1A). Haematopoietic cells (CD45/Ter-
119-PE) were also excluded (Figure 3-1B). The final gate allowed clear identification 
of dual positive PαS cells which are then readily sorted in to αMEM + 10%FCS 
(Figure 3-1C). 
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Figure 3-1 Representative flow cytometric profiles of collagenase-digested bone 
stained with CD45, Ter-119, PDGFRα and Sca-1. 
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3.2.2 Cell morphology and growth 
 
Freshly isolated cells were cultured in αMEM + 10% FCS with media changed every 
3 days. Their morphology and growth kinetics are assayed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PαS MSCs developed a spindle shaped morphology after 3 days in culture (Figure 
3-2A). When cultured in SM, 5,000 PαS proliferate robustly with almost 9 population 
doublings over 2 months (Figure 3-2B). PαS cells formed far more CFU-Fs compared 
to whole BM (Figure 3-2C&D) demonstrating significant enrichment of MSCs in the 
PαS fraction. 
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Figure 3-2 PαS cells have spindle like morphology and robust growth kinetics 
in vitro. 
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3.2.3 Surface marker expression 
 
I then examined surface marker expression in cultured PαS MSCs. MSCs were 
therefore stained with appropriate antibodies for the previously described MSC 
markers CD29, CD90, CD49e, Sca-1, CD44, CD105 and CD140a and the 
haematopoietic markers CD45, Ter-119 and CD34. 
 
 
 
 
 
 
 
 
 
 
 
 
Dead cells were excluded by selecting propidium iodide negative cells (Figure 3-3A). 
PαS cells lack expression of haematopoietic markers (CD45, Ter-119, CD34) and 
possess the MSC markers (CD29, CD90, CD49e, Sca-1, CD44, CD105 and CD140a) 
(Figure 3-3B). Negative and isotype controls are shown. 
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Figure 3-3 Surface marker expression on PαS MSCs was examined by flow 
cytometry. 
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3.2.4 Tri-lineage differentiation 
 
I then examined tri-lineage differentiation of PαS MSCs to cartilage, fat and bone. 
Staining with toluidine blue, Oil red O and alkaline phosphatase demonstrate robust 
differentiation to cartilage, fat and bone (Figure 3-4 A, B & C). Alizarin Red staining 
and quantification confirmed bone mineralisation and was increased compared to 
undifferentiated cells (*P<0.05) (Figure 3-4 D & E).  
50µM 
A 
B 
C 
D 
E 
Figure 3-4 Tri-lineage differentiation of PαS MSCs. 
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3.2.5 Immunosuppressive effects of MSCs 
 
The immunosuppressive effects were assayed in a lymphocyte proliferation assay. 
The assay was performed as described in the methods section. Graded numbers of 
MSCs were added to the reaction and their effects on CD4+ cell proliferation was 
assessed. 
 
 
 
 
 
 
 
 
 
 
 
 
CD4+ CD25- T-cells were purified from lymph nodes of BALB/c mice by magnetic 
bead separation. 3-day cultures were set up using 2.5 x 104 T-cells stimulated by 5 x 
104 B-cells and 0.8µg/ml of anti-mouse CD3e antibody. CD4+ T-cells were counted 
and percentage of maximal response across the groups calculated. MSCs exert a 
potent suppressive effect at 1:16, 1:8 and 1:4 ratios. (n=3, ***P<0.001 vs No MSCs). 
 
Figure 3-5 PαS MSCs exert potent immunosuppressive effects on lymphocyte 
proliferation in vitro. 
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3.2.6 Mechanism of MSC immunosuppression 
 
To determine the mechanism of MSC mediated suppression inhibitors of NO (L-
NMMA), PGE2 (Indomethacin), MMP 2&9 (SB-3CT) and IDO (1-Methyltryptophan) 
respectively were added individually to the proliferation assay.  
 
 
 
Figure 3-6 PαS MSC immunosuppression is mediated by NO production. 
The proliferation assay was repeated as described including the inhibitors described 
above. Addition of L-NMMA (1mM) potently inhibited the inhibitory effects of PαS 
MSCs on lymphocyte proliferation in vitro (n=3, wP<0.001 vs AMEM). The other 
inhibitors did not affect the immunosuppressive effect of the MSCs. 
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3.2.7 Replicative senescence of MSCs 
 
The effects of prolonged culture on PαS MSCs properties including tri-lineage 
differentiation and growth were examined.  
 
 
 
β-galactosidase staining was used to assess senescence. The proportion of senescent 
cells in standard PαS MSC culture increased over time (Figure 3-7A) [** p<0.01 vs. 
P3]. Following passage 7 almost half the cells in culture demonstrated positive β-
galactosidase staining (Figure 3-7B). Interestingly bone formation increased with 
higher passage numbers [*** p<0.001 vs. P0] (Figure 3-7C & D).  
A 
C 
B 
D 
Figure 3-7 Effects of prolonged culture on senescence and bone 
differentiation. 
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3.2.8 Fat differentiation after prolonged culture 
 
To examine if prolonged culture of PαS MSCs altered fat differentiation I induced 
adipocyte differentiation in PαS MSCs at different passage numbers as described in 
the Methods section.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3-8 Fat differentiation of PαS cells at different passage numbers. 
PαS cells were cultured as previously descried. At passage 1, 3 and 5 once confluent 
media was changes to adipogenic induction media for 4 days followed by adipogenic 
maintenance media. Cells were stained for Oil red O (Figure 3-8). Unlike bone, fat 
differentiation is lost in during long-term culture of PαS MSCs.  
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3.2.9 MSC immuosuppression after prolonged culture 
 
I then examined the effects of prolonged culture on the immunosuppressive potential 
of MCSs in the CD4+ T cell proliferation assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-9 Immunosuppressive effects of PαS MSCs at P3, P5 and P7 on CD4+ T-
cell proliferation. 
PαS MSCs at P3, P5 and P7 were added to the CD4 T-cell proliferation assay as 
previously described. PαS at P5 and P7 were significantly less potent at inhibiting 
CD4 T-cell proliferation and MSC to lymphocyte ratios of 1/32, 1/16, 1/8 and 1/4 
(n=3, wP<0.001 vs P3). 
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3.3 Discussion 
 
PαS cells were isolated accordingly to a published methodology (Morikawa et al., 
2009a, Houlihan et al., 2012). The PαS fraction is greatly enriched for CFU-F 
generating almost 30 colonies per 2000 cells seeded.  1 in every 50 PαS cells is a 
CFU-F, almost 20,000 fold greater than that of whole BM.   PαS cells differentiate 
robustly into fat, bone and cartilage and express typical MSC markers.  This is the 
first demonstration that PαS MSCs exert a potent immunosuppressive effect on 
lymphocyte proliferation. This effect was mediated by NO production. Despite the 
potent nature of these cells, prolonged culture on plastic changes their phenotype 
profoundly. Over time cellular senescence increases (as evidenced by increased β-
galactosidase staining) and fat differentiation potential diminishes. In contrast, bone 
differentiation increases as the cells age. Similar findings have been described before 
in hMSCs (Wagner et al., 2008). 
 
PαS MSC isolation is a significant advance in the field. As previously stated 
traditional MSC isolations methods have been fraught with complications (Phinney et 
al., 1999). The prospective isolation of PαS MSCs avoids cellular contamination and 
the need for long-term culture. Additionally the identification specific murine MSCs 
markers (PDGFRα and Sca-1) allow in vivo visualization of MSCs within their niche 
(Morikawa et al., 2009a). These advances will enable investigators to interrogate 
MSC functions in vivo as well as define conditions to optimise their therapeutic 
potential. MSCs have potent immunosuppressive properties in vitro and in vivo 
(Uccelli et al., 2008). NO has been reported as a mechanism through which MSCs 
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suppress the immune system (Sato et al., 2007). In vivo, MSC infusion into a murine 
model of GVHD produced a significant survival benefit. MSCs isolated from NO 
knockout mice or use of the NO inhibitor L-NMMA blocked this effect entirely (Ren 
et al., 2008). Therefore PαS MSCs may provide a useful substrate for defining 
conditions that optimizing therapeutic potential of hMSCs. 
 
PDGF-BB, TFG-β and bFGF signalling is activated during MSC differentiation to fat, 
bone and cartilage (Ng et al., 2008). I will examine the effects of these GFs on the 
growth kinetics, differentiation potential and immunosuppressive properties of freshly 
isolated PαS MSCs to test the hypothesis that in vitro culture conditions influence the 
fate and therapeutic potential of MSCs. 
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4 Growth factors direct the lineage fate of cultured MSCs 
 
4.1 Introduction 
 
4.1.1 Does an MSC hierarchy exist? 
 
Lineage priming is a model of stem cell signalling and differentiation in which the 
proliferating cell expresses a subset of genes associated with the differentiation 
pathways to which they can commit (Delorme et al., 2009). In the HSC field, 
significant progress has been made in delineating developmental pathways of 
lymphoid and myeloid lineages that establish their fate (Laiosa et al., 2006). Lineage 
trees demonstrating HSC differentiation hierarchy and the key genetic regulation 
points, are now a familiar sight in the published literature (Figure 4-1). Studies 
identifying transcriptional programs involved in lineage priming are providing novel 
biological insight into the earliest stages of haematopoiesis (Ng et al., 2009) and are 
of significant relevance to the clinical field identifying therapeutic targets for specific 
haematological diseases. In contrast to HSCs, the molecular mechanisms that 
maintain MSCs in their undifferentiated state, or determine their differentiation 
pathways, are still poorly understood. Due to traditional limitations of the methods 
used to isolate MSCs, it has not been possible to obtain a sufficiently pure MSC 
population to address these questions. 
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Figure 4-1 Lineage tree of adult haematopoiesis and lymphoid-myeloid branching 
points. 
HSCs are defined by their ability to generate all mature blood cell types and 
unlimited self renewal potency. This figure illustrates key steps in HSC differentiation 
to multipotent, oligopotent and unipotent progenitors that eventually give rise to 
terminally differentiated cells. Specific master regulator genes that determine each 
stage in the HSC differentiation and lineage fate have been identified. Although a 
similar schematic has been described for MSCs there are little data to support its 
existence. This figure was adapted from Laiosa et., 2006. 
 
4.1.2 Master regulators of fat, bone and cartilage have been identified 
 
To investigate if MSC can be lineage primed by culture conditions it is first necessary 
to identify key genes or master regulators that pre-determine lineage specification. 
Master regulators of bone, fat and cartilage have been identified and will be discussed 
here. Sox9 mRNA is expressed at high levels predominantly in mesenchymal 
condensations throughout the embryo before and during the deposition of cartilage 
(Wright et al., 1995). Sox9-/+ mice die shortly after birth, due to complications of 
skeletal malformation including respiratory distress supporting a critical role for Sox9 
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in regulating the rate of hypertrophic chondrocyte differentiation during development 
(Kist et al., 2002). Additionally, a Sox9 mutation was found to cause Campomelic 
dysplasia in humans, a rare genetic disorder characterised by significant skeletal 
abnormality (Wagner et al., 1994). Runx2 has been proposed as bone master 
regulator. Mice with a homozygous mutation in Runx2 lack of ossification of almost 
all bones and have significant skeletal abnormality (Kist et al., 2002, Komori et al., 
1997). In humans it is linked to a rare condition called Cleidocranial dysplasia, which 
is characterized by severe skeletal dysplasia (Lee et al., 1997). Peroxisome 
proliferator-activated receptor gamma (PPARγ) is known to be a master regulator of 
fat differentiation (Tontonoz and Spiegelman, 2008). Forced expression of PPARγ is 
sufficient to induce adipocyte differentiation in fibroblasts. In fact no other factor 
promotes adipogenesis in fibroblasts in the absence of PPARγ (Tontonoz et al., 1994). 
 
4.1.3 Aims 
 
Hypothetically, defining conditions that lineage prime MSCs may be used to tailor 
cell therapy for specific indications. For example an osteogenic primed MSC would 
be an ideal choice for a patient with OI. Alternatively, a chondrogenic primed MSC 
would best treat a patient with cartilage damage or osteoarthritis. Defining precise 
culture conditions that lineage prime MSCs to their respective fates therefore is of 
significant interest. In addition to matrix stiffness it is likely that selected GFs might 
influence MSC fate. Ng et al. used a broad transcriptomics approach to identify 
PDGF-BB, FGF2, and TGF-β1 as key signalling pathways in human MSC 
proliferation and differentiation (Ng et al., 2008). PDGF signalling was active during 
adipogenesis and chondrogenesis, TGF-β signalling was active during 
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chondrogenesis, and FGF signalling was active during osteogenesis, adipogenesis and 
chondrogenesis. Inhibition of any of the three pathways resulted in an altered 
differentiation potential and increased population doubling times. Conversely, the 
addition of all three GFs was sufficient to maintain MSCs in serum-free media (Ng et 
al., 2008). The aim of this Chapter is therefore to assess lineage priming of PαS MSCs 
at a genetic level following culture in SM (αMEM +10%FCS) alone or supplemented 
with either bFGF, PDGF-BB or TGF-β. 
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4.2 Results 
 
4.2.1 Gene expression during bone, cartilage and fat differentiation 
 
A list of genes involved bone, fat and cartilage development and differentiation was 
compiled. Genes involved in the patterning and development of each tissue during 
growth of the embryo were listed (Section 1.2).  Genes involved in lineage priming of 
MSCs to bone, cartilage and fat were listed (Delorme et al., 2009). Finally genes up 
regulated during MSC differentiation to each lineage were listed (Ng et al., 2008). 
  
Table 4-1 Genes involved in the development of cartilage, bone and fat. 
Condition Master 
Regulators 
Transcription 
factors 
Signalling pathways 
Cartilage Sox5 
Sox9 
HoxA, HoxD, Hoxd11, 
Hoxd13, Cebpb, Tfap2a, 
Nkx3.2, Gli3, Plzf, 
Sox6, Runx3 
Shh, Smo, Ptch1, Bmp2, Bmp4, Bmp7, 
Bmpr1a, Bmpr1b, Smad1, Smad5, 
Smad8, Mapk14, Mapk3, Mapk1, Fgf8, 
Fgf10, Wnt2, Wnt2c, Wnt3a, Ctnnb1, 
Col2a1, Col11a2, CDRAP, Col9a1, 
Acan, Ihh, Wnt4, Fgfr3, Pthr1, Comp, 
Col10a1, Agc1, Col2a1, Col11a1, 
Rankl, Mef2c, Hapln1, Col10a1 
Bone Runx2 
SP7 
Cbfb, Gata1, Gata2, 
Gata3, Cebpb, Ets1, 
Men1, Msx1, Msx 2, 
Dlx5, Dlx6, Jun, Egr2, 
SP3, Atf4, Osx, Znf145 
Bmp2, Bmp4, Bmp7, Wnt3a, Wnt10b, 
Lrp5, Smad1, Smad4, Smad5, Ctnnb1, 
Ihh, Bmp6, Igf1, Dkk1, Dkk2, Wisp1, 
Wisp2, Bmpr1a, Pthr1, Lifr, Thy1, 
Col1a2, Bgn, Dcn, Opn, Ogn, Comp, 
Alpl, Opg, Csf1, Il18, Kitl, Esr1, 
Col1a1, Ibsp, Tnfsf11, Bmp6 
Fat 
 
Cebpa 
Pparg 
Hoxa5, Hoxa4, Hoxc8, 
Nr2f1, Hoxa10, Hoxc9, 
Twist1, Tbx15, Shox2, 
Gata3,  Gli3, Cebpb, 
Cebpd, Srebf1, Cited1 
Bmp4, Fgf1, Fgf10, Fgf16, Fgf19, 
Gpc4, Sfrp2, Nodal, Nog, Dlk1, Wisp2, 
Smo, Pdgfrb, Cspg4, CD24, Col6a2, 
Sfrp2, Igf1, Adfp, Aoc3, Slco2a1, Lifr, 
Fabp4, Aqp7, Lpl, Plin1, Angptl4, 
Acdc, Rxra, Gpd1, Adipoq, Apoe, 
Apol6, Flrt3,Mrap 
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4.2.2 Additional genes of interest 
 
In addition to examining genes involved in cartilage, bone and fat development we 
also identified a panel of genes expressed in naive undifferentiated MSCs (Delorme et 
al., 2009). These might identify culture conditions that prevent MSC differentiation 
and maintain MSCs in a multipotent state. Cell cycle genes and embryonic stem cell 
markers are included to identify MSC potency. Finally, I have listed the genes that 
encode for FGF, PDGF and TGF receptor families. 
 
Table 4-2 Additional genes of interest to this study. 
Condition Gene symbols 
 
Growth factor  
receptors 
 
 
Pdgfra, Pdgfrb, Fgfr1, Fgfr2, Fgfr3, Fgfr4, Fgfrl1, 
Tgfbr1, Tgfbr2, Tgfbr3 
 
 
MCS markers 
 
 
Eras, Zfp42, Nr0b1, Gdf3, Dppa5a, Nanog, Pou5f1, 
Sox2, Gata2, Gata6, Fog2, Mef2a, LifIl6, Fgf2, Inha, 
Nrg1, Grem1, Ccl26, Wnt7b, Dlk1, Cd200, Bst1, 
Nt5e, Met, Eng, Dpp4, Tnfrsf12a 
 
Cell cycle 
 
Birc5, Ccnb1, Cdkn3, P16INK4a, P21, P14ARF 
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4.2.3 Master regulators of bone, cartilage and fat.  
 
Here we examine the expression of master regulator genes involved in fat, cartilage 
and bone differentiation. Gene expression was normalized to the mean value across 
all the groups to allow ease of comparison. The data are expressed as a fold change 
above or below the mean. For statistical comparison gene expression was normalised 
to control tissue (SM alone) and expressed as fold change.  
 
 
 
Figure 4-2 Master regulators for fat, bone and cartilage differentiation are 
shown. 
Expression of the master regulators of fat differentiation, Cebpa and PPARγ, was 
significantly increased in bFGF (2.55 and 4.53 fold) and PDGF-BB (1.7 and 2.97 
fold) compared to SM (P<0.001 for all comparisons). In contrast, expression of the 
bone master regulator, Runx2, was significantly reduced in bFGF (-1.31 fold) and 
PDGF-BB (-1.3 fold) (P<0.001 for all comparisons). Finally, Sox5 and Sox9 
(chondrogenic genes) expression were significantly increased in bFGF (4.56 and 
1.42) and PDGF-BB (3.28 and 1.38 fold) compared to SM (P<0.01). 
SM 
    
bFGF PDGF-BB TFG-β 
Fat 
Bone 
Cartilage 
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4.2.4 Mesenchymal stem cell markers 
  
In addition to examining genes involved in cartilage, bone and fat development I also 
identified gene expressed in naive undifferentiated MSCs (Delorme et al., 2009). A 
list of these genes including embryonic stem cells markers can be found in Table 4-2. 
 
 
The MSC markers examined include transcription factors, extracellular mediators 
and cell cycle regulators. The heat map demonstrated higher expression of these 
markers in the bFGF and PDGF-BB groups. Specifically expression of Sox2 (7.39 
fold), GATA2 (1.56 fold), GATA6 (1.9 fold), and Dlk1 (11.07 fold) were increased in 
bFGF group compared to SM (P<0.01 for all comparisons).   
 
 
SM bFGF PDGF-BB TFG-! 
Cartilage 
 
 
Figure 4-3 Naive MSC markers and embryonic stem cell markers are shown. 
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4.2.5 Surface receptors and cell cycle genes 
 
bFGF signals through FGFR 1-4 and FGF receptor-like 1. PDGF-BB signals through 
receptors compromised of PDGFRα and PDGFRβ subunits. TGF-β signals through 
TGF-βR 1-3. Genes regulating cell cycle were also examined. 
 
Figure 4-4 Cell cycle and growth factor receptor gene expression in the different 
groups is shown. 
This figure shows relative expression of growth factor cell cycle genes in each group.  
Expression of FGFR1 (1.42 fold), FGFrl1 (1.54 fold) and PDGFRα	  (1.62	  fold) were 
increased in the bFGF group (P<0.01 vs SM). Similarly, PDGFRα	   (1.79	   fold)	  
expression	  was	  increased	  in	  PDGF-­‐BB	  cells	  (P<0.01	  vs	  SM).	  Interestingly	  expression	  
of	  PDGFRβ	  was	  increased	  on	  TGF-­‐β	  cells	  (P<0.05	  vs	  SM).	  	  Expression	  of	  the	  cell	  cycle	  
genes	  Birc5	   (1.51	  and	  1.71	   fold)	   and	  Cdkn3	   (1.4	   and	  1.65	   fold)	  was	   increased	   in	  
bFGF	  and	  PDGF-­‐BB	  respectively	  (P<0.01	  vs	  SM).  
 
SM 
    
bFGF PDGF-BB TFG-β 
Growth factor 
receptors 
Cell cycle  
genes 
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4.2.6 Transcription factors that regulate fat development 
 
In order to look in detail at genes that might regulate tri-lineage differentiation I 
examined genes that encode transcription factors and signalling molecules involved in 
fat development. A list of transcription factors expressed during fat development is 
shown in Table 4-1. 
 
 
 
Figure 4-5 Transcription factor expression for fat development are shown for all 
groups. 
The heat map demonstrates higher gene expression in bFGF and PDGF-BB groups. 
The homeobox gene family plays an important role in mesenchymal lineage 
development. bFGF  and PDGF-BB cells up regulate Hoxc8 (1.48 and 1.41 fold 
respectively; P<0.001 vs SM). Additionally bFGF cells have increased expression of 
Hoxc9 (1.37 fold) and Hoxa5 (1.92 fold) and Srebf1 compared to SM cells (2.47 fold) 
(P<0.001 vs SM for all comparisons). 
 
SM 
    
bFGF PDGF-BB TFG-β 
Transcription 
factors 
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4.2.7 Adipogenic signalling molecules 
 
 
 
Figure 4-6 Genes encoding for signalling molecules involved in fat development 
are shown. 
The heat map demonstrates highest expression of gene transcripts in bFGF and 
PDGF-BB groups. These data combined with master regulator and transcription 
factor expression strongly suggest that addition of bFGF and PDGF-BB to culture 
media lineage prime MSCs to adipocytes. 
 
SM 
    
bFGF PDGF-BB TFG-β 
Signaling 
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4.2.8 Bone transcription factors 
 
Transcription factors implicated in bone development were then examined.  
 
 
Figure 4-7 Transcription factors involved in bone development. 
Runx2 (master regulator for bone differentiation) was expressed at higher levels in 
SM cells compared to other groups (Figure 4-2). Additionally, Dlx5, Cebpb, Msx2 
and Atf4 were expressed at higher levels in the SM group compared to bFGF and 
PDGF-BB (P<0.01 for all comparisons). Interestingly TGF-β cells up regulated 
several genes including Msx5 (1.45 fold), Gata1 (1.22 fold), Ets1 (1.37 fold), Atf4 
(1.45 fold) above SM cells (P<0.001).  bFGF and PDGF-BB also up regulated genes 
(Dlx6, Gata2, Men1, Sp3, Jun, Egr2) suggesting maintenance of multipotent 
phenotype. 
 
SM 
    
bFGF PDGF-BB TFG-β 
Transcription 
factors 
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4.2.9 Bone signalling molecules 
 
Down stream signalling during bone development was examined. 
 
Figure 4-8 Signalling molecules involved in bone development. 
The heatmap demonstrates a clustering of high signal in the SM group. Quantitative 
assessment of gene expression is shown in Appendix 1. 
SM 
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4.2.10 Chondrogenic transcription factors 
 
The expression of chondrogenic transcription factors was compared across the groups. 
We previously identified increased expression of the master regulators Sox5 and Sox9 
in bFGF and PDGF-BB groups. 
 
 
Figure 4-9 Transcription factors involved in cartilage development. 
There is no clear pattern of chondrogenic gene expression between the groups. 
Differentially expressed genes include reduced expression of Hoxa13, Nkx3-2, Gli3, 
Cebpb in bFGF (P<0.01 vs SM). Runx3 expression was increased in TGF-β 
compared to SM (P<0.01). Finally, Tfap2a, Zbtb16 and Hoxa7 expression was 
increased bFGF and PDGF-BB compared to SM.  These data might suggest that SM 
and TGF-β are lineage primed towards cartilage. 
 
SM 
    
bFGF PDGF-BB TFG-β 
Transcription 
factors 
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4.2.11 Cartilage signalling molecules 
 
I then examined the relative gene expression of down stream molecules that 
determine chondrogenic development.  
 
Figure 4-10 Signalling molecules involved in cartilage development is shown. 
MSCs cultured in SM, bFGF and PDGF-BB have increased expression of 
chondrogenic genes. These data suggest that TGF-β reduces chondrogenic potential 
of MSCs.  
SM 
    
bFGF PDGF-BB TFG-β 
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4.3 Discussion 
 
PαS MSCs cultured in SM alone are lineage primed towards bone. Addition of bFGF 
or PDGF-BB to SM significantly up regulated master regulators of fat (PPARγ) and 
cartilage (Sox9) compared to SM. These data strongly suggest that addition of GF to 
culture media can influence MSC fate. Additionally, cells cultured in bFGF maintain 
expression of naïve MSC markers (GATA2, GATA6, PDGFRα and Dlk1) and 
express higher levels of the pluripotency marker Sox2. bFGF and PDGF-BB groups 
have increased expression of cell cycle genes Birc5 and Cdkn3, suggesting 
augmented growth which is also a marker of MSC potency. Analysis of a broad 
selection of transcription factors and signalling proteins involved in tri-lineage 
differentiation broadly supported lineage priming of SM cells. The situation however 
appears less clear for cartilage. Although bFGF and PDGF-BB conditions up 
regulated Sox9 and Sox5, expression of other transcription factors and signalling 
molecules was highly variable between the groups. Further phenotypic study is 
required to confirm if supplementing media with GF can prime MSCs towards 
cartilage. 
 
There are only limited data examining lineage priming in MSCs. One such study 
investigated mMSCs and hMSCs at a genetic and protein level for commitment to the 
following lineages: fat, bone, cartilage, vascular smooth muscle, cardiac and skeletal 
muscle, haematopoietic, hepatocytic and neuronal lineages (Delorme et al., 2009). 
Analogous to our approach they first identified 300 mRNA transcripts involved in 
lineage differentiation. They then compared genetic signatures of differentiated and 
undifferentiated cells to evaluate MSC lineage priming down selective routes. They 
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found that undifferentiated BM-MSCs were primed towards osteogenic, chondrocytic, 
adipocytic and vascular smooth muscle lineages. Primed cells readily differentiated 
down their pre-destined lineages. Additional evidence suggests that the stiffness of 
matrix upon which MSCs are cultured may lineage prime or restrict their fate (Engler 
et al., 2006). In brief, MSCs cultured on matrices of increasing elasticity or stiffness 
(1, 11, 34 kPa), preferentially express transcripts indicating neurogenic, myogenic and 
osteogenic differentiation respectively. Our data add to the existing literature and 
suggest further interrogation MSC differentiation is merited to help tease out 
mesenchymal hierarchy. 
 
There are limitations of this work. Our results supports lineage priming of MSCs by 
supplementing culture media with GFs, these results need to be verified at a 
phenotypic level. Malignant transformation of murine MSCs after prolonged culture 
is well described and addition of GF to media may accelerate this process. While cells 
cultured in SM alone are primed towards osteogenic lineage and those cultured with 
bFGF or PDGF-BB are lineage primed to fat and cartilage, the situation is less clear 
for TGF-β. Nonetheless these data may have therapeutic implications with different 
culture media being selected depending on the therapeutic indication. 
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5 Growth factors influence the characteristics of cultured MSCs 
 
5.1 Introduction 
 
5.1.1 Commercially available contain GFs 
 
I previously showed that supplementing culture media with different GFs (bFGF, 
PDGF-BB and TGF-β) activates genes involved in differentiation pathways for bone, 
cartilage and fat. There are currently several commercially available media for the 
expansion of hMSCs including Mesencult-XF (STEMCELL Technologies), StemPro 
MSC SFM Zeno-Free (Invitrogen), MSCGM-CD (Lonza) and PPRF-msc6 (Lonza). 
Many of these are xenobiotic-free, serum-free media, and are supplemented with GFs 
(Jung et al., 2010). These media are specifically designed to enhance MSC growth 
and fat differentiation, which are considered hallmarks of potency. Commonly used 
growth factors for expansion of MSCs in vitro include bFGF, PDGF-ββ and TGF-β 
(Chase et al., 2010, Jung et al., 2012b).  Our previous results suggest that each of 
these GFs may lineage prime or restrict MSCs towards fat, bone or cartilage. It is 
currently not clear how GF lineage priming may affect the regenerative and 
immunosuppressive properties of MSCs.  
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This figure illustrates the worldwide distribution of clinical trials using MSCs. There 
is significant interest the therapeutic potential of MSCs for a wide variety of diseases.  
 
5.1.2 MSCs are being used in clinical trials 
 
The therapeutic potential of MSCs has generated significant excitement. There are 
currently 276 studies registered on ‘ClinicalTrials.gov’ investigating MSCs in a 
variety of different diseases. The worldwide distribution of these trials is shown in 
Figure 5-1. The speed at which MSCs have progressed from test tubes in laboratories 
to human therapies has been remarkable. There are several reasons for this. The most 
obvious of these is the significant clinical demand for novel therapies for difficult to 
treat conditions such as steroid refractory GVHD. mMSCs have been disappointing 
for pre-clinical testing. As highlighted earlier they are difficult to isolate and cultured 
Frequency of clinical trials 
Figure 5-1 Distribution of MSC clinical trials worldwide. 
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murine MSCs often undergo malignant transformation (Pittenger et al., 1999, Tolar et 
al., 2007).  Several questions relevant to the use of MSCs therapeutically have 
therefore remained largely unanswered. These include 1. What is the best MSCs 
isolation method? 2. Do culture conditions including the addition of GFs to culture 
media influence their regenerative or immunosuppressive potential? 3. What is the 
optimal transfusion route and dosing schedule? The prospective isolation of a PαS 
MSCs provides an ideal substrate to address some of these questions. 
 
5.1.3 Chapter Aims 
 
The aims of this Chapter are manifold. Firstly, I wanted to compare the growth of PαS 
MSCs cultured in SM alone and supplemented with bFGF, PDGF-BB or TGF-β 
respectively. As robust proliferation and fat differentiation are indicative of a potent 
MSC population, I examine the phenotypic effects of GFs on fat differentiation. 
Thirdly, I examine the effects of GF priming on bone differentiation and 
immunosuppressive potential. Recent data in the literature suggest that mMSCs are 
prone to malignant transformation during prolonged culture. I therefore finish by 
examining the karyotype of cells cultured in each media type. 
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5.2 Results 
 
5.2.1 Effects of GFs on colony forming potential 
 
The CFU-F assay was performed as previously described. 2000 freshly isolated PαS 
cells were cultured in SM alone or supplemented with the following cytokines: bFGF, 
TGF-β or PDGF-ββ. Following 2 weeks of culture the colonies were stained with 
crystal violet. 
 
 
 
 
 
 
 
 
 
 
 
Colony formation was increased following supplementation of the media with each 
growth factor (Figure 5-2). The effects were most pronounced following addition of 
bFGF or PDGF-BB as can be seen from this figure. 
 
Figure 5-2 CFU-F formation in the different media types. 
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5.2.2 Effects of cytokines on MSC growth curve 
 
The proliferative effects of GFs on PαS growth were examined. 4,000 freshly isolated 
cells were cultured in SM alone or supplemented individually with the following 
cytokines: bFGF, TGF-β or PDGF-ββ. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Growth curves for MSCs cultured in each media type are shown. Cells were split 
when confluent and re-seeded in a 1 to 2 ratio. Cells were counted after 30 days in 
culture. PαS cells cultured in the presence of GFs (bFGF > PDGF-ββ> TGF-β) 
grew more quickly than cells cultured in SM (Figure 5-3).  
Figure 5-3 Representative growth curves from each media type. 
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5.2.3 Effects of cytokines on MSC growth 
 
The morphology of PαS cells cultured in the different media types varied. In general 
smaller cells were observed in bFGF and TGF-β groups. Passage number was 
therefore not entirely reliable as an indicator of growth. Cell counts in each group 
were therefore performed at day 30. 
 
 
 
 
 
 
 
 
 
 
 
 
 
30 days following initial seeding of PαS MSCs, all cells were harvested in each group 
and counted. There were significantly more cells in the bFGF group compared with 
SM (n=3, P<0.001 vs SM). TGF-β and PDGF-BB increased growth of PαS cells 
compared to SM, but failed to reach statistical significance (Figure 5-4).  
 
 
Figure 5-4 Total cell numbers in each group following 30 days in culture. 
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5.2.4 Effects of GFs on cellular senescence 
 
To ascertain if the pro-proliferative effects of GFs was due to a reduction in cellular 
senescence, cells from each group were stained for β-galactosidase at day 30. 
 
 
 
 
 
 
 
 
 
 
 
The proportion of senescent cells (evidenced by positive β-galactosidase staining) 
following 30 days in culture is show for each group. The proportion of cells positive 
for β-galactosidase per field of view were counted and expressed as a proportion of 
the total cell number. These data are expressed as the mean number of cells from 10 
fields of view in each condition. The addition of growth factors to culture media 
appears to inhibit senescence. The most potent effects were seen with bFGF and 
TGF-β (n=3, ***P<0.001 vs AMEM). Addition of PDGF-BB also inhibited cellular 
senescence (n=3, **P<0.01 vs AMEM). 
Figure 5-5 Cellular senescence in each group after 30 days in culture. 
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5.2.5 Effects of GFs on fat differentiation 
 
The effects of GFs on PαS fat differentiation were investigated. In brief, 2000 freshly 
cells were seeded in a 48 well in each media type. When 90% confluent the cells were 
split or differentiated to fat. Cells in each condition were differentiated to fat up to 
passage 5. Fat differentiation was achieved by washing the cultured cells and placing 
them in fat induction media (Lonza) for 4 days. The cells were then cultured in fat 
maintenance media for a further 4 days. Cells were then fixed and stained for Oil Red 
O. 
 
 
 
 
 
 
 
 
Illustrative images of fat differentiation for each group at P0, P3 and P5 are shown 
(Figure 5-6). PαS cells lose their ability to differentiate into adipocytes after 
prolonged culture on plastic. The addition of bFGF and PDGF-ββ to the media 
greatly enhanced fat differentiation. These data support adipogenic lineage priming 
of bFGF and PDGF-BB from the microarray. 
!-MEM + bFGF + TGF" + PDGF-BB 
P0 
P3 
P5 
Figure 5-6 Oil Red O staining of each group at different passage numbers. 
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5.2.6 Effects of cytokines on bone differentiation 
 
We then assessed the effects of each culture media on PαS bone differentiation. In 
brief, 2000 freshly cells were seeded in a 48 well in each culture media. When 50% 
confluent the cells were split or underwent osteogenic differentiation. Following 2 
weeks in differentiation media cells were fixed and stained with Alizarin Red to 
demonstrate calcium deposition.  
 
 
 
 
 
 
 
 
 
This figure shows calcium production for each group at P0, P3 and P5 following 
differentiation to bone. Alizarin Red staining was quantified and used to calculate 
calcium concentration in each well (Figure 5-7). All GFs reduced calcium deposition 
compared to SM at P5 (n=3, uP<0.001 vs AMEM).   
Figure 5-7 Calcium quantification following bone differentiation in the different 
groups. 
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5.2.7 Effects of GFs on anti-proliferative effects of PαS MSCs 
 
The CD4+ T cell proliferation assay was carried out as before. Cells from each media 
type were added to the wells and their inhibitory effect measured. 
 
Figure 5-8 Inhibitory effects of each cell type on CD4+ T cells. 
The immunosuppressive potency of each group following titration into a lymphocyte 
proliferation assay is illustrated in this figure. After 3 days in culture the CD4+ cells 
were counted. Addition of GFs to MSC culture media had a significant impact on 
their anti-proliferative effects.  There was no difference between cells cultured in 
TGF-β compared to AMEM at the higher concentrations (n=3) (Figure 5-8). In 
contrast bFGF and PDGF-BB had significant attenuation of immunosuppression at 
all tested doses (n=3, **P<0.01, wP<0.001 vs AMEM). 
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5.2.8 Effects of GFs on nitric oxide production by PαS MSCs 
 
We previously identified NO as a primary mechanism of MSC mediated 
immunosuppression. We therefore wanted to assess if the different anti-proliferative 
effects seen in the groups could be explained by differential production of NO.  
 
 
 
 
 
 
 
 
 
 
Figure 5-9 NO production in the different groups. 
The Greiss assay was used to measure NO production in the different groups. There 
was a significant reduction in NO production following addition of GFs to media 
(n=3, ***P<0.001 vs AMEM) (Figure 5-9). NO production appears to explain the 
different immunosuppressive effects among the groups observed in the CD4+ T 
lymphocyte proliferation assay. 
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5.2.9 Can addition of TGF-β maintain the anti-proliferative effects of MSCs? 
 
We previously demonstrated that the anti-proliferative effects of PαS MSCs cultured 
in SM diminish over time. I examined if addition of TGF-β to culture media might 
maintain the anti-proliferative effects of MSCs. PαS MSCs were isolated and cultured 
in SM alone or supplemented with TGF-β. At passage 7 the cells were assayed in the 
CD4+ lymphocyte proliferation assay. 
 
 
 
 
 
 
 
 
 
Figure 5-10 PαS MSCs cultured in SM with TGF-β retain immunosuppressive 
potency. 
This figure shows the immunosuppressive effects of P7 cells with and without TGF-β. 
These data confirm that MSCs cultured in SM loose their anti-proliferative effects 
following prolonged culture (Figure 5-10). Addition of TGF-β to culture media 
maintained immunosuppression even after 7 passages (n=3, wP<0.001 vs No MSCs).   
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5.2.10 bFGF signalling and fat priming 
 
In order to determine downstream signalling of bFGF, we added selective inhibitors 
to the growth media. Dasatinib is an inhibitor of Src while SU5402 inhibits Akt 
signalling. bFGF mediates it’s effects via these divergent pathways. Cells were 
isolated and cultured in SM supplemented with bFGF with and without each of these 
inhibitors. Upon reaching confluence cells were swapped to fat differentiation media 
as described earlier. Staining for adipocytes was then carried out to determine the 
impact of each inhibitor on bFGF signalling. 
 
 
Control Dasatinib SU5402  
 
 
Figure 5-11 Images of bFGF cells after fat differentiation in the presence and 
absence of Dasatinib and SU5402. 
The addition of the Src inhibitor Dasatinib did not affect fat differentiation. In 
contrast, SU5402 potently inhibited fat differentiation suggesting that the 
morphological changes induced by culturing PαS MSCs in media supplemented with 
bFGF occur in part via Akt signalling. 
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5.2.11 Mechanism of action FGF 
 
Using Image J the area of fat differentiation in each well was quantified. 4 pictures 
were taken from each quadrant of the well. The total area staining positive for Oil Red 
O was then calculated and a mean generated by averaging the 4 values. Experiments 
were repeated at P0, P1 and P2. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-12 bFGF priming of PαS MSCs down adipogenic lineage is mediated by 
Akt signalling. 
Addition of SU5402, an inhibitor of Akt, markedly inhibited fat differentiation at all 
the passage numbers (n=3, uP<0.001 vs bFGF at each passage number). In contrast 
addition of Dasatinib had a minimal effect compared SU5402, suggesting that fat 
priming occurs through Akt signalling. 
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5.2.12 Mechanism of fat priming of PDGF-BB 
 
In order to determine which receptor is responsible for PDGF-BB fat priming, 
differentiation studies using MSCs expanded in SM supplemented with PDGF-BB or 
PDGF-AA were performed.  PDGF-BB is a promiscuous ligand binding all receptor 
isoforms including PDGFαα, PDGFββ. In contrast PDGF-AA only binds the PDGFαα 
receptor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-13 PDGF-BB priming of PαS MSCs down adipogenic lineage is 
mediated by the PDGF-ββ receptor. 
PαS MSCs cultured in media supplemented with PDGF-BB and not PDGF-AA 
demonstrate robust fat differentiation (Figure 5-13). 
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5.2.13 Karyogram of PαS MSCs cultured in SM with PDGF-BB 
 
A significant amount of literature suggests that mMSCs transform rapidly in culture 
and following infusion give rise to sarcoma’s in rodent models. Our results suggests 
that such changes are present as early as passage 3. I therefore wanted to analyse the 
karyotype of our cultured cells to ensure that addition of bFGF, PDGF-BB and TGF-β 
had not selected for malignant clones. 
 
 
Figure 5-14 Karyogram of P3 PαS MSCs cultured in SM with PDGF-BB. 
The figure shows a normal mouse karyogram 40XY (Figure 5-14).  
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5.2.14 Karyogram of PαS MSCs cultured in SM with bFGF 
 
I also analysed the karyotype of our cultured cells to ensure that addition of bFGF to 
the culture media did not selected for malignant clones. 
 
 
 
 
Figure 5-15 Karyogram of P5 PS MSCs cultured in SM with bFGF. 
The figure shows a normal mouse karyogram 40XY (Figure 5-15). There are no 
obvious deletions or insertions here. 
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5.2.15 Karyogram of PαS MSCs cultured in media supplemented with TGF-β 
 
I also analysed the karyotype of our cells cultured in SM supplemented with TGF-β to 
ensure this media type did not select malignant clones. 
 
 
 
 
Figure 5-16  Karyogram of P3 PαS MSCs cultured in SM with TGF-β 
Figure 5-16 shows a diploid mouse karyogram 80XXYY . While this is not normal it 
has been associated with reduced tumourigenicity (Shoshani et al., 2012).  
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5.2.16 Karyogram abnormalities  
 
With the help of the Mary Strachan, Sara Dyer, Mike Griffiths and in the West 
Midlands Regional Genetics Laboratory, Birmingham Women’s Hospital, multiple 
chromosomal spreads were analysed for error from each group and the results are 
tabulated below. 
 
Table 5-1 Summary of chromosomal abnormality identified in multiple chromosomal 
spreads in bFGF, PDGF-BB and TGF-β groups. 
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The frequency of abnormality detected varied between 15 – 30%. Abnormalities 
include chromosomal deletions, insertions and polyploidy.  
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5.3 Discussion 
 
We demonstrate that the addition of GFs to MSC culture media alters cell 
morphology, growth kinetics and differentiation potential. These data support our 
observations from the microarray. The most significant increase in MSC growth was 
with bFGF followed by TGF-β and finally PDGF-BB. These observations correlated 
with lower levels of senescence (visualised by β–galactosidase staining) observed in 
cells cultured in SM with GFs. Interestingly, PαS MSCs cultured in bFGF and PDGF-
BB supplemented media also robustly differentiate to fat suggesting that these GFs 
allow expansion of MSCs with retention of their plasticity. All GFs appear to 
attenuate bone differentiation compared with cells expanded in SM. There was 
significant variation in the immunosuppressive potential of the different groups with 
the order of potency as follows: SM > TGF-β > PDGF-BB > bFGF. These data 
provide additional evidence for lineage priming of MSCs and suggest that GFs can be 
used to augment or diminish specific MSC properties. 
 
The use of mMSCs as a research tool has been significantly damaged by numerous 
reports demonstrating that traditionally isolated and expanded cells are transformed 
(Shoshani et al., 2012, Zhou et al., 2006). The prospective isolation of PαS MSCs 
avoids the need for prolonged culture during which transformation occurs. PαS MSCs 
cultured in media supplemented with bFGF, PDGF-BB and TGF-β have karyotype 
errors when examined between P3 – P5, at a frequency of between 15 – 30 %. 
Abnormalities included chromosomal deletions, insertions and polyploidy. 
Karyotypic abnormality been demonstrated in MSC cell lines that generate sarcomas 
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in vivo (Tolar et al., 2007, Shoshani et al., 2012) (Table 5-2). The mechanism of 
mutagenesis most likely results from spontaneous unrepaired chromosomal lesion(s) 
that preceded the transposon insertion (Tolar et al., 2007) 
 
Table 5-2 Karyotype abnormalities in MSC cell lines 
 
  
 
Our cells demonstrated far fewer chromosomal abnormalities in comparison and since 
cellular transformation appears to result from an accumulation of chromosomal 
abnormality we hypothesise that our cells lines are more stable. In vivo 
transplantation experiments are on going to investigate their safety.  
 
PαS cells will provide a robust substrate to interrogate physiological function and  
biology of MSCs. Additionally, they can be used to treat rodent models of disease and 
used to define conditions to optimise therapeutic potential, examine different routes 
and timing of infusions, and track the infused cells. In the next Chapter we will 
investigate in detail the potential of PαS MSCs for chondrogenesis. 
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6 Optimising cartilage production from mMSCs 
 
6.1 Introduction 
 
6.1.1 Cartilage 
 
Cartilage is a flexible connective tissue found throughout the human body. It is 
composed of extracellular matrix (mostly Collagen II) admixed with ground 
substance (proteoglycan and aggrecan) and cartilage forming cells called 
chondrocytes (Hunziker, 2002). There are several different types of cartilage in the 
human body including: elastic cartilage, hyaline cartilage and fibrocartilage. Articular 
cartilage covers the ends of long bones and lies within the synovium. It provides an 
essential cushion that protects bone from ware and tear of every day life. It is a 
relatively avascular tissue with exchange of nutrients and waste occurring mostly by 
diffusion. Osteoarthritis (OA) describes a spectrum of pathological changes with the 
synovial cavity of long weight bearing bones and leads to pain, stiffness loss of 
function (Dieppe and Lohmander, 2005). It is the commonest cause of arthritis in the 
world and a significant health care burden (Peat et al., 2001). The pathological 
hallmark of OA is loss of cartilage that leads to boney injury and reactive changes 
within the joint. There is increasing focus on alternative therapies to joint replacement 
for the therapy of OA (Smelter and Hochberg, 2013).  
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6.1.2 MSC-derived cartilage to generate transplant grafts 
 
The successful transplantation of a bioengineered trachea in 2008 by UK and Spanish 
teams, has generated significant excitement within the field of regenerative medicine 
(Macchiarini et al., 2008). Since this pioneering work was performed, it is estimated 
that 14 other patients including paediatric cases have received bioengineered tracheal 
transplants for indications ranging from carcinoma to stenosis (Vogel, 2013). These 
procedures have not been without complication and one report estimated that at least 
2 patients have died in the early post-operative period from torrential bleeding which 
may have been caused by the implant eroding adjacent blood vessels. In the reported 
case series, recurrent collapse of the graft requiring stenting is a common problem 
(Elliott et al., 2012, Macchiarini et al., 2008). Pioneering techniques including the use 
of bioartificial scaffolds have been used to overcome some of these issues (Jungebluth 
et al., 2011). These problems may stem from poor quality cartilage, weakening of the 
tracheal scaffold during the bioengineering process and lack of a viable blood supply 
to maintain the healthy graft. Critics of field claim that there is not enough pre-clinical 
evidence and too many unanswered questions to justify continuing with a human 
transplant program (Delaere, 2013). Large animal studies are few and lack long-term 
follow to provide answers to pressing question (Birchall et al., 2012). Nonetheless the 
field has attracted significant investment and clinical trials will soon be underway.     
 
6.1.3 Chapter Aims 
 
In this Chapter, I will examine if culturing PαS MSCs in SM supplemented with GFs 
generates superior quality cartilage as evidenced by bigger pellet size and higher 
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content of collagen type II and glycosaminoglycan. This work was performed in 
collaboration with Shang Zhang and Anthony Hollander (Bristol University). 
Cartilage differentiation was confirmed by Safranin O staining and with additional 
immunohistochemical stains for collagen type I and II. Using lineage primed MSCs 
we then screen a number of growth factors including TGF-β3, BMP-2, BMP-6 alone 
or in combination to identify optimal conditions for cartilage production from PαS 
MSCs. Finally using the information we attempt to make tissue-engineered cartilage 
that might be suitable of therapeutic use. 
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6.2 Results 
 
6.2.1 Chondrogenic assays using lineage primed PαS MSCs 
 
To characterize the chondrogenic capacity of lineage primed PαS MSCs we first used 
the pellet culture system. In brief, pellets of PαS cells cultured in SM or supplemented 
with bFGF, PDGF-BB or TGF-β were produced by centrifugation and then 
transferred into chondrogenesis medium containing TGF-β3 for 3 weeks culture.  
 
 
 
 
 
 
 
 
Figure 6-1 Immunohistochemical staining of ECM in the different groups. 
Sections of cartilage pellets from each group were stained for ECM as shown (Figure 
6-1). PαS MSCs cultured in SM alone or supplemented with bFGF make superior 
quality cartilage to the PDGF-BB and TGF-β groups as evidenced by more intense 
staining for collagen type II and GAGs (Safranin O). Additionally cells expanded in 
SM supplemented with TGF-β frequently failed to form solid a pellet supporting this 
hypothesis.  
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6.2.2 Pellet size and GAG content following chondrogenic differentiation 
 
In order to quantify the quality of the cartilage in each pellet more objectively, ECM 
content (Collagen type I an II) was measured by ELISA. DMB was used to measure 
the GAG content of each pellet as described in the Methods section. We started by 
screening pellets from each group (SM, bFGF, PDGF-BB and TGF-β) to decide 
which conditions to further investigate in more complex assays. 
 
 
 
 
 
 
 
 
Figure 6-2 Chondrogenesis related production of ECM in the pellets. 
This figure shows collagen and GAG content (expressed as a percentage of dry 
weight) as measured by ELISA in each group. Good quality cartilage has a high 
Collagen type II and GAG content and low Collagen type I content. αMEM and bFGF 
groups produced the best collagen quality cartilage (Figure 6-2). TGF-β produced the 
poorest quality cartilage. We selected SM, bFGF and TGF-β for further study as 
bFGF media give the optimal in vitro expansion while TGF-β signalling is important 
in chondrogenesis. SM was the control. 
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6.2.3 Quality of cartilage produced by the different groups 
 
The pellet size and GAG content was compared between the groups. The dry weight 
of each pellet was measured after freeze drying. DMB was used to measure the GAG 
content of each pellet as described in the Methods section.  
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Figure 6-3 The dry weight and GAG content of cartilage pellets produced from 
each culture condition.  
5 × 105 cells cultured in each media type were used to produce the cellular pellet 
prior to differentiation.  SM supplemented with bFGF produced a significantly larger 
cartilage pellet compared to the other groups (Figure 6-3) (n=3, **P<0.01 vs. 
αMEM; *P<0.05 vs TGF-β) The GAG content did not differ between the groups, 
however there was a suggestion that cells expanded in SM supplemented with bFGF 
produced the most. Bars show the mean value for each group. 
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6.2.4 Collagen I and II content following chondrogenic differentiation  
 
Collagen type I and II content was then measured in all groups. High Collagen II 
content and a high Collagen type II : type I ratio indicate good quality cartilage.  
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 6-4 Collagen type I and II content of each group.  
αMEM and bFGF groups had a higher Collagen type II content and Collagen type II 
: Type I ratio compared to TGF-β (n=3, *P<0.05 vs TGF-β) Bars show the mean 
value for each group. 
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6.2.5 Optimising chondrogenic differentiation bFGF MSCs 
 
It was clear that PαS MSCs expanded in media supplemented with bFGF produced 
the best quality cartilage. We therefore selected this cell type for all further study. To 
improve chondrogenesis further we investigated addition of GFs including TGF-β3, 
BMP-2, BMP-6 alone or in combination to the chondrogenic media. Comparative Q-
PCR analysis of chondrogenic differentiation-related genes was carried in the 
monolayer culture system. 
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Figure 6-5 Chondrogenic gene expression is hown for bFGF PαS MSCs 
differentiated in the different media types. 
Cells cultured in bFGF media were differentiated to cartilage using various media 
types. High expression of Col2 and Acan expression in the pellet suggests high quality 
cartilage. These data suggest that supplementing chondrogenic media with either 
BMP-2 and BMP-6 produces the highest quality cartilage using bFGF PαS MSCs 
(Figure 6-5). Bars show the mean value for each group. 
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6.2.6 Optimising chondrogenic differentiation of bFGF MSCs 
 
The same experiment was performed and once again the quality of cartilage was 
assayed by examining gene expression of Collagen X and Aggrecan expression by Q-
PCR. Low expression of ColX and high expression of Acan represents good quality 
cartilage. The previous data suggest that BMP-2 or BMP-6 added to chondrogenic 
differentiation media produces best quality cartilage. 
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Figure 6-6 Col1 and ColX expression in bFGF PαS MSCs differentiated in the 
media types. 
Good quality cartilage also expresses low levels of Collagen type I and type X. The 
results here show that BMP-2 in particular produces the lowest levels of Col1 and 
ColX gene expression (Figure 6-6). Therefore the logical choice for further study is to 
add BMP-2 to differentiation media. Bars show the mean value for each group. 
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6.2.7 Tissue engineering with PαS MSCs expanded in SM with bFGF 
 
PαS MSCs expanded SM supplemented in bFGF were used to make tissue-engineered 
cartilage on biodegradable PGA scaffolds.  The chondrogenic media contained TGF-
β3 alone or was supplemented with BMP-2 (as a result of previous data). Pictures of 
the tissue engineered cartilage pellets are shown. 
A. 
 
B. 
 
 
Figure 6-7 Tissue engineered cartilage pellets differentiated in the presence or 
absence of BMP2. 
Chondrogenic differentiation medium containing the combination of TGF- β3 and 
BMP2  (Fig 6-7B) derived bigger cartilage then TGF- β3 alone (Fig 6-7A).  
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6.2.8 ECM measurement in tissue engineered cartilage formed in media with and 
without BMP-2 
 
Collagen type II, type I and GAGs were measured as previously described. Cartilage 
with high Collagen type II and GAG content is considered high quality. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-8 Comparison of ECM components in tissue engineered cartilage in the 
presence and absence of BMP-2. 
The combination of TGF- β3 and BMP2 increased GAG production (Figure 6-8). For 
group TGF- β3, three tissue engineered cartilage samples were pooled to derive one 
measurement. For group TGF- β3 + BMP-2, each symbol in the graph stands for one 
tissue engineered cartilage sample. 
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6.3 Discussion 
 
The chondrogenic differentiation of murine PαS cells was tested on three different 
systems including: 1. Monolayer culture for chondrogenesis related gene analysis 2. 
Pellet culture system for ECM production and 3. Tissue engineering culture (cells on 
biodegradable scaffold). We hypothesised, based on gene array data, that addition of 
bFGF, PDGF-BB, or TGF-β might lineage prime or restrict towards or away from 
cartilage. Immunohistochemistry demonstrated robust Safranin O staining using 
αMEM alone or that supplemented with bFGF suggesting that these groups are 
primed for cartilage formation. Measurement of the pellet size and chondrogenic 
markers (GAGs and Collagen type II) confirmed these findings. PαS MSCs grow far 
more quickly in SM with bFGF compared to PDGF-BB and only the former were 
carried forward for further study. A direct comparison between αMEM, bFGF and 
TGF-β cells demonstrated that the TGF-β MSCs produced inferior cartilage as 
evidenced by low levels of Collage type II and GAGs. Although αMEM and bFGF 
cells generated cartilage of equivalent quality, MSCs cultured with bFGF grow far 
more quickly and generate much larger pellets. Therefore, all further studies were 
carried out with PαS MSCs that were cultured in media supplemented with bFGF.  
 
Standard chondrogenic differentiation media is supplemented with TGF-β3 (Kafienah 
et al., 2007). BMP-2 and BMP-6 are important regulators of MSC chondrogenic 
differentiation (Sekiya et al., 2005). We therefore examined the impact of adding 
BMP-2 and BMP-6 to TGFβ3 in chondrogenic media. We noted that the addition of 
either BMP-2 or BMP-6 to the differentiation media (containing TFGβ3) enhanced 
gene expression for cartilage markers Col2 and Acan suggesting better quality 
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cartilage. Finally, we generated cartilage by tissue engineering on biodegradable 
scaffold using standard chondrogenic differentiation media or that supplemented with 
BMP-2. Addition of BMP-2 lead to increases in the size of cartilage generated. 
Additionally, the larger scaffolds contained increased amount of GAGs. 
 
There are many challenges to successfully using MSCs for cartilage repair or 
regenerative therapy. For a start the MSCs should be readily available, expandable 
and capable of robust differentiation to cartilage. PαS MSCs expanded in standard 
culture media supplemented with 10ng/ml bFGF generate 20-fold more cells than 
SM. These cells produce a greater quantity of high quality cartilage pellets compared 
to control. Therefore PαS provide a robust substrate for regenerative therapy. 
Additionally, differentiated cells should maintain features of mature chondrocytes that 
are resistant to hypertrophy and terminal differentiation. We define optimal conditions 
by adding BMP-2 to chondrogenic media to produce high quality chondrocytes as 
evidenced by low expression of Col I and Col X (indicating hypertrophy) and higher 
expression of Col2 and Acan. High quality cartilage such as this may avoid common 
complications of mineralisation and vascularisation (Pelttari et al., 2008). Finally, to 
treat patients with OA it is likely that cartilage must be engineered as 3-D implants. I 
demonstrate using novel tissue engineering techniques that PαS MSCs cultured in SM 
supplemented with bFGF, then differentiated in standard chondrogenic media 
supplemented with BPM-2, generated substantial 3-D cartilage pellets. These data 
have significant translational relevance for human regenerative therapy.  
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7 Discussion 
 
7.1 Summary of principle findings 
 
I have for the first time reproducibly isolated murine MSCs based on expression of 
PDGFRα and Sca-1 outside Japan where the technique was originally described 
(Houlihan et al., 2012). PαS MSCs are highly proliferative and robustly differentiate 
into bone, cartilage and fat. In addition PαS MSCs suppress the proliferation of 
stimulated CD4+ lymphocytes via NO production in vitro. During culture MSCs 
enlarge, their doubling time diminishes and expression of β-galactosidase increases 
indicating progressive cellular senescence. The addition of the GFs bFGF, PDGF-BB 
and TGF-β to culture media alters gene expression in PαS MSCs. Cells cultured in 
SM are lineage primed towards an osteogenic lineage. In contrast, cells cultured in 
media supplemented with PDGF-BB and bFGF have higher expression of genes that 
regulate adipogenic and chondrogenesis.  
 
The addition of GFs to MSC culture media produces significant phenotypic changes 
in cultured PαS cells. In summary cell morphology, growth kinetics, differentiation 
immunosuppressive potential were altered. In particular cells cultured in bFGF have 
an elongated slender appearance and are much smaller that cells cultured in SM. Cells 
cultured with TGF-β appear fibroblastic and are also smaller then cells cultured in 
SM. The most significant increase in MSC growth also occurred following the 
addition of bFGF. These data correlated with lower levels of senescence (visualised 
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by β–galactosidase staining) observed in this group. Interestingly, PαS MSCs cultured 
in bFGF and PDGF-BB supplemented media also robustly differentiate to fat 
suggesting that these growth factors allow expansion of MSCs with retention of their 
plasticity. All growth factors appear to attenuate bone differentiation compared with 
cell expanded in SM, suggesting that PαS are naturally primed towards a bone 
phenotype. There was significant variation in the immunosuppressive potential of the 
different groups with the order of potency as follows: SM > TGF-β > PDGF-BB > 
bFGF. This correlated with differential production of NO across the groups. Finally, 
karyotypic abnormality was identified in cells cultured in growth factor supplemented 
media the frequency of these changes low and not reflective of transformed cells.  
 
We hypothesised, based on gene array data, that addition of bFGF, PDGF-BB, or 
TGF-β might lineage prime or restrict towards or away from cartilage. We therefore 
assessed cartilage differentiation in the different groups. Immunohistochemistry 
demonstrated robust Safranin O staining using SM or that supplemented with bFGF 
suggesting that these groups are primed for cartilage formation. Measurement of the 
pellet size and chondrogenic markers, GAGs and Collagen type II, confirmed these 
findings. All further studies were carried out with PαS MSCs that were cultured in 
media supplemented with bFGF as these culture conditions yield the greatest number 
of cells and good quality cartilage. In collaboration with Shang Zhang and Prof 
Anthony Hollander in Bristol we then optimised chondrogenic differentiation 
conditions for bFGF PαS MSCs and assayed the effectiveness of this modification 
using tissue engineering on biodegradable scaffold. I demonstrate that PαS MSCs 
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expanded in SM supplemented with bFGF form robust cartilage pellets when 
differentiated in chondrogenic media supplemented with BMP-2.  
 
7.2 Current literature and what this adds 
 
7.2.1 Pure population of MSCs. 
 
The Tissue Stem Cell Committee of the International Society for Cellular Therapy has 
defined the hMSCs as plastic adherent cells that express CD73, CD90 and CD105, 
without expression of CD45, CD34, CD14 or CD11b, CD79 or CD19 and HLA-DR 
surface markers. MSCs must also be capable of differentiating into osteoblasts, 
adipocytes and chondrocytes in vitro (Dominici et al., 2006). This definition has 
however been heavily criticised (Bianco et al., 2013). MSCs defined in this way do 
not fulfil the basic requirements of a stem cell (Bianco et al., 2008). Additionally, due 
to lack of specificity of the surface markers, much of the MSC literature is not 
representative of true MSCs, but rather a heterogeneous population of stromal cells 
(Haniffa et al., 2009). Despite this the therapeutic potential of MSCs are now 
routinely being investigated in clinical trials. The reasons for this include startling 
reports of efficacy in difficult to treat diseases including GVHD and OI ((Horwitz et 
al., 2001, Le Blanc et al., 2004) and significant limitations in the mMSC field 
including cellular contamination and malignant change (Phinney et al., 1999, Zhou et 
al., 2006). I demonstrate that a pure population of MSCs can be isolated prospectively 
from murine BM. These cells appear to be stable in culture demonstrating only minor 
karyotypic change at P5. I identify culture conditions that enhance or diminish basic 
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MSCs properties including tri-lineage differentiation and immunosuppression and 
show that bFGF cells would most likely be advantageous for cartilage regeneration.  
This model is of direct relevance to human MSC therapy and provides a framework in 
which to model human therapy.  
 
7.2.2 Effects of growth factors  
 
The addition of GFs to enhance or retain certain MSC properties is not novel.  Murine 
MSCs isolated by plastic adherence contain contaminating cells (Pittenger et al., 
1999). Immunodepletion of haemopoiteic cells has been successfully used to purify 
the isolates MSCs. FGF2 has been previously used to overcome poor growth 
following immunodepletion and to maintain MSC multi-potency during culture. More 
recently it has been demonstrated that rare mesenchymal progenitors residing in the 
MSC niches in vivo express FGFR1/2 (Coutu et al., 2011), suggesting FGF signalling 
may be an important self-maintenance factor for mMSCs. There are limited data on 
the impact of GF supplementation on lineage priming or therapeutic potential of 
MSCs. FGF2 expanded MSCs have been successfully used to induce healing in a 
rodent bone fracture model (Baddoo et al., 2003). Other studies suggest that MSC 
culture in media supplemented with bFGF and TGF-α can improve differentiation to 
bone and cartilage respectively (Yamachika et al., 2012, Zhao and Hantash, 2011). 
Despite our limited understanding of the impact of GFs on mMSCs, there has been 
widespread use of growth factors for hMSCs expansion (Jung et al., 2012a). My 
results demonstrate the addition of GFs to culture media lineage primes MSCs. Gene 
expression and phenotypic data demonstrate that PαS cultured in SM are primed 
towards osteogenic lineage. bFGF and PDGF-BB enhance fat and cartilage gene 
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expression and differentiation. Interestingly, the addition of TFG-β to culture media 
impaired tri-lineage differentiation but maintained the immunosuppressive effects of 
MSCs during in vitro expansion. In contrast bFGF and PDGF-BB significantly 
attenuated the immunosuppressive effects of PαS MSCs in vitro. These data have 
significant implications for the expansion of human MSCs intended for therapeutic 
use in humans. For bone disease, cells cultured without GFs may provide the most 
effective therapy. In contrast for cartilage repair cells cultured in media supplemented 
with bFGF would seem a good choice. Finally for autoimmune and inflammatory 
disease supplementing culture media with TGF-β over comes cellular senescence and 
maintains potent immunosuppression. 
 
7.2.3 MSC derived cartilage for the treatment of osteoarthritis 
 
There are currently 16 trials investigating the efficacy of MSCs for the treatment of 
OA. The majority of these are using BM derived MSCs (n=14) with the remaining 
trials using adipose tissue derived cells. Isolated case reports have suggested benefits 
of MSC infusion of the treatment of both OA and cartilage injury (Kuroda et al., 
2007, Wakitani et al., 2007). One of the largest studies carried out to date compared 
the therapeutic benefit of chondrocyte infusion (n=36) to MSC infusion in 72 matched 
patients (Nejadnik et al., 2010). Patients were evaluated at regular intervals for 2 
years following the treatment. Therapeutic response was assessed with the 
“International Cartilage Repair Society Cartilage Injury Evaluation Package’. 
Improvements were broadly similar in both groups however Physical Role 
Functioning was higher in the MSC treated group. In addition to providing 
symptomatic improvement MSCs appear to heal cartilage defects as evidenced by 
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MRI imaging and biopsy (Davatchi et al., 2011, Centeno et al., 2008).  Nonetheless 
some studies are less encouraging reporting only modest benefit, suggesting the there 
is significant work left to optimise MSC therapy (Davatchi et al., 2011). There is little 
consensus on the ideal isolation method, culture conditions or differentiation media to 
optimise cartilage differentiation for therapeutic use. I demonstrated for the first time 
that using tissue engineering, cartilage scaffolds can be made using mMSCs cultures 
expanded in media supplemented with bFGF and differentiated in media 
supplemented with BMP-2. 
 
7.3 Future directions 
 
7.3.1 Toxic and Immune mediated liver disease 
 
7.3.1.1 Autoimmune hepatitis 
 
Autoimmune hepatitis is a chronic hepatitis characterized by circulating auto-
antibodies frequently directed to self antigen (ANA, ASMA, ASLA, ALP and 
ALKM) and a high serum globulin concentration.  Liver injury is initiated by naïve 
CD4+ T cells that recognize self-antigen (Krawitt, 2006). Following their activation, 
naïve CD4+ T cells differentiate into distinct T helper cell lineages, including pro-
inflammatory Th1 cells, anti-inflammatory Th2 cells, T regs and Th17 cells (Oo et al., 
2010).  Autoimmune hepatitis has been associated with a dominant Th1 response and 
a reduction in functioning T regs, and as such is thought to occur predominantly due 
to a defect in the regulation of the immune response (Longhi et al., 2006).  
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Subsequent activation and recruitment of CD8 T cells, γδ T cells, cytotoxic T cells 
and NKT cells to the liver cause waves inflammation and progressive fibrosis. For 
most patients a prolonged period of treatment with immunosuppressive medications 
(steroids and Azathioprine) brings about a lasting remission, unfortunately 
approximately 10 percent of patients have clinical and laboratory deterioration despite 
compliance with conventional treatment (Manns et al., 2010). Despite augmentation 
of the immunosuppression or the introduction of newer agents these patient frequently 
decompensate or develop liver failure and liver transplantation is the only therapeutic 
option for such individuals and this is associated with significant morbidity and 
mortality. We currently see 10-20 patients per year in our unit that have refractory 
autoimmune hepatitis.  
 
7.3.1.2 Alcoholic Hepatitis 
 
Nearly one third of the patients presenting with alcoholic liver disease will have 
evidence of alcohol-induced hepatic inflammation (Hislop et al., 1983). Alcoholic 
hepatitis is the most dramatic presentation of alcoholic liver disease, and may be 
potentially reversible. Scoring systems have been developed to assess the severity and 
prognosis of this condition, and those scoring 9 or more on the Glasgow Alcoholic 
Hepatitis Score (GAHS) have a 28-day mortality of 60% (Forrest et al., 2005). 
Controversy exists about the efficacy of current treatments, corticosteroids and 
pentoxyphylline (Parker et al., 2013). Even if their efficacy is proven there will still 
be a large unmet need as, from prior trials indicate a 15% mortality at 28 days in 
treated patients (Mathurin et al., 2002).  
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In alcoholic hepatitis, immune mediated injury occurs secondary to increased 
translocation of lipopolysaccharide from the bowel into the portal venous system, 
which together with elevated reactive oxygen species levels directly activate Kupffer 
cells leading to up regulation of nuclear factor kappa-b (Wiest and Garcia-Tsao, 2005, 
Adachi et al., 1994). This results in the production of several inflammatory cytokines 
including TNF-alpha, IL-8 and monocyte chemotactic protein 1 resulting in the 
recruitment and activation of inflammatory cells (neutrophils/macrophages) to the 
liver propagating cellular injury (Zhao et al., 2008, Williams and Barry, 1987). 
Moreover, lipid-peroxidation products combine with alcohol breakdown products 
(acetaldehyde) to produce neoantigens which can also stimulate a T cell driven 
autoimmune response (Meagher et al., 1999). Thus amelioration of macrophage, 
neutrophil and T cell function in alcoholic hepatitis has potential to reduce the 
severity of liver damage. Activated MSCs (stimulation with TNF-alpha, LPS) 
produce TNF-alpha stimulated gene/protein 6 and PGE2, which switch activated pro-
inflammatory macrophages to a regulatory phenotype (Prockop and Oh, 2012). MSCs 
have also been shown to suppress T cell proliferation and function as well as 
neutrophil function (Raffaghello et al., 2008).  
 
Moreover, sepsis is a major cause of death in patients with alcoholic hepatitis, and 
studies have indicated anti-septic properties of MSC in a variety of different animal 
models. Mechanisms underpinning this are incompletely understood but likely relate 
to an augmentation of bacterial killing and phagocytosis (Mei et al., 2010). 
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7.3.2 Murine models of liver disease 
 
7.3.2.1 OVA-bil model of autoimmune liver injury 
 
I have recently established a transgenic murine model of AIH (Ova-bil model) in 
Birmingham. Ova-bil mice specifically express ovalbumin on the biliary epithelium 
of their liver. Adoptive transfer of OVA-specific CD4+ and CD8+ T cells into Ova-bil 
mice results in their migration to the biliary tree where they proliferate and induce 
necro-inflammatory damage (Buxbaum et al., 2006). I have completed preliminary 
studies to show that peak liver inflammation occurs 10 days following adoptive 
transfer and is characterized by a mean peak ALT of 500 and a 10 fold increase in 
mononuclear cell infiltration to the injured livers (Figure 7-1). Liver damage is 
reflected by high serum levels of TNF-α and IFN-γ and raised serum transaminases 
due to spill over of biliary inflammation into the parenchyma. Liver histology 
typically shows a mononuclear infiltrate in the biliary tract with mild/moderate 
interface hepatitis. I have infused MSC cultured in SM and SM supplemented with 
TGF-β into OVA-Bil mice to assess impact on liver injury. I have examined various 
outputs including peak ALT at day 10 and quantitive and qualitative analysis of 
biliary infiltration by flow cytometry and histology. The early data are encouraging 
however further work is required to show definitive differences. 
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Figure 7-1 ALT concentration in OVA-bil mice at different time points following 
infusion of OT1 and OT2 cells. 
This figure shows the mean ALT level in OVA-Bil mice at different stages following 
re-constitution with OT1 and OT2 splenocytes. The peak injury occurs at day 9.  
 
7.3.2.2 Nrf2-/- model of alcohol hepatitis 
 
Rodent models of alcoholic hepatitis have been problematic. The nuclear factor-
erythroid 2-related factor 2 knockout (Nrf2-/-) mouse develops a florid pattern of acute 
liver injury after alcohol administration with a high mortality (Buxbaum et al., 2006). 
Nrf2 protects cells from oxidative and xenobiotic stress, such that Nrf2-/- mice 
exposed to alcohol rapidly deplete their glutathione stores and demonstrate 
abnormalities of mitochondrial function. Mice subsequently develop a profound 
Kupffer cell mediated inflammatory response as reflected by high levels of TNF-α. 
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Mice develop hepatic steatosis, progressive hepatocellular injury, hypoglycaemia and 
death (Figure 7-2).  
 
 
Figure 7-2 Survival curve of NRF2-/- mice fed on an alcohol diet. 
This figure shows survival curves for NRF2-/- mice and control mice fed the Lieber-
DeCarli diet. Mice lacking the anti-oxidant NRF2 develop steatoheptatis with 
inflammation that closely resembles human alcoholic hepatitis. The mice die from 
liver failure as is often the case with the human condition. 
 
I recently acquired these mice from Sabrina Werner’s laboratory in the University of 
Vienna and am currently expanding the mouse colony. I have the Lieber-DeCarli diet 
in house and will establish this model. I will infuse MSCs (1 million IP on day 3 and 
7) and examine the impact on the natural course of murine alcoholic hepatitis. 
Specifically I will measure the proportion that develop hypoglycaemia (surrogate for 
death), peak ALT prior to culling (approximately 4000IU/ml and 
immunohistochemistry to examine infiltrating/proliferating neutrophils and 
lymphocytes will be measured. 
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7.4 Limitations 
 
There are limitations to this work. The prospective isolation of PαS MSC is a 
significant development for the field. For the first time scientists interrogate the basic 
biology a pure MSC population. Additionally, the use of PαS MSC in rodent models 
of disease will provide critical translational information that may make hMSC therapy 
more effective and safer. The isolation of these cells is however far more challenging 
compare to traditional methods. In addition to several delicate isolation steps, 
experience and access to high-speed cell sorter is required. This may limit access of 
some laboratories to these cells. Although our data suggest that PαS MSC are not 
transformed by in vitro expansion, confirmation of these findings will only be 
provided following in vivo injection into immunodeficient recipients with long-term 
follow-up.  
 
We show exciting results supporting lineage priming of MSCs when cultured in GF 
supplemented media. Additional experiments using combinations of GFs would be of 
interest. Additionally, withdrawal of the GF following a period of expansion might be 
studied. For example it is possible MSCs expanded in bFGF supplemented media 
regain their osteogenic and immunosuppressive potential following removal of the 
GF. One exciting finding is that cells cultured in SM alone and supplemented with 
TGF-β have potent in vitro immunosuppressive potential.  This has not however been 
confirmed in vivo. Finally, cell homing to target organ is likely to be of critical for 
effective cellular therapy. Further studies are required to interrogate this property for 
each cell group. Additional projects might focus on augmenting cell homing as has 
been described in the Introduction. 
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7.5 Conclusions 
 
Testing experimental drugs in rodent models of disease is a critical and necessary step 
for drug development. Information regarding dosage, route of infusion, potential 
toxicity ensure as far as possible drug safety and efficacy when tested in early clinical 
trials. Due to limitations in the isolation and expansion in mMSCs, cell therapy has 
progressed uncomfortably quickly in humans, potentially putting patients at risk.  The 
prospective isolation of PαS MSCs overcomes many of avoid many complications of 
traditional murine isolation. They are multipotent and immunosuppressive in vitro and 
will provide invaluable pre-clinical data pertaining to MSC cellular therapy. 
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APPENDIX 1- List of genes that were significantly up or down regulated in the 
treatment groups compared to SM 
 
GeneID Symbol Description FGF 
Fold.Change 
PDGF 
Fold.Change 
TGFb 
Fold.Change 
11450 Adipoq adiponectin, C1Q 
and collagen 
domain 
containing 
27.50 11.66 -3.22 
11647 Alpl alkaline 
phosphatase, 
liver/bone/kidney 
-3.08 -5.69 -20.04 
11754 Aoc3 amine oxidase, 
copper containing 
3 
2.17 1.15 -3.86 
11770 Fabp4 fatty acid binding 
protein 4, 
adipocyte 
8.85 4.80 -2.24 
11799 Birc5 baculoviral IAP 
repeat-containing 
5 
1.51 1.71 1.17 
11816 Apoe apolipoprotein E 3.32 1.95 -1.43 
11832 Aqp7 aquaporin 7 27.09 10.20 -1.74 
12156 Bmp2 bone 
morphogenetic 
protein 2 
33.49 2.93 2.89 
12159 Bmp4 bone 
morphogenetic 
protein 4 
-20.15 -8.20 -3.99 
12161 Bmp6 bone 
morphogenetic 
protein 6 
-2.44 -1.15 -1.39 
12167 Bmpr1b bone 
morphogenetic 
protein receptor, 
type 1B 
-2.66 1.10 2.46 
12182 Bst1 bone marrow 
stromal cell 
antigen 1 
-10.85 -7.09 -10.06 
12484 Cd24a CD24a antigen 1.52 1.32 -1.76 
12606 Cebpa CCAAT/enhancer 
binding protein 
(C/EBP), alpha 
2.55 1.70 -3.33 
12609 Cebpd CCAAT/enhancer 
binding protein 
(C/EBP), delta 
-1.72 -1.92 -1.38 
12813 Col10a1 collagen, type X, 1.06 4.16 -2.23 
	  
 
	   ii	  
alpha 1 
12814 Col11a1 collagen, type XI, 
alpha 1 
-2.55 -2.33 2.44 
12834 Col6a2 collagen, type VI, 
alpha 2 
1.10 1.07 -1.94 
12842 Col1a1 collagen, type I, 
alpha 1 
-6.28 -2.27 1.20 
12843 Col1a2 collagen, type I, 
alpha 2 
-3.23 -1.68 1.28 
12845 Comp cartilage 
oligomeric matrix 
protein 
-4.54 -2.63 -3.19 
13380 Dkk1 dickkopf 
homolog 1 
(Xenopus laevis) 
1.55 1.13 1.10 
13386 Dlk1 delta-like 1 
homolog 
(Drosophila) 
11.07 5.09 -2.06 
13395 Dlx5 distal-less 
homeobox 5 
-2.76 -1.63 -1.40 
13805 Eng endoglin -1.93 -1.61 -1.06 
13865 Nr2f1 nuclear receptor 
subfamily 2, 
group F, member 
1 
4.31 1.47 1.20 
14164 Fgf1 fibroblast growth 
factor 1 
1.60 1.39 1.30 
14165 Fgf10 fibroblast growth 
factor 10 
2.16 3.00 -4.98 
14183 Fgfr2 fibroblast growth 
factor receptor 2 
-4.12 -2.63 -6.97 
14184 Fgfr3 fibroblast growth 
factor receptor 3 
-1.47 -1.54 -1.66 
14461 Gata2 GATA binding 
protein 2 
1.56 1.38 -1.11 
14462 Gata3 GATA binding 
protein 3 
1.28 2.15 1.09 
14465 Gata6 GATA binding 
protein 6 
1.90 2.05 1.56 
14555 Gpd1 glycerol-3-
phosphate 
dehydrogenase 1 
(soluble) 
25.26 5.75 -1.32 
15398 Hoxa13 homeobox A13 -1.73 -1.18 -1.46 
15402 Hoxa5 homeobox A5 1.92 1.09 -1.10 
15891 Ibsp integrin binding 
sialoprotein 
-5.15 -4.28 -5.37 
16000 Igf1 insulin-like 
growth factor 1 
-4.63 -6.59 -1.64 
16173 Il18 interleukin 18 -1.32 -1.51 -1.81 
16193 Il6 interleukin 6 -19.29 -5.78 -2.95 
16878 Lif leukemia 
inhibitory factor 
-1.17 -1.22 5.93 
16880 Lifr leukemia 
inhibitory factor 
receptor 
-2.01 -2.44 -3.29 
16956 Lpl lipoprotein lipase 2.76 1.69 -27.46 
	  
 
	   iii	  
16973 Lrp5 low density 
lipoprotein 
receptor-related 
protein 5 
1.65 -1.14 -1.25 
17258 Mef2a myocyte 
enhancer factor 
2A 
1.11 -1.03 -1.53 
17260 Mef2c myocyte 
enhancer factor 
2C 
-1.14 1.38 -1.98 
17311 Kitl kit ligand -1.07 1.45 -10.27 
17470 Cd200 CD200 antigen 5.67 1.07 5.63 
18295 Ogn osteoglycin -6.13 -1.30 -1.42 
18595 Pdgfra platelet derived 
growth factor 
receptor, alpha 
polypeptide 
1.62 1.79 -1.50 
18596 Pdgfrb platelet derived 
growth factor 
receptor, beta 
polypeptide 
-1.77 -1.33 1.17 
19016 Pparg peroxisome 
proliferator 
activated receptor 
gamma 
4.53 2.97 -3.24 
19228 Pth1r parathyroid 
hormone 1 
receptor 
-1.65 -2.36 -1.44 
20181 Rxra retinoid X 
receptor alpha 
1.24 1.03 -1.53 
20319 Sfrp2 secreted frizzled-
related protein 2 
-79.67 -7.34 -89.78 
20429 Shox2 short stature 
homeobox 2 
1.14 1.15 1.53 
20674 Sox2 SRY-box 
containing gene 2 
7.39 1.16 1.19 
20678 Sox5 SRY-box 
containing gene 5 
4.56 3.28 1.05 
20750 Spp1 secreted 
phosphoprotein 1 
1.73 1.57 1.49 
20787 Srebf1 sterol regulatory 
element binding 
transcription 
factor 1 
2.47 1.12 1.25 
21418 Tfap2a transcription 
factor AP-2, 
alpha 
1.98 1.50 1.12 
21812 Tgfbr1 transforming 
growth factor, 
beta receptor I 
1.42 -1.25 -1.60 
21813 Tgfbr2 transforming 
growth factor, 
beta receptor II 
-1.62 -1.34 1.05 
21814 Tgfbr3 transforming 
growth factor, 
beta receptor III 
1.34 1.28 -2.43 
22402 Wisp1 WNT1 inducible 
signaling 
-9.65 -5.13 2.25 
	  
 
	   iv	  
pathway protein 1 
22403 Wisp2 WNT1 inducible 
signaling 
pathway protein 2 
-6.24 -2.12 -1.65 
22413 Wnt2 wingless-related 
MMTV 
integration site 2 
-3.37 -1.65 -3.19 
23959 Nt5e 5' nucleotidase, 
ecto 
2.19 1.13 7.95 
24059 Slco2a1 solute carrier 
organic anion 
transporter 
family, member 
2a1 
2.03 4.87 -1.24 
27279 Tnfrsf12a tumor necrosis 
factor receptor 
superfamily, 
member 12a 
-1.25 1.45 1.87 
71436 Flrt3 fibronectin 
leucine rich 
transmembrane 
protein 3 
2.50 -1.62 1.15 
77037 Mrap melanocortin 2 
receptor 
accessory protein 
2.36 1.13 1.11 
103968 Plin1 perilipin 1 24.26 8.11 -1.23 
116701 Fgfrl1 fibroblast growth 
factor receptor-
like 1 
1.54 -1.02 -1.64 
121021 Cspg4 chondroitin 
sulfate 
proteoglycan 4 
1.56 2.54 2.91 
211323 Nrg1 neuregulin 1 -4.77 -2.26 1.63 
235320 Zbtb16 zinc finger and 
BTB domain 
containing 16 
2.32 1.71 -1.05 
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